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Introduction: Drug delivery to the brain to treat neurological disorders is a challenge due 
to the blood-brain barrier, which physically and actively restricts the transport of 
molecules into the brain. Implantable drug delivery systems (e.g. hydrogels and 
nano/micro-particles) have been developed to overcome the blood-brain barrier issues. 
However, limitations such as excessive swelling or disintegration of the hydrogel, 
retaining the particles at the site of action, low loading efficiency and burst release of the 
drug can occur. Therefore, the overarching aim of this thesis was to develop and 
characterise implantable nanofibres (NF) for drug delivery to treat neurological disorders 
using low toxic solvent systems. 
 
Methods: NFs were prepared using the technique of electrospinning using biodegradable 
polymers. For the first time, a new, low toxicity solvent system consisting of acetone 
(ACE) and ethyl acetate (EtAc) (Class III solvents) was used to prepare poly-(lactic-co-
glycolic acid) (PLGA) NFs. The electrospun PLGA NFs were characterised based on 
morphology, solid-state characteristics, tensile strength and hydrophobicity and 
compared to NFs electrospun using more toxic solvent systems of dichloromethane 
(DCM) and dimethylformamide (DMF) (Class II solvents). The incorporation and release 
kinetics of drugs with different molecular weights (paracetamol 151.17 g/mol, ampicillin 
349.41 g/mol and tetracycline 480.90 g/mol) were investigated. 
 
Poly-(caprolactone) (PCL) was also investigated as a NF drug delivery system and was 
co-electrospun with chitosan (CH), gelatine (GEL) or poly-(ethylene oxide) (PEO). The 
NFs were compared to determine if the blended polymers improved the chemical and 
physical properties of PCL NFs. In vitro degradation studies were conducted and the drug 
release kinetics of L-655,708 from PCL and the PCL/blend NFs was investigated. Further 
release studies from PCL/CH NFs were undertaken, with a comparison between the 
neuroactive-drug L-655,708 and indomethacin. The in vitro cytotoxicity and immune 




Results: Compared to PLGA NFs produced using the conventional solvents DCM and 
DMF, the new ACE:EtAc solvent system resulted in NFs with a decrease in fibre 
diameter uniformity and an increased hydrophobic surface as determined by field 
emission scanning electron microscopy (FE-SEM) and water contact angle 
measurements, respectively. NFs made using both solvent systems were amorphous, 
however, the residual solvent could be detected by thermogravimetric analysis. 
Attenuated total reflectance-Fourier transform infrared spectroscopy analysis showed 
there was no change in PLGA chemical composition after electrospinning. Tensile 
strength studies showed that NFs prepared using the less toxic ACE:EtAc solvent system 
was lower in tensile strength and underwent a different mechanical deformation process 
compared with DCM:DMF NFs.  
 
The solid-state analysis confirmed the incorporation of the drug in the PLGA NFs, with 
FE-SEM and hot stage microscopy identifying drug on the surface of the NFs. The drug 
release kinetics of tetracycline and paracetamol were similar from both NFs with an 
initial burst release, followed by a gradual release over 504 h. Assessment, however, of 
the release profile for ampicillin revealed a smaller initial bolus release with the release 
from PLGA ACE:EtAc being slower than PLGA DCM:DMF. The release kinetics 
indicated that the molecular weight of the incorporated drug, nor fibre diameter 
influenced drug release.  
 
FE-SEM analysis of PCL and PCL/blend NFs showed smooth, bead-free NFs with 
average fibre diameter in the order of PCL/CH < PCL < PCL/PEO < PCL/GEL. The 
polymers incorporated into the NFs were chemically unchanged by the electrospinning 
process and the NFs did not appear to have residual solvent present. The PCL component 
of PCL/CH and PCL/GEL NFs had reduced crystallinity, while PCL/PEO NF was the 
most thermally stable and had the highest mechanical strength. The hydrophobic surface 




An in vitro degradation study revealed a reduction in mass of 44% and 38% from 
PCL/PEO and PCL/GEL, with negligible loss over the 4-weeks from PCL and PCL/CH. 
With polymer degradation said to influence drug release, it was interesting to observe 
that the degradation study did not translate into the faster release of L-655,708 from 
PCL/PEO or PCL/GEL, as PCL/CH showed the fastest release with 100% release after 
24 h. The drug release from PCL/CH was further investigated as a charge interaction was 
postulated to be the mechanism of release, however, the release of the neutral drug 
indomethacin was similar to the release of L-655,708. Two theories were put forward to 
explain the release kinetics from the PCL/CH NF; 1) phase separation of the polymers 
occurred during electrospinning, forming two distinct fibres with the hydrophobic drugs 
favouring the lesser hydrophobic interaction with CH resulting in drug diffusion out of 
the CH NF. Alternatively, a core/sheath NF occurred where the drug was located in the 
CH sheath around a PCL core resulting in drug distributed at the surface of the NF. 2) 
During the electrospinning process, nano-pores were created on the surface of the NF 
that facilitated the diffusion of the drugs from the NF. In vitro cell culture studies showed 
PCL/GEL had the greatest cell proliferation over 24 h and the highest cell viability over 
3 days. NFs with fibroblast cells cultured on the surface did not elicit an immune 
response, however further studies need to be conducted to confirm biocompatibility.  
 
Conclusion: This thesis demonstrates the development of a drug delivery system using 
the electrospinning process that utilises less toxic solvent systems. Drug release was 
sustained over 21 days and supports the use of a NF as a promising candidate for the 




First and foremost, I would like to express my sincere appreciation to my supervisors, 
Assoc. Prof.. Arlene McDowell who came on board under difficult circumstances, 
without her guidance and advice this work would not have been realised. Dr Andrew 
Clarkson for his input and feedback and Dr Greg Walker for the initial stages of the 
project. 
 
Thank you to all the staff at the School of Pharmacy for the incredible help and patience 
I always received. In particular, my facilitators David Schmierer and Assoc. Prof. Joel 
Tyndall. The administrative staff for their support and assistance with any admin issues 
that arose. Brian and Tim for their assistance with computer and technical issues, I owe 
a lot to Kevin for all the hard work he did behind the scenes making/developing and 
fixing equipment. Mike Broughton and Pummy for their assistance with the HPLC. 
Kathy and Jo for assisting with the purchasing of goods, general enquiries and the banter. 
 
I would also like to thank all the postgraduate students, visiting researchers, honours and 
elective students I have met over the years in the lab. In particular, Silke, Kan, Momin 
and Basanth who I shared the trials and tribulations of PhD life with, I appreciate their 
ideas, help and good humour. 
 
I wish to extend my thanks to the people who assisted me from other departments within 
the University of Otago. Especially Liz Girvan for her time and effort helping me with 
the FE-SEM. Dr Antonio Berretta and Katie Young for spending their time teaching me 
cell culture an answering my queries.   
 
Finally, I wish to express my deepest gratitude for the love, support and patience I 
received from my family and friends. Bettina, Mum and Smeats, Dad and Justine, Jenz 
and Mike, Nana, and Johnny and Fenella. To all my friends of which there are too many 
to name individually. They kept me going on and this work would not have been possible 
without their input, I thank you all.  
 
vii 
Publications arising from this thesis 
Submitted manuscript 
McLaughlin, A., McDowell, A., Clarkson, A.N., Walker, G.F. (submitted). 
Characterisation of poly-(lactic-co-glycolic acid) nanofibers electrospun using a 
sustainable green chemistry for producing solvents with low toxicity solvent system of 
acetone and ethyl acetate. Journal of Material Sciences 
Referenced journal articles 
Smith, G. P. S., McLaughlin, A., Clarkson, A. N., Gordon, K. C., & Walker, G. F. (2017). 
Raman microscopic imaging of electrospun fibers made from a polycaprolactone and 
polyethylene oxide blend. Vibrational Spectroscopy, 92, 27-34. 
Conference contributions 
Oral presentations  
McLaughlin, A., Clarkson, A., Walker, G. Physical Properties of PCL Nanofiber blends 
for Drug Delivery Implants. D4: Devices for Diagnostics and Drug Delivery Conference, 
Dunedin, New Zealand, 2015. 
Poster presentations 
McLaughlin, A., Berretta, A., Clarkson, A., Walker, G. An Alternative Solvent System 
for Electrospinning Poly-(caprolactone). D4: Devices for Diagnostics and Drug Delivery 
Conference, Dunedin, New Zealand, 2014. 
McLaughlin, A., Clarkson, A., Walker, G. A New Solvent for Electrospinning Poly-
(caprolactone), 42th Annual Meeting & Exposition of the Controlled Release Society 
(CRS), Edinburgh, Scotland, UK, 2015. 
Additional conference contributions 
McLaughlin, A., Nothnagel, L., Schmid, M., Walker, G. Nanofibre ‘Textile-Like’ 
Dressing Which Slowly Releases Wine Waste Bioactives. Australasian Pharmaceutical 
Science Association (APSA) Conference, Dunedin, New Zealand, 2014.  
 
viii 
Table of contents 
Abstract ......................................................................................................................... iii 
Acknowledgements ........................................................................................................ vi 
Publications arising from this thesis ...........................................................................vii 
Table of contents ......................................................................................................... viii 
List of figures ............................................................................................................... xvi 
List of tables .............................................................................................................. xxiii 
List of abbreviations .................................................................................................. xxiv 
1 Introduction ............................................................................................................ 2 
1.1 Neurological disorders ..................................................................................... 2 
1.1.1 Drug delivery for neurological disorders ................................................... 2 
1.1.1.1 The blood-brain barrier: A hurdle for the treatment of neurological 
disorders  ............................................................................................................. 3 
1.1.2 Implantable drug delivery systems ............................................................. 5 
1.1.2.1 Solid drug delivery implants ............................................................... 6 
1.1.2.2 Hydrogel implants for drug delivery to the brain ................................ 8 
1.1.2.3 Microparticle implants for drug delivery to the brain ....................... 10 
1.1.2.4 Hydrogel composite implants for drug delivery to the brain ............ 12 
1.1.3 Nanofibres as an implantable drug delivery system ................................. 15 
1.2 Production of nanofibres using the electrospinning technique ................. 18 
 
ix 
1.2.1 Electrospinning processing parameters and their effect on the nanofibre 19 
1.2.1.1 Applied voltage ................................................................................. 19 
1.2.1.2 Flow rate ............................................................................................ 20 
1.2.1.3 Distance from needle to the collector ................................................ 21 
1.2.1.4 Temperature and humidity ................................................................ 22 
1.2.2 Electrospinning solution parameters and their effect on the nanofibre .... 22 
1.2.2.1 Concentration of polymer ................................................................. 22 
1.2.2.2 The viscosity of the polymer solution ............................................... 23 
1.2.2.3 The surface tension of the polymer solution ..................................... 24 
1.2.2.4 Solution conductivity ........................................................................ 24 
1.2.2.5 Solvent dielectric constant ................................................................ 25 
1.2.2.6 Polymer molecular weight ................................................................ 26 
1.2.3 Organic solvents used in electrospun nanofibre drug delivery systems ... 26 
1.2.4 Techniques employed to load nanofibre with drug .................................. 29 
1.2.4.1 Post-modification of nanofibre for drug loading .............................. 31 
1.2.4.2 Co-electrospinning of polymer and drug .......................................... 31 
1.2.4.3 Coaxial electrospinning to form drug core and polymer sheath ....... 32 
1.2.4.4 Emulsion electrospinning to form drug core and polymer sheath .... 32 
1.2.4.5 Influence of drug physicochemical characteristics in drug release from 
nanofibre  ........................................................................................................... 33 
1.3 Application of a nanofibre delivery system for stroke ............................... 34 
1.3.1 Stroke ........................................................................................................ 34 
 
x 
1.3.2 Ischemic stroke ......................................................................................... 35 
1.3.3 Current clinical treatments for ischemic stroke ........................................ 36 
1.3.3.1 Tissue plasminogen activator to promote reperfusion for stroke ...... 36 
1.3.3.2 Endovascular mechanical device for clot removal in stroke ............. 36 
1.3.4 A new pharmacological intervention for the treatment of stroke ............. 37 
1.4 Thesis aims...................................................................................................... 38 
2 Materials and methods ......................................................................................... 42 
2.1 Materials ......................................................................................................... 42 
2.2 Preparation of nanofibres ............................................................................. 43 
2.2.1 Preparation of nanofibre solutions ............................................................ 43 
2.2.1.1 PLGA solution .................................................................................. 43 
2.2.1.2 PLGA drug-loaded nanofibre solutions ............................................ 43 
2.2.1.3 PCL and PCL/blend solutions ........................................................... 43 
2.2.1.4 PCL and PCL/blend drug-loaded nanofibre solutions ...................... 44 
2.2.2 Electrospinning nanofibre solutions ......................................................... 44 
2.3 Characterisation of nanofibres ..................................................................... 46 
2.3.1 Field emission-scanning electron microscopy.......................................... 46 
2.3.2 Attenuated total reflectance Fourier-transform infrared spectroscopy ..... 46 
2.3.3 Differential scanning calorimetry ............................................................. 47 
2.3.4 Thermogravimetric analysis ..................................................................... 47 
2.3.5 X-ray diffraction ....................................................................................... 47 
2.3.6 Hot stage microscopy ............................................................................... 48 
 
xi 
2.3.7 Mechanical strength of nanofibre ............................................................. 48 
2.3.8 Water contact angle of nanofibre ............................................................. 49 
2.3.9 Mass loss from PCL and PCL/blend nanofibre ........................................ 49 
2.4 In vitro drug release ....................................................................................... 50 
2.4.1 RP-HPLC analysis of L-655,708 .............................................................. 50 
2.4.1.1 Instrumentation ................................................................................. 50 
2.4.1.2 L-655,708 stock preparation and standards ...................................... 50 
2.4.2 RP-HPLC analysis of indomethacin ......................................................... 51 
2.4.2.1 Instrumentation ................................................................................. 51 
2.4.2.2 Indomethacin stock preparation and standards ................................. 51 
2.4.3 RP-HPLC analysis of paracetamol ........................................................... 52 
2.4.3.1 Instrumentation ................................................................................. 52 
2.4.4 RP-HPLC analysis of ampicillin .............................................................. 52 
2.4.4.1 Instrumentation ................................................................................. 52 
2.4.5 RP-HPLC analysis of tetracycline ............................................................ 53 
2.4.5.1 Instrumentation ................................................................................. 53 
2.4.5.2 Tetracycline, ampicillin and paracetamol stock preparation and 
standards  ........................................................................................................... 53 
2.4.6 In vitro release of drug from nanofibre .................................................... 54 
2.5 In vitro cell studies.......................................................................................... 54 
2.5.1 Cell Culture .............................................................................................. 54 
2.5.1.1 Normal human dermal fibroblast cell culture ................................... 54 
 
xii 
2.5.2 Nanofibre cytotoxicity and biocompatibility............................................ 55 
2.5.2.1 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide assay 
  ........................................................................................................... 55 
2.5.2.2 In vitro cytokine production .............................................................. 55 
2.5.2.3 Cytometric bead array ....................................................................... 56 
2.6 Statistical analysis .......................................................................................... 56 
3 Development and characterisation of PLGA nanofibres using low toxic solvents
  ................................................................................................................................ 58 
3.1 Introduction .................................................................................................... 58 
3.1.1 Poly-(lactic-co-glycolic-acid) (PLGA) ..................................................... 58 
3.1.2 Applications of PLGA and its biocompatibility and toxicity ................... 59 
3.1.3 Electrospinning PLGA and the use of alternative, low toxic solvents ..... 60 
3.2 Chapter aims .................................................................................................. 62 
3.3 Methods........................................................................................................... 63 
3.4 Results ............................................................................................................. 63 
3.4.1 Production and characterisation of PLGA nanofibres .............................. 63 
3.4.1.1 Electrospinning and nanofibre morphology ...................................... 63 
3.4.1.2 Attenuated total reflectance-Fourier transform infra-red spectroscopy 
  ........................................................................................................... 67 
3.4.1.3 Differential scanning calorimetry ..................................................... 68 
3.4.1.4 Thermogravimetric analysis .............................................................. 69 
3.4.1.5 Mechanical strength .......................................................................... 72 
3.4.1.6 Surface hydrophobicity of nanofibre ................................................ 76 
 
xiii 
3.4.2 Production and characterisation of drug-loaded PLGA nanofibres ......... 78 
3.4.2.1 Electrospinning and drug-loaded nanofibre morphology ................. 78 
3.4.2.2 Attenuated total reflectance-Fourier transform infra-red spectroscopy 
of drug-loaded NF .............................................................................................. 82 
3.4.2.3 Thermogravimetric analysis of drug-loaded nanofibre ..................... 86 
3.4.2.4 Differential scanning calorimetry of drug-loaded nanofibre ............ 89 
3.4.2.5 Hot stage microscopy of drug-loaded nanofibres ............................. 91 
3.4.2.6 In vitro drug release from drug-loaded nanofibre ............................. 96 
3.5 Discussion ....................................................................................................... 98 
3.5.1 Solvent system development and nanofibre morphology ........................ 98 
3.5.2 Physical and chemical properties of PLGA nanofibres ............................ 99 
3.5.3 Tensile strength and deformation process of PLGA nanofibres ............ 101 
3.5.4 Hydrophobic characteristics of PLGA nanofibres ................................. 102 
3.5.5 Physical and chemical properties of drug-loaded PLGA nanofibres ..... 103 
3.5.6 Drug release kinetics and mechanism of release from drug-loaded PLGA 
nanofibres ............................................................................................................. 105 
3.5.7 Conclusion .............................................................................................. 108 
4 Development and characterisation of PCL and PCL/blend nanofibres using 
low toxic solvents ........................................................................................................ 110 
4.1 Introduction .................................................................................................. 110 
4.1.1 Poly-(caprolactone) (PCL) ..................................................................... 110 
4.1.1.1 Electrospinning of poly-(caprolactone) ........................................... 111 
4.1.2 Polymer blend nanofibres for devices .................................................... 113 
 
xiv 
4.1.2.1 Poly-(ethylene oxide) – a synthetic polymer for electrospinning ... 115 
4.1.2.2 Chitosan – a natural polymer for electrospinning ........................... 117 
4.1.2.3 Gelatine – a natural polymer for electrospinning ............................ 119 
4.1.3 In vitro degradation and drug release mechanisms for nanofibres ......... 120 
4.1.4 Biocompatibility and immune response to nanofibres ........................... 123 
4.1.5 Chapter aims ........................................................................................... 125 
4.2 Methods......................................................................................................... 125 
4.3 Results ........................................................................................................... 126 
4.3.1 Production and characterisation of PCL and PCL/blend nanofibres ...... 126 
4.3.1.1 Electrospinning and scanning electron microscopy ........................ 126 
4.3.1.2 Attenuated total reflective-Fourier transformed infra-red spectroscopy
  ......................................................................................................... 129 
4.3.1.3 Thermogravimetric analysis ............................................................ 133 
4.3.1.4 X-ray diffraction .............................................................................. 134 
4.3.1.5 Differential scanning calorimetry ................................................... 136 
4.3.1.6 Mechanical strength of nanofibres .................................................. 140 
4.3.1.7 Hydrophobicity of nanofibres ......................................................... 141 
4.3.2 In vitro mass loss of nanofibres .............................................................. 143 
4.3.3 In vitro drug release from nanofibres ..................................................... 144 
4.3.4 The effect of charge interaction between the drug and chitosan on in vitro 
release  ................................................................................................................ 146 
4.3.5 In vitro cell culture studies ..................................................................... 148 
4.3.5.1 Nanofibre in vitro cytotoxicity ........................................................ 148 
 
xv 
4.3.5.2 Immune response to nanofibres ...................................................... 149 
4.4 Discussion ..................................................................................................... 152 
4.4.1 Electrospinning and nanofibre morphology ........................................... 152 
4.4.2 Solid-state properties of electrospun PCL and PCL/blend nanofibres ... 153 
4.4.3 Tensile strength of PCL and PCL/blend nanofibres ............................... 157 
4.4.4 Hydrophobic characteristics of PCL and PCL/blend nanofibres ........... 158 
4.4.5 Drug release characteristics of PCL and PCL/blend nanofibres ............ 161 
4.4.6 In vitro biocompatibility of PCL and PCL/blend nanofibres ................. 165 
4.4.7 Conclusion .............................................................................................. 168 
5 General discussion and future directions ......................................................... 170 
References ................................................................................................................... 180 
Appendix ..................................................................................................................... 237 
Appendix A.............................................................................................................. 237 




List of figures 
Figure 1-1 Schematic overview demonstrating the tight and adherens junctions that make 
up the physical aspect of the blood-brain barrier of the CNS. The junctions 
are formed between endothelial cells and span the intracellular space to 
restrict the transport of exogenous molecules from the systemic blood 
circulation into the brain [21]. Figure adapted from Polakis, J. Cell bio. 2008, 
183, (3), 371-373 [24].................................................................................... 4 
Figure 1-2 Schematic illustration of the multidrug-resistant protein P-glycoprotein (P-
gp) (green shapes) that act as an active barrier removing exogenous 
molecules (blue triangles) that have passed from the systemic blood 
circulation into the central nervous system of the brain endothelial cell [27]. 
Efflux transporters use the energy from the hydrolysis of adenosine 
triphosphate to pump molecules up their concentration gradient and out of 
the BBB [27]. Figure adapted from Osherovich, L. Sci.-Bus. eXchange, 2009, 
2, (19) 773 [30]. ............................................................................................. 5 
Figure 1-3 Photograph of Gliadel® wafers being surgically implanted into a tumour 
recess following the surgical removal of a malignant glioma. Figure adapted 
from Maciej and Brem [49], reprinted with permission from Nature 
Publishing Group: Nature Reviews Drug Discovery 2004, 3 (6), 499-508, 
copyright 2004. .............................................................................................. 7 
Figure 1-4 Illustration depicting the encapsulation of the active drug (orange spheres) in 
microparticles (blue spheres). The microparticles are approximately 100 μm 
in diameter. Adapted from Cavanagh. CC BY-NC, Welcome collection, 
https://wellcomecollection.org/works/df6vfbzr. .......................................... 11 
Figure 1-5 Illustration of microparticles (blue spheres) containing the active drug 
(orange spheres) entrapped in the hydrogel matrix (green lines) forming the 
hydrogel composite. The entrapment of the microparticles in the hydrogel is 
thought to attenuate the burst release of the active drug. Figure adapted from 
Zhao et al. Nanomaterials, 2015, 5 (4), 2054-2130 [91]............................. 13 
Figure 1-6 A scanning electron micrograph at 5,000x magnification displaying the 
intricate matrix of a nanofibre (NF) network. The NF was prepared by 
electrospinning poly-(caprolactone) and chitosan at a 50:50 ratio with a 
solvent system consisting of acetic acid and formic acid. ........................... 16 
Figure 1-7 Schematic representation of a typical electrospinning setup. After the 
formation of the Taylor cone at the needle tip, NF is ejected and collected on 
the grounded rotating collector when the applied voltage overcomes the 
surface tension [108]. Figure adapted from Sorayani Bafqi et al. J. Polymer 
Res. 2015, 22, 130 [111]. ............................................................................. 19 
Figure 1-8 A scanning electron micrograph depicting a single NF with ribbon-like 
morphology prepared from polystyrene. Figure adapted from Megelski et al. 
[122]. Reprinted with permission from American Chemical Society: 
Macromolecules 2002, 35 (22), 8456-8466, copyright 2002. ..................... 20 
 
xvii 
Figure 1-9 A scanning electron micrograph demonstrating bead formation along the 
length of the PEO NF after electrospinning. Figure adapted from Fong et al. 
[127]. Reprinted with permission from Elsevier: Polymer 1999, 40, 4585-
4592, copyright 1999. .................................................................................. 21 
Figure 1-10 A scanning electron micrograph displaying the spindle-like structures along 
the length of the PEO NF after electrospinning. Figure adapted from Fong et 
al. [127]. Reprinted with permission from Elsevier: Polymer 1999, 40, 4585-
4592, copyright 1999. .................................................................................. 23 
Figure 1-11 The different electrospinning techniques used to load the active drug into 
the NF matrix. a) post-modification of NF with the drug, b) co-
electrospinning with polymer and drug, c) coaxial electrospinning forming 
drug core and polymer sheath, d) emulsion electrospinning forming drug core 
and polymer sheath [150]. Figure adapted from Meinel et al. Eur. J. Pharm.  
Biopharm. 2012, 81 (1), 1-13 [150]............................................................. 30 
Figure 1-12 Schematic illustration outlining how an ischemic stroke develops in the 
brain. A blood clot blocks blood flow to part of the brain causing necrosis. 
Source: National Heart, Lung, and Blood Institute; National Institutes of 
Health; U.S. Department of Health and Human Services. Reprinted with 
permission. ................................................................................................... 35 
Figure 1-13 Illustration of the Solitaire™ FR EMD. The device is deployed at the site of 
occlusion and embedded into the clot, they are then both withdrawn from the 
vessel restoring blood flow. Copyright © 2017 Medtronic. All rights 
reserved. Reprinted with permission. .......................................................... 37 
Figure 3-1 Chemical structure of the poly-(lactic-co-glycolic-acid) repeating monomer 
unit. The lactic acid repeating unit is in the square bracket labelled n and the 
glycolic acid repeating unit is in the square bracket labelled m. ................. 58 
Figure 3-2 FE-SEM micrographs of PLGA 75:25 electrospun with solvent system (a) 
ACE:EtAc (80:20), (b) ACE:EtAc (70:30) and (c) DCM:DMF (70:30). ... 65 
Figure 3-3 FE-SEM micrographs and corresponding graph of fibre diameter distribution, 
(a, b) PLGA ACE:EtAc and (c, d) PLGA DCM:DMF. (e) Mean fibre 
diameter of each NF (n=100). Columns represent the mean of 100 fibres from 
each NF ± SD. ............................................................................................. 66 
Figure 3-4 ATR-FTIR spectra of pure PLGA (black line), PLGA ACE:EtAc NF (orange 
line) and PLGA DCM:DMF NF (blue line). ............................................... 67 
Figure 3-5 DSC thermogram of the glass transition of pure PLGA (black line), PLGA 
ACE:EtAc NF (orange line) and PLGA DCM:DMF NF (blue line) over the 
temperature range of 40-56°C. .................................................................... 69 
Figure 3-6 TGA thermograms of pure PLGA and PLGA NFs. (a) Over the range of 35-
120°C of pure PLGA (black line), PLGA ACE:EtAc NF (orange line) and 
PLGA DCM:DMF NF (blue line). (b) Over the range of 35-600°C of pure 
 
xviii 
PLGA (black line), PLGA ACE:EtAc NF (orange line) and PLGA 
DCM:DMF NF (blue line). .......................................................................... 71 
Figure 3-7 Graph showing the measurement of the force applied to the NFs over time of 
PLGA ACE:EtAc (orange line) and PLGA DCM:DMF (blue line) NF. Each 
line represents the mean of three individual experiments. .......................... 72 
Figure 3-8 Photograph of the deformation at the plastic region (red box) of (A) PLGA 
DCM:DMF NF and (B) PLGA ACE:EtAc NF. .......................................... 73 
Figure 3-9 FE-SEM images of PLGA DCM:DMF and PLGA ACE:EtAc NF taken at the 
different regions during the deformation process. The direction of tension 
applied is shown in the figure and is the same for all FE-SEM images. (1a) 
PLGA DCM:DMF NFs before deformation, (2a) PLGA ACE:EtAc NFs 
before deformation, (1b) PLGA DCM:DMF NFs at the elastic region, (2b) 
PLGA ACE:EtAc NFs at the elastic region, (1c) PLGA DCM:DMF NFs at 
the plastic region, (2c) PLGA ACE:EtAc NFs at the plastic region, (1d) 
PLGA DCM:DMF NFs at the fracture point, (2d) PLGA ACE:EtAc NFs at 
the fracture point, (1e) high magnification of PLGA DCM:DMF NFs at the 
fracture point, (2e) high magnification of  PLGA ACE:EtAc NFs at the 
fracture point. ............................................................................................... 75 
Figure 3-10 Photograph of the water droplets on (a) PLGA DCM:DMF at 1 s, (b) PLGA 
DCM:DMF at 5 min and (c) PLGA ACE:EtAc at 1 s, (d) PLGA ACE:EtAc 
at 5 min. ....................................................................................................... 77 
Figure 3-11 Water contact angles of PLGA ACE:EtAc (blue line) and PLGA DCM:DMF 
(orange line) as a function of time. Each point represents the mean of three 
individual experiments ± SD. Statistical significance was determined by two-
way ANOVA with Bonferroni’s post hoc test, ***p<0.001 and is the 
comparison of the two NF. .......................................................................... 78 
Figure 3-12 FE-SEM micrographs of (a) PLGA DCM:DMF + tetracycline, (b) PLGA 
ACE:EtAc + tetracycline, (c) PLGA DCM:DMF + ampicillin, (d) PLGA 
ACE:EtAc + ampicillin, (e) PLGA DCM:DMF + paracetamol and (f) PLGA 
ACE:EtAc + paracetamol NF. Arrows indicate the irregular structures found 
on the NF surface. ........................................................................................ 79 
Figure 3-13 Histogram representing the NF diameter range and distribution of (a) PLGA 
DCM:DMF + tetracycline, (b) PLGA ACE:EtAc + tetracycline, (c) PLGA 
DCM:DMF + ampicillin, (d) PLGA ACE:EtAc + ampicillin, (e) PLGA 
DCM:DMF + paracetamol and (f) PLGA ACE:EtAc + paracetamol. ........ 80 
Figure 3-14 The mean fibre diameter of each PLGA drug-loaded NF. PLGA DCM:DMF 
+ tetracycline (grey bar), PLGA ACE:EtAc + tetracycline (orange bar), 
PLGA DCM:DMF + ampicillin (yellow bar), PLGA ACE:EtAc + ampicillin 
(green bar), PLGA DCM:DMF + paracetamol (blue bar) and PLGA 
ACE:EtAc + paracetamol (red bar). Bars represent the mean of 100 fibres 
from each NF ± SD. Statistical significance was determined by one-way 
ANOVA with Dunnett’s multiple comparison test, ***p<0.001. ............... 81 
 
xix 
Figure 3-15 ATR-FTIR spectra of (a) pure tetracycline (black line), PLGA ACE:EtAc + 
tetracycline NF (orange line) and PLGA DCM:DMF + tetracycline NF (blue 
line), (b) pure ampicillin (black line), PLGA ACE:EtAc + ampicillin NF 
(orange line) and PLGA DCM:DMF + ampicillin NF (blue line) and (c) pure 
paracetamol (black line), PLGA ACE:EtAc + paracetamol NF (orange line) 
and PLGA DCM:DMF + paracetamol NF (blue line). ................................ 85 
Figure 3-16 TGA thermogram over the temperature range of 20-600°C of (a) pure 
tetracycline (black line) PLGA ACE:EtAc + tetracycline (orange line) and 
PLGA DCM:DMF + tetracycline (blue line), (b) pure ampicillin (black line) 
PLGA ACE:EtAc + ampicillin (orange line) and PLGA DCM:DMF + 
ampicillin (blue line) and (c) pure paracetamol (black line) PLGA ACE:EtAc 
+ paracetamol (orange line) and PLGA DCM:DMF + paracetamol (blue 
line). ............................................................................................................. 88 
Figure 3-17 DSC thermogram over the temperature range of 25-250°C of (a) PLGA 
DCM:DMF + tetracycline NF (blue line) and PLGA ACE:EtAc + 
tetracycline (orange line), (b) PLGA DCM:DMF + ampicillin NF (blue line) 
and PLGA ACE:EtAc + ampicillin (orange line) and (c) PLGA DCM:DMF 
+ paracetamol NF (blue line) and PLGA ACE:EtAc + paracetamol (orange 
line). ............................................................................................................. 90 
Figure 3-18 Hot stage microscopic images of the thermal transitions and solid-state 
structure of PLGA DCM:DMF + tetracycline NF at (1a) before the glass 
transition of PLGA at 30°C, (1b) the PLGA glass transition temperature 
midpoint of 54°C, (1c) after the PLGA glass transition at 75°C, (1d) 
crystalline tetracycline at 99°C and (1e) the degradation of tetracycline at 
230°C. PLGA ACE:EtAc + tetracycline NF at (2a) before the glass transition 
of PLGA at 30°C, (2b) the PLGA glass transition temperature midpoint of  
54°C, (2c) after the PLGA glass transition at 75°C, (2d) crystalline 
tetracycline at 96°C and (2e) the degradation of tetracycline at 230°C. ..... 92 
Figure 3-19 Hot stage microscopic images of the thermal transitions and solid-state 
structure of PLGA DCM:DMF + ampicillin NF at (1a) before the glass 
transition of PLGA at 30°C, (1b) the PLGA glass transition temperature 
midpoint of 54°C, (1c) after the PLGA glass transition temperature at 75°C, 
(1d) crystalline ampicillin at 103°C and (1e) the degradation of ampicillin at 
217°C. PLGA ACE:EtAc + ampicillin NF at (2a) before the glass transition 
of PLGA at 30°C, (2b) the PLGA glass transition temperature midpoint of 
54°C, (2c) after the PLGA glass transition temperature at 75°C, (2d) 
crystalline ampicillin at 102°C and (2e) the degradation of ampicillin at 
219°C. .......................................................................................................... 93 
Figure 3-20 Hot stage microscopic images of the thermal transitions and solid-state 
structure of PLGA DCM:DMF + paracetamol NF at (1a) before the glass 
transition of PLGA at 30°C, (1b) the PLGA glass transition temperature 
midpoint of 46°C, (1c) after the PLGA glass transition temperature at 70°C, 
(1d) crystalline paracetamol at 88°C and (1e) the degradation of paracetamol 
at 144°C. PLGA ACE:EtAc + paracetamol NF at (2a) before the glass 
transition of PLGA at 30°C, (2b) the PLGA glass transition temperature 
midpoint of 44°C, (2c) after the PLGA glass transition temperature at 70°C, 
 
xx 
(2d) crystalline paracetamol at 87°C and (2e) the degradation of paracetamol 
at 141°C. ...................................................................................................... 94 
Figure 3-21 Hot stage microscopic images of the thermal transitions in the PLGA 
DCM:DMF NF at (1a) before the glass transition of PLGA at 30°C, (1b) the 
PLGA glass transition temperature midpoint of 50°C, (1c) after the PLGA 
glass transition temperature at 75°C, (1d) before the degradation of PLGA at 
100°C and (1e) the degradation of PLGA at 230°C. PLGA ACE:EtAc NF at 
(2a) before the glass transition of PLGA at 30°C, (2b) the PLGA glass 
transition temperature midpoint of 50°C, (2c) after the PLGA glass transition 
temperature at 75°C, (2d) before the degradation of PLGA at 100°C and (2e) 
the degradation of PLGA at 230°C ............................................................. 95 
Figure 3-22 In vitro cumulative release of tetracycline, ampicillin and paracetamol from 
PLGA DCM:DMF and PLGA ACE:EtAc NF (A) over the first 12 h and (B) 
over 504 h. PLGA DCM:DMF + tetracycline (orange dashed line), PLGA 
ACE:EtAc + tetracycline (orange line), PLGA DCM:DMF + ampicillin 
(green dashed line), PLGA ACE:EtAc + ampicillin (green line), PLGA 
DCM:DMF + paracetamol (blue dashed line) and PLGA ACE:EtAc + 
paracetamol (red line).  Mean ± SD, n=3. ................................................... 97 
Figure 4-1 Chemical structure of the poly-(caprolactone) repeating monomer unit. .. 110 
Figure 4-2 Chemical structure of the PEO repeating monomer unit. .......................... 116 
Figure 4-3 Schematic representation of polymer erosion of (a) surface erosion, when 
hydrolysis of the polymer bonds is faster than the diffusion of water into the 
bulk of the polymer and degradation proceeds at the surface. (b) Bulk erosion, 
when the polymer degrades equally throughout the whole material, the 
volume of the material remains the same while the mass reduces. Figure 
adapted from Rohman G. Biodegradable polymers: recent developments and 
new perspectives. Rohman G, editor. Zagreb, Croatia: IAPC Publishing; 
2017, pp.108-140 [380]. ............................................................................ 122 
Figure 4-4 FE-SEM micrographs of electrospun PCL and PCL/blend NFs. (a) PCL, (b) 
PCL/CH, (c) PCL/GEL and (d) PCL/PEO NF. ......................................... 127 
Figure 4-5 Diameter range and distribution histogram of electrospun PCL and 
PCL/blend NFs: (a) PCL NF, (b) PCL/CH NF, (c) PCL/GEL NF and (d) 
PCL/PEO NF. ............................................................................................ 128 
Figure 4-6 The mean fibre diameter of electrospun PCL and PL/blend NFs. Bars 
represent the mean of 100 fibres from each NF ±SD. Statistical significance 
was determined by one-way ANOVA with Dunnett’s multiple comparison 
test, *p < 0.05, ***p <0.001 and is the comparison of the PCL NF to blend 
NF groups. ................................................................................................. 129 
Figure 4-7 ATR-FTIR spectra of pure PCL (grey line) and PCL NF (blue line). Each line 
represents the mean of three independent experiments. ............................ 131 
 
xxi 
Figure 4-8 ATR-FTIR spectra of pure PCL (grey line), pure chitosan (black line) and 
PCL/CH NF (orange line). Each line represents the mean of three 
independent experiments. .......................................................................... 131 
Figure 4-9 ATR-FTIR spectra of pure PCL (grey line), pure GEL (black line) and 
PCL/GEL NF (yellow line). Each line represents the mean of three 
independent experiments. .......................................................................... 132 
Figure 4-10 ATR-FTIR spectra of pure PCL (grey line), pure PEO (black line) and 
PCL/PEO NF (green line). Each line represents the mean of three 
independent experiments. .......................................................................... 132 
Figure 4-11 TGA curves of pure polymers and electrospun PCL and PCL/blend NFs. (a) 
pure PCL (grey line) and PCL NF (blue line), (b) pure CH (black line), 
PCL/CH NF (orange line) and PCL NF (blue line), (c) pure GEL (black line), 
PCL/GEL NF (yellow line) and PCL NF (blue line) and (d) pure PEO (black 
line), PCL/PEO NF (green line) and PCL NF (blue line). ........................ 134 
Figure 4-12 XRD patterns of pure polymers and electrospun PCL and PCL/blend NFs. 
(a) pure PCL (grey line) and electrospun PCL NF (blue line), (b) pure CH 
(black line), PCL/CH NF (orange line) and PCL NF (blue line), (c) pure GEL 
(black line), PCL/GEL NF (yellow line) and PCL NF (blue line) and (d) pure 
PEO (black line), PCL/PEO NF (green line) and PCL NF (blue line). ..... 135 
Figure 4-13 DSC thermogram over the range of -80-160C of pure PCL (grey line), PCL 
NF (blue line). Inset of (a) PCL glass transition temperature and (b) PCL NF 
glass transition temperature. ...................................................................... 138 
Figure 4-14 DSC thermogram over the range of -80-160C of pure CH (black line), 
PCL/CH NF (orange line) and PCL NF (blue line). Inset of (a) PCL NF glass 
transition temperature and (b) PCL/CH NF glass transition temperature. 138 
Figure 4-15 DSC thermogram over the range of -80-160C of pure GEL (black line), 
PCL/GEL NF (yellow line) and PCL NF (blue line). Inset of PCL NF glass 
transition temperature (blue line) and PCL/GEL NF glass transition 
temperature (yellow line). .......................................................................... 139 
Figure 4-16 DSC thermogram over the range of -80-160C of pure PEO (black line), 
PCL/PEO NF (green line) and PCL NF (blue line). Inset of PCL NF glass 
transition temperature (blue line) and PCL/PEO NF glass transition 
temperature (green line). ............................................................................ 139 
Figure 4-17 The maximum tensile strength of PCL and PCL/blend NFs. Bars represent 
the mean of three independent experiment ±SD. Statistical significance was 
determined by one-way ANOVA with Dunnett’s multiple comparison test, 
*p < 0.05, ***p < 0.001 and is the comparison of the PCL NF to blend NF 
groups. ....................................................................................................... 140 
Figure 4-18 Kinetics of water contact angles on the surface of PCL and PCL/blend NFs 
over a 300 s period. PCL (blue line), PCH/CH (orange line), PCL/GEL 
(yellow line) and PCL/PEO (green line). Each line represents the mean of 
 
xxii 
three individual experiments ± SD. Statistical significance was determined 
by two-way ANOVA with Bonferroni’s post hoc test, ***p < 0.001 and is 
the comparison of the PCL NF to PCL/blend NF groups.......................... 141 
Figure 4-19 Water droplets on the surface of PCL and PCL/blend NFs at 1 and 300 s. (a) 
PCL NF at 1 s, (b) PCL NF at 300 s, (c) PCL/CH NF at 1 s, (d) PCL/CH NF 
at 300 s, (e) PCL/GEL at 1 s, (f) PCL/GEL at 30 s,  (g)  PCL/PEO NF at 1 s 
and (h) PCL/PEO NF at 300 s. .................................................................. 142 
Figure 4-20 Mass loss from PCL and PCL/blend NFs over a 4-week time period in 
phosphate buffered saline (pH 7.4) at 37°C. PCL (blue line), PCL/CH 
(orange line), PCL/GEL (yellow line) and PCL/PEO (green line). Straight 
lines have been used between the points and each point represent the mean 
±SD of three independent experiments. .................................................... 143 
Figure 4-21 In vitro cumulative release of L-655,708 from PCL and PCL/blend NFs in 
phosphate buffer saline (pH 7.4) at 37°C, (A) over the first 12 h and (B) over 
504 h. PCL (blue line), PCL/CH (Orange line), PCL/GEL (yellow line) and 
PCL/PEO (green line). Mean ±SD, n=3. ................................................... 145 
Figure 4-22 In vitro cumulative drug release from PCL/CH NF in phosphate buffered 
saline (pH 7.4) at 37°C, (A) over the first 8 h and (B) over 504 h. 
Indomethacin (blue line), L-655,708 (Orange line), Mean ±SD, n=3. ...... 147 
Figure 4-23 Cell viability of fibroblast cells after incubation of the cells on the NF 
surface. NHDF cells were seeded on NF for a) 24, b) 48 and c) 72 h at 37°C 
5% CO2. Cell viability was determined using the MTT assay. Bars represent 
the mean of three independent experiments ±SD. Statistical significance was 
determined by two-way ANOVA with Bonferroni’s post hoc test, *p < 0.05, 
***p < 0.001 and is the comparison of the control (cells grown on cell culture 
well) to treatment groups. .......................................................................... 149 
Figure 4-24 Secretion of pro-inflammatory cytokines from NHDF cells when incubated 
on NFs at 37°C 5% CO2. a) TNF-α, b) IL-6, c) IL-10, d) IL 12p70 and e) 
MCP-1. Media was collected after 24 and 48 h, cytokine concentrations were 
determined by flow cytometry and LPS was used as the positive control. Bars 
represent the mean of three independent experiments ±SD. Statistical 
significance was determined by two-way ANOVA with Bonferroni’s post 
hoc test, ***p < 0.001 and is the comparison of the non LPS control to 




List of tables 
Table 1-1 Class I residual organic solvents to be avoided during the manufacture of 
nanofibres due to being carcinogenic and toxic. ......................................... 27 
Table 1-2 Class II residual organic solvents that should be limited to patients and should 
not exceed the permitted daily exposure limits. .......................................... 27 
Table 2-1 The processing parameters used for the polymer/solvent solutions of poly-
(lactic-co-glycolic acid) acetone:ethyl acetate, poly-(lactic-co-glycolic acid) 
dichloromethane:dimethylformamide, poly-(caprolactone), poly-
(caprolactone)/chitosan, poly-(caprolactone)/gelatine, poly-
(caprolactone)/poly-(ethylene oxide) and the associated drugs for 
electrospinning a solution into a nanofibre. ................................................. 45 
Table 3-1 Common solvent systems used to electrospin PLGA. .................................. 61 
Table 4-1 USP Class II solvents frequently used to electrospin PCL. USP exposure limits 
and assessments of Class II solvents are given. Adapted from USP 40, 
Residual Solvents [86]. .............................................................................. 112 
Table 4-2 USP Class III solvents used to electrospin PCL and assessment. Adapted from 
USP 40, Residual Solvents [86]. ............................................................... 113 
Table 4-3 Electrospinning parameters for nanofibre formation. ................................. 126 
Table 4-4 Enthalpy of fusion and crystallinity as determined from DSC data of polymers 




List of abbreviations 
α5-GABAAR Alpha-5-gamma-aminobutyric acid A receptor 
ε Dielectric constant 
AA Acetic acid 
ACE Acetone 
ACN Acetonitrile 
AFM Atomic force microscopy 
ATR-FTIR Attenuated total reflectance Fourier-transform infrared 
spectroscopy 
BBB Blood-brain barrier 
BCRP Breast cancer resistant protein 
BDNF Brain-derived neurotrophic factor 
CA Cellulose acetate 
CBA Cytometric bead assay 
CH Chitosan 
CHCl3 Chloroform 
CNS Central nervous system 
CsA Cyclosporine A 
DCM Dichloromethane 
DMEM Dulbecco’s modified eagle medium 
DMF N, N-dimethylformamide 
DMSO Dimethyl sulfoxide 
DSC Differential scanning calorimetry 
EGF Epidermal growth factor 
EMD Endovascular mechanical device 
EPO Erythropoietin 
EtAc Ethyl acetate 
FA Formic acid 
FBR Foreign body response 
FBS Fetal bovine serum 
FDA U.S. food and drug administration 
FE-SEM Field emission-scanning electron microscopy 
FITC-BSA Fluoroscein isothiocyanate-conjugated bovine serum albumin 
GA Glycolic acid 
GABA Gamma-aminobutyric acid 
GEL Gelatine 
GDNF Glial cell line-derived neurotrophic factor 
GFAP Glial fibrillary acidic protein 
HA Hyaluronan acid 
HAMC Hyaluronan acid and methyl cellulose 
HCl Hydrochloric acid 





LA Lactic acid 
LDH  Lactate dehydrogenase 
 
xxv 
LPS Lipopolysaccharide  
MeOH   Methanol 
MRP   Multidrug resistance-associated protein 
MTT 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide 
MW Molecular weight 
NF Nanofibre 
NHDF Normal human-derived fibroblast 
O/W Oil-in-water 
PBS Phosphate buffered saline 
PCL Poly-(caprolactone) 
PCLEEP Poly-(caprolactone-ethyl ethylene phosphate) 
PDE Permitted daily exposure  
PDLA Poly-(D, L-lactic acid) 
PEG Poly-(ethylene glycol) 
PEG-EGF Poly-(ethylene glycol) modified epidermal growth factor 
PEO Poly-(ethylene oxide) 
PEVA Poly-(ethylene-co-vinyl acetate) 
PGA Poly-(glycolic acid) 
P-gp P-glycoprotein 
PLA Poly-(lactic acid) 
PLGA Poly-(lactic-co-glycolic acid) 
PVA Poly-(vinyl alcohol) 
PVP Poly-(vinyl pyrrolidone) 
RP-HPLC Reverse-phase high-performance liquid chromatography 
Tg Glass transition temperature 
TGA Thermogravimetric analysis 
THF Tetrahydrofuran 
Tm Melting temperature 
TNF-α Tumor necrosis factor-alpha 
ToF-SIMS Time of flight-secondary mass spectroscopy 
tPA Tissue plasminogen activator 
USP United States Pharmacopeia 
VEGF Vascular endothelial growth factor 
W/O Water in oil 
XPS X-ray photoelectron spectroscopy 











1 Introduction  
1.1 Neurological disorders  
Neurological disorders affecting the brain such as dementia, Parkinson’s, epilepsy and 
stroke are debilitating diseases that impair everyday living. In New Zealand it is 
estimated 62,287 people are affected by dementia, 9,500 live with Parkinson’s disease, 
45-50,000 people have epilepsy and approximately 9,000 people suffer a stroke every 
year with an estimated 50,000 stroke survivors in New Zealand as of 2018 [1–4]. The 
prevalence of these neurological disorders is set to increase as the population ages and 
currently, neurological disorders account for one in every five deaths in New Zealand 
[5]. While there is no cure for many neurological disorders, pharmacological intervention 
is available for some, that can help treat symptoms, however, this can be limited as the 
disorder progresses [6].  
 
1.1.1 Drug delivery for neurological disorders 
Oral delivery of an active drug provides a route to the systemic circulation and is one of 
the most common and convenient routes for drug administration [7–10]. However, the 
delivery of drugs to the brain via the systemic route poses a unique challenge. To be 
successful, the active drug must be transported into the brain via an active transporter, or 
if the drug is lipophilic in nature and less than 400-500 Da in molecular weight (MW), 
the drug can passively diffuse into the brain [11–13]. Although there are some U.S. Food 
and Drug Administration (FDA) approved drug classes such as cholinesterase inhibitors, 
for the treatment of Alzheimer’s, levodopa or dopamine agonists for Parkinson’s and 
anti-epileptic drugs for epilepsy, tissue plasminogen activator (tPA) is the only 
pharmacological intervention for the treatment of stroke. However, the success rate of 
new drugs for neurological disorders is poor [14,15]. The success rate of drugs targeting 
the central nervous system (CNS), defined by obtaining FDA marketing approval, was 
less than half the rate for non-CNS drugs for the period from 1995-2007 [16]. The low 
success rate is mainly attributed to the complex nature of the brain and the blood-brain 
barrier (BBB) and lack of sufficient technologies to overcome it [17]. 
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1.1.1.1 The blood-brain barrier: A hurdle for the treatment of neurological 
disorders 
The BBB is a highly selective permeable seal that limits the efficient transport of drugs 
from the circulating blood into the brain [18,19]. It is a specialised structure composed 
of tight and adherens junctions (Figure 1-1) that are formed between adjacent endothelial 
cells connecting the cell membranes, designed to protect the brain and restrict the 
transport of exogenous molecules [20]. Although over 40 proteins participate in tight 
junctions, the claudin and occludin transmembrane family of proteins are the main 
components [21,22]. These proteins span the intercellular space, establishing adhesion 
between cells of the BBB and provide a physical barrier [21,22]. Adherens junctions are 
composed of transmembrane cadherin proteins that bind to adjacent cell cadherin 
proteins forming homodimers that serve as the physical intercellular barrier [21]. 
Cadherin proteins also bind to catenin proteins, that in turn connect to actin filaments, 
anchoring the cytoskeleton of each cell together [21]. Consequently, this structure does 






Figure 1-1 Schematic overview demonstrating the tight and adherens junctions that make up 
the physical aspect of the blood-brain barrier of the CNS. The junctions are formed between 
endothelial cells and span the intracellular space to restrict the transport of exogenous 
molecules from the systemic blood circulation into the brain [21]. Figure adapted from Polakis, 
J. Cell bio. 2008, 183, (3), 371-373 [24]. 
 
The physical barrier has low permeability that allows the BBB to control the passage of 
ions and molecules into the brain from the systemic circulation by using transporters [25]. 
Efflux transporters such as P-glycoprotein (P-gp), work as a physiologically active 
barrier to remove exogenous molecules that have passed into the endothelial cells from 
the blood, inhibiting their transport into the brain (Figure 1-2) [26–28]. Efflux 
transporters include multi-drug resistant proteins such as P-gp, breast cancer resistant 
protein (BCRP) and multidrug resistance-associated protein (MRP) [25]. Generally, the 
efflux transporters are found on the luminal side of the endothelial cells and use the 
energy from the hydrolysis of adenosine triphosphate to drive the transport of molecules 
up their concentration gradient and back into the systemic blood circulation [25]. Small 
lipophilic molecules that could passively diffuse through the endothelial cell membrane 
are easily and efficiently removed by the transporters [25]. The transporters have a broad 
range of molecular selectivity to molecules however, each type of transporter does have 
some preferences to molecules with certain physicochemical properties [29]. P-gp shows 
specificity for molecules that are of low molecular weight (300-1,000 Da), amphipathic, 
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lipophilic, planar and either neutral or cationic at physiological pH [29]. BCRP removes 
molecules that are positively or negatively charged and conjugated to organic anions, 
while MRPs remove anionic and conjugated molecules [29]. Therefore, the BBB elicits 
a major physical and chemical hurdle to achieve a therapeutic concentration of drug in 
the brain for the treatment of neurological disorders. 
 
 
Figure 1-2 Schematic illustration of the multidrug-resistant protein P-glycoprotein (P-gp) 
(green shapes) that act as an active barrier removing exogenous molecules (blue triangles) that 
have passed from the systemic blood circulation into the central nervous system of the brain 
endothelial cell [27]. Efflux transporters use the energy from the hydrolysis of adenosine 
triphosphate to pump molecules up their concentration gradient and out of the BBB [27]. Figure 
adapted from Osherovich, L. Sci.-Bus. eXchange, 2009, 2, (19) 773 [30]. 
 
1.1.2 Implantable drug delivery systems 
An alternative approach to oral administration for neurological drug delivery is by 
surgically implanting a drug-eluting system into the brain. Implantation provides a drug 
with the ability to circumvent the BBB and directly target the desired site of action within 
the brain tissue. An implant that is surgically administered directly into the brain can 
release the active drug into the brain tissue near the implant in a controlled manner 
[31,32]. The result is a high drug concentration at the brain region while reducing 
systemic exposure of the drug, thereby decreasing adverse events caused by delivery of 
the drug to other tissues such as nausea, vomiting and hypotension in the case of levodopa 
[33]. An implant can also provide an extended drug exposure to the brain tissue, as 
delivery systems can release drug over a period of weeks [34,35]. Due to the potential 
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advantages, several different delivery systems have been investigated that can be 
surgically implanted into the brain [36–39]. 
 
1.1.2.1 Solid drug delivery implants  
Solid, implantable drug delivery systems can consist of a core composed of solid drug 
particles, encased by a polymeric membrane or drug can be distributed in a polymer 
matrix that forms a solid system [40–42]. Research into implantable controlled drug 
delivery technologies started in the 1960s, with the advent of a silicone-based polymeric 
reservoir [40]. The first commercial non-biodegradable implants came onto the market 
in the 1970s. Ocusert®, an eye implant, released an anti-glaucoma drug and Progestesert® 
was an intrauterine implant for contraception [42–44]. Both implants were developed by 
Alza Corporation and employed poly-(ethylene-co-vinyl-acetate) as a drug reservoir 
membrane [42–44]. Ocusert® released pilocarpine for one week, whilst Progestesert® 
released progesterone for up to one year [42,43]. The first implant that utilized silicone 
as the polymeric membrane material was Norplant® in the 1980s. Silicone tubes were 
filled with the contraceptive steroid levonorgestrel [42,43]. The first-generation implants 
were non-biodegradable, therefore, removal after the depletion of the drug was necessary, 
adding cost and associated risk with surgical removal. The problems associated with 
removal of the implants was evident with Norplant®. Incorrect insertion technique led to 
the implant being embedded too deep or displaced. Removal was difficult, with some 
reports of broken implants remaining in the patients or requiring a second incision to 
locate and remove the implant [42,45]. Norplant® was subsequently removed from the 
US market in 2002 [42]. Biodegradable polymers, e.g. poly-(lactic-co-glycolic acid) 
(PLGA), are now being investigated for drug delivery systems because a second surgery 
to remove the implant is not needed.  
 
There is currently only one drug delivery brain implant product in the market. Gliadel® 
is a wafer implant for the treatment of glioblastoma multiforme that gained FDA approval 
in 1996 [46,47]. The wafer is composed of a biodegradable poly-(anhydride) and the 
chemotherapeutic carmustine (Figure 1-3). After surgically removing the tumour, the 
wafer is placed in the tumour recess and provides the local delivery of the drug to the 
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surrounding tissue that is controlled by the degradation of the polymer. Gliadel® is 
currently approved and marketed in 30 countries worldwide [38,48]. 
 
 
Figure 1-3 Photograph of Gliadel® wafers being surgically implanted into a tumour recess 
following the surgical removal of a malignant glioma. Figure adapted from Maciej and Brem 
[49], reprinted with permission from Nature Publishing Group: Nature Reviews Drug Discovery 
2004, 3 (6), 499-508, copyright 2004. 
 
A major limitation to the success of solid implants is their poor biocompatibility [50]. 
Generally, the body’s immune system identifies an implant as a foreign body and triggers 
an immune reaction called the foreign body response (FBR) [51]. Implants in the CNS 
activate microglial cells that extend processes toward the surface of the implant and after 
approximately 24 h, microglia cell bodies surround the implant forming a thin capsule 
[52–54]. After approximately 1-week, a layer of astrocyte cells develops a compact 
sheath, forming a glial scar [52–54]. The glial scar encapsulates the implant, this can 
hinder drug release from the implant or reduce the diffusion of the drug to the site of 
action within the brain tissue [55,56]. The extent of the FBR is influenced by the size, 
shape, surface chemistry and morphology of the implant [57–61]. For example, studies 
of periphery macrophages have shown a preference for rough surfaces over smooth ones 
and elongate of the macrophages on implants with grooved structures [57,60]. The 
surface chemistry of implants can be manipulated with the addition of different chemical 
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functional groups to control protein binding. For instance, poly-(propylene) particles 
coated with –OH2 and –NH2 surface groups caused a thick fibrous capsule, in contrast, 
particles with –COOH coated surfaces showed a decreased fibrotic response [58]. 
Spherical materials 1.5 mm in diameter have been shown to reduce the FBR compared 
to spheres with a diameter of 0.5 mm or materials with different shapes [61]. The reduced 
FBR is thought to be because fewer macrophages are surrounding the larger spheres, 
these macrophages are also not becoming activated and recruiting macrophages to the 
area [61]. With a better understanding of the implant properties and the FBR, implants 
can be designed to reduce the FBR and improve and prolong drug release. 
 
1.1.2.2 Hydrogel implants for drug delivery to the brain  
Hydrogels are composed of cross-linked polymer(s) and have a high water content 
(typically 70-99%) [62]. The gelation rates, porosity and water content can be altered 
depending on the polymers and crosslinking methods used, leading to the loading of both 
small or macromolecules and tailored drug release through the gel network [63–65]. 
Hydrogel gelation can take place ex vivo or in situ. Ex vivo gelation requires surgery to 
implant the gel whereas in situ gelling allows the hydrogel to be injected through a needle 
to the desired location in the body where it forms the hydrogel once at the tissue site [62]. 
In situ gelling hydrogels have been developed that respond to a stimulus such as pH or 
temperature to trigger the gelation and facilitate subsequent drug release, which can be 
desirable for brain delivery due to ease of application [66–68].  
 
Hydrogels have been investigated as drug delivery systems targeting different parts of 
the body for a range of conditions, including the brain to treat neurological disorders 
[62,63,69]. A hydrogel formulated using poly-(N-isopropylacrylamide) and crosslinked 
with poly-(amidoamine) was loaded with activin B for the treatment of Parkinson’s 
disease [36]. The drug-loaded hydrogel was administered by stereotaxic injection to the 
mouse striatum [36]. Using the open field and rotarod test, an improved behavioural 
outcome was observed in a mouse Parkinson’s disease model that received drug-loaded 
hydrogel [36]. The immunohistochemistry data concluded the activin B could be detected 
in the brain 5-weeks after drug-loaded hydrogel implantation. The study demonstrated 
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the hydrogel delivery system can deliver a drug for 5-weeks although, this a short 
timeframe as Parkinson’s disease is a chronic condition [36]. 
 
Hyaluronan (HA) based hydrogels are appealing for brain implantation because 
hyaluronan is a component of the extracellular matrix that provides structural support to 
surrounding cells, therefore, delivery systems made from this material have excellent 
biocompatibility [70]. A hydrogel composed of HA and methylcellulose (HAMC) that 
forms a physical cross-link via hydrogen bonds has been used to release the protein 
erythropoietin (EPO) to stimulate endogenous stem cells and aid in stroke recovery [71]. 
The hydrogel was injected under the skull but on the surface of the rat brain, known as 
epi-cortical delivery [71]. Although infarct size was reduced following administration of 
the hydrogel, the limitation with this approach is the drug needs to diffuse through the 
brain tissue to reach the target site [71]. While epi-cortical hydrogel delivery may be 
acceptable in rats, because protein diffusion has been reported to be 1-2 mm through the 
rat brain tissue, in humans the distance the protein needs to travel through the brain is 
even more pronounced (65–67). Therefore, protein delivery from an epi-cortical 
implanted hydrogel may not be feasible in a clinical setting due to the short diffusion 
distance of protein drugs [72].  
 
The drug release profile from hydrogels tends to be rapid in vitro or in vivo, with drug 
release occurring over hours to days [63]. Large molecules such as proteins typically take 
longer to diffuse out of the porous hydrogel structure and have an attenuated burst 
release, however, small molecules are less hindered, easily diffusing through the pores 
and, therefore, rapid drug release occurs during the initial hydrogel swelling [63,69]. Our 
research group investigated the in vitro release of the low MW drug L-655,708 (MW 
341.36 g/mol) from Extracel-HP™, a hydrogel composed of thiol-modified hyaluronate, 
thiol-modified gelatine, and crosslinked with poly-(ethylene diacrylate). The release was 
rapid with an initial burst release of 20% after 1 h and by 8 h, 80% of the drug was 
released [73]. A disadvantage, however, with hydrogels is that the rapid release of some 
drugs can cause local toxicity to the surrounding tissue. For example, bupivacaine caused 





Many small molecules are poorly water-soluble, this makes hydrophobic drug loading 
difficult and inefficient in the hydrogel environment due to the hydrophilic nature of 
hydrogels [63]. For example, solid molecular dispersions of the hydrophobic drugs 
naproxen and piroxicam loaded into a poly-(2-hydroxyethyl methacrylate) hydrogel 
resulted in a maximum loading level of 17% w/w for naproxen and 10% w/w for 
piroxicam [75]. In contrast, the maximum loading level for the more soluble sodium 
diclofenac in the hydrogel was 41% w/w [75]. Furthermore, the extent to which a 
hydrogel swells or the amount of hydrogel injected into the brain can also hinder its 
application for brain delivery, as excess swelling or the amount injected can put pressure 
on the surrounding brain tissue or cause further brain damage in the case of stroke 
[76,77]. For example, an injection to the stroke cavity with 8 mg/mL of in situ forming 
hydrogel, resulted in a 67% increase in intracranial pressure [77]. The pressure was 
reduced to 10% when a drainage hole was used to displace excess fluid within the cavity 
while simultaneously injecting the hydrogel [77].  These limitations with hydrophobic 
drug loading and excess swelling may limit hydrogels as a successful drug delivery 
system for the CNS. 
 
1.1.2.3 Microparticle implants for drug delivery to the brain 
Microparticles are another drug delivery system that have been employed to deliver an 
active drug to the brain (Figure 1-4). Microparticles are composed of polymers and can 
be fabricated by several different techniques and the method used will depend on the 
formulation properties, i.e. drug chemical properties, stability of biomacromolecules and 
particle size, as well as the desired characteristics of the formulation including controlled 
drug release and dispersion in aqueous vehicles for injection [78–80].  For example, 
double emulsion techniques can be employed to improve the encapsulation of 
hydrophilic drugs [80]. Spray drying has been employed to improve the stability of 






Figure 1-4 Illustration depicting the encapsulation of the active drug (orange spheres) in 
microparticles (blue spheres). The microparticles are approximately 100 μm in diameter. 
Adapted from Cavanagh. CC BY-NC, Welcome collection, 
https://wellcomecollection.org/works/df6vfbzr. 
 
Drug release from microparticles can occur by three mechanisms, 1) drug release due to 
erosion of the polymer, 2) diffusion of the drug through the microparticle polymer matrix, 
and 3) release of drug from the surface of the microparticle [81]. Microspheres composed 
of poly-(caprolactone) (PCL) and loaded with phenytoin using an oil-in-water (O/W) 
emulsion solvent evaporation method were investigated as injectable drug-loaded 
microspheres for the treatment of frontal lobe epilepsy [37]. During the first 2 days of in 
vitro release, 80% of phenytoin had been released from the microspheres and this 
increased to 90% after day 4 [37]. The microspheres containing the drug were injected 
into the hippocampus of a rat model of temporal lobe epilepsy, induced by an injection 
of tetanus toxin [37]. A reduced number of seizures within 3 days of in vivo implantation 
occurred, corresponding with the in vitro release data. However, there was no statistically 
significant difference in the number of seizures after 3 days between rats that received 
drug-loaded microspheres and rats that received blank microspheres [37]. The rapid 
release of phenytoin from the microspheres indicates drug release is by diffusion rather 
than a sustained release from polymer degradation, thus repeat injections would be 




Microparticles composed of PLGA are the most commonly employed polymer system to 
deliver a range of pharmaceutical compounds for different therapeutic conditions. 
However, a burst release is often observed from PLGA microparticles [82]. PLGA 
microspheres prepared using a water-in-oil-in-water emulsion solvent evaporation 
technique were loaded with glial cell line-derived neurotrophic factor (GDNF) for the 
treatment of Parkinson’s disease [83]. The in vitro drug release demonstrated 67% of 
GDNF was released over 40 days however, an initial burst release of ~40% was observed 
over the first day [83]. A burst release of the drug can cause potential toxic effects to the 
surrounding tissue but also shorten the release profile limiting the effectiveness of the 
delivery system over the regenerative period [80,84].  
 
In the application for stroke, retaining the microparticles within the stroke cavity is 
another hurdle to overcome. Following administration, the microparticles may move 
away from the site of action due to cerebrospinal fluid flow thus, reducing the therapeutic 
effect [85]. Other potential drawbacks of microparticles include low drug loading 
efficiency, uncontrollable microparticle size and distribution from scaling up to larger 
production and toxicity that may be caused by residual solvents, stabilisers or emulsifiers 
used during the formation of particles[78,80]. Due to the different methods employed to 
produce microparticles, the residual solvent concentration is likely to be variable across 
the different methods therefore, residual solvents should be quantified as outlined in the 
United States Pharmacopeia [86].  
 
1.1.2.4 Hydrogel composite implants for drug delivery to the brain 
To combat the shortcomings of microparticles and hydrogels, drug-loaded micro/nano-
particles have been encapsulated in hydrogels to provide controlled release of the active 
drug (Figure 1-5) [87–90]. The microparticles provide controlled release properties and 





Figure 1-5 Illustration of microparticles (blue spheres) containing the active drug (orange 
spheres) entrapped in the hydrogel matrix (green lines) forming the hydrogel composite. The 
entrapment of the microparticles in the hydrogel is thought to attenuate the burst release of the 
active drug. Figure adapted from Zhao et al. Nanomaterials, 2015, 5 (4), 2054-2130 [91].  
 
Microspheres entrapped in a hydrogel have been used for the controlled delivery of 
cyclosporine A (CsA), an immunosuppressant that has neuroprotective and neuro-
regenerative effects [92,93]. CsA was loaded into PLGA microspheres using an O/W 
emulsion solvent evaporation technique, the microspheres were then entrapped in a 
HAMC hydrogel [94]. The in vitro release of CsA from the hydrogel composite was 
compared to a CsA HAMC hydrogel and CsA particulates dispersed in HAMC. The 
release rate of CsA from the HAMC hydrogel was rapid, with a burst release of ~90% 
after day 1 and 100% release by day 2 [94]. Particulate CsA dispersed in HAMC hydrogel 
had a sustained release of 7-10 days, while CsA release from microspheres encapsulated 
in HAMC was over 28 days with little to no burst release [94]. The same group compared 
epi-cortical delivery of the HAMC hydrogel containing CsA loaded microspheres to CsA 
administrated via subcutaneous osmotic mini-pump in a stroke injured rat model induced 
by injecting endothelin-1. Delivery of CsA loaded microspheres entrapped in the HAMC 
hydrogel was more efficient and less toxic to non-CNS organs. The in vivo sustained 




In an extension of the concept of encapsulating drug-loaded microparticles into 
hydrogels, the hydrogel can act as a carrier system to deliver multiple microparticles 
loaded with different drugs. Epidermal growth factor (EGF) was modified with poly-
(ethylene glycol) (PEG)  to form PEG-EGF and this was loaded into PLGA nanoparticles 
using the double emulsion method [96]. Secondly, EPO was encapsulated in a delivery 
system consisting of a PLGA nanoparticle core coated in poly-(sebacic acid) by single 
emulsion, to produce a biphasic microparticle [96]. Each particulate system was then 
embedded in the same HAMC hydrogel [96]. In vitro studies revealed 75% of PEG-EGF 
was released after day 4 with 100% release after 2 weeks. The initial release of EPO was 
low out to day 4 and then increased linearly to 100% release after 28 days [96]. The 
hydrogel composite was applied epi-cortically to the rat brain for the treatment of stroke. 
The in vivo release profile of both of the active drugs was comparable to in vitro, with 
80% of PEG-EGF released after 7 days and ~80% of EPO release after 21 days [96]. 
Although a sustained period of drug release occurred, the delivery system is rather 
complex making it difficult to scale up to larger production. The hydrogel composite was 
also not directly injected into the stroke cavity but rather applied epi-cortically. As 
discussed in Section 1.1.2.2, protein drugs have poor penetration through brain tissue 
[96]. Therefore, the system relies on the particles to diffuse through the brain to reach the 
target site. As the particles diffuse through the brain, the drug is being released, this limits 
the amount of drug reaching the target site.  
 
The fabrication process of microparticles is thought to influence the release profile of the 
active drug. PLGA microspheres loaded with either brain-derived neurotrophic factor 
(BDNF) or vascular endothelial growth factor (VEGF) were entrapped in a crosslinked 
HA hydrogel [97]. The PLGA microsphere loading efficiency was 52% and 84% for 
VEGF and BDNF, respectively [97]. The in vitro release rate from the microspheres for 
VEGF and BDNF was 30 and 20% of total drug-loaded, for 150 h with no apparent burst 
release [97]. During the fabrication process, the microspheres were washed to remove 
any surface-bound protein and the washing step is thought to be the reason as to why no 
initial burst release was observed [97]. However, a drawback to washing the 
microspheres is the total amount of drug-loaded will be reduced, as surface-bound protein 




While the hydrogel composites may address microparticle instability, retention in the 
brain tissue and the drug release limitations of the individual systems, drug loading 
efficiency and microparticle size reproducibility are still issues that need to be overcome. 
The complexity of the system is also a drawback to progress this approach further into a 
clinical application due to difficulties with larger-scale up production. 
 
1.1.3 Nanofibres as an implantable drug delivery system 
Nanofibres (NF) are a recent development in the drug delivery field and are made up of 
a network of fibres in the nanometre diameter range (Figure 1-6). The structure and 
properties of NFs has led to the investigation of a wide variety of applications including 
protective clothing, cosmetics, energy generation, filtration, biosensors, and medical 
applications such as tissue engineering, wound healing scaffolds and drug delivery 
systems [98–103]. Due to their structure and properties, that include a high surface area 
to volume ratio, high porosity, excellent mechanical strength and flexibility, the NF can 





Figure 1-6 A scanning electron micrograph at 5,000x magnification displaying the intricate 
matrix of a nanofibre (NF) network. The NF was prepared by electrospinning poly-
(caprolactone) and chitosan at a 50:50 ratio with a solvent system consisting of acetic acid and 
formic acid. 
 
The first report of a NF mat as a drug delivery system was published in 2002 [104].  The 
report investigated the in vitro release of tetracycline hydrochloride from NF composed 
of poly-(lactic acid) (PLA), poly-(ethylene-co-vinyl acetate) (PEVA) or a 50:50 blend of 
the two, for the potential as a drug-releasing system to treat periodontal disease [104]. 
By using different polymers in the fabrication of the drug-loaded NF, the release rate was 
altered. The release after 120 h for PLA, PLA/PEVA blend (ratio of 50:50) and PEVA 
was 35, 40 and 60%, respectively [104]. 
 
NF-based drug release implants have been investigated for several disease states. For 
instance, the antibiotic vancomycin or ceftazidime was dissolved in 1, 1, 1, 3, 3, 3-
hexafluoro-2-propanol (HFIP) with PLGA and electrospun into a NF for the treatment of 
bone infection known as osteomyelitis [35]. An initial burst release after 2 days followed 
by a sustained release for 32 days was observed in vitro [35]. To treat osteomyelitis, the 
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drug-eluting NFs were enveloped on the surface of a stainless steel plate for implantation 
in rabbits. A sustained in vivo release of vancomycin occurred over 8 weeks, while 
ceftazidime displayed a fast release rate over 7 days followed by a sustained release over 
8 weeks. In both cases, the drug concentration remained higher than the minimum 
inhibitory concentration in the blood required to inhibit organism growth [35].  Another 
example is the incorporation of titanocene dichloride in a PLA NF that was assessed in 
vitro for the treatment of lung cancer [105]. After 180 h, the release rate ranged from 
15% in phosphate-buffered saline (PBS) to 90% release in PBS containing proteinase K, 
due to proteinase K increasing the degradation rate of PLA [105]. Antitumor activity 
against human lung tumour spc-a-1- cells was observed when incubated with titanocene 
dichloride loaded NF in vitro, indicating the NF drug delivery system has potential as an 
implant after surgery for the treatment of lung cancer [105]. 
 
NFs have been investigated as an improved alternative for the current drug delivery 
system Gliadel® for malignant glioblastoma multiforme (Section 1.1.2.1). Ranganath and 
Wang (2008) selected PLGA as the polymer of choice due to the ability to tailor drug 
release and polymer degradation, by altering the lactic to glycolic acid ratio. In vitro 
release of paclitaxel-loaded PLGA NF occurred over 80 days, with release ranging from 
26-45% from the 4 different formulations. Cell culture studies revealed constant 
apoptosis of C6 glioma cells for 12 days when incubated with the drug-loaded NF 
indicating the release rate was within the therapeutic range [106]. Furthermore, 
paclitaxel-loaded NF surgically implanted into glioma tumours of mice had a larger 
reduction in tumour growth after 24 days compared to a direct injection of paclitaxel into 
the tumour [106]. Similarly, electrospun blends of PLGA, PLA and poly-(caprolactone) 
(PCL) loaded with the anticancer drug temozolomide as a drug delivery implant system 
for combating brain tumours were investigated [34]. By altering the ratio of the polymers 
in the blend solution, the in vitro release profile of the drug was able to be changed [34]. 
Six formulations were fabricated and the release profiles ranged from 100% over 16 days 
with an initial burst release of ~75% to 20% release after 30 days and no burst release. 
The implant that produced a release of 20% over 30 days was selected to take forward in 
an animal model, where it was surgically implanted into a C6 glioma tumour [34]. The 
release was faster in vivo than in vitro with an initial burst release of 75% and 100% 
release after 7 days. This implant was then optimised by changing the polymer blend 
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composition and new implants were tested in vivo; the initial burst release ranged from 
~20-60% and the sustained release ranged from ~15-80% after 30 days [34]. 
Furthermore, 85% of animals survived more than  4 months when they received an 
implant with drug release of up to 30 days [34]. Both studies demonstrate the ability to 
alter the release profile of the active drug from the NF by changing the blend ratio of 
polymers and although in vivo release was faster than in vitro, the in vivo effects were 
observed for 3 weeks or more.  
 
1.2 Production of nanofibres using the electrospinning technique 
The first report of electrospinning was in the 1930s but since then, electrospinning has 
only gained traction in recent years mainly due to the increased interest and rise of 
nanotechnology [107]. Producing NF is a relatively simple technique for the fabrication 
of continuous fibres with diameters in the nanometre range [108,109]. The low cost, 
reproducibility and the industrial scale-up potential of electrospinning warrants it as an 
attractive process for development as a drug delivery system. The method for producing 
NFs involves dissolving a polymer in a solvent(s) and applying a high voltage to the 
solution [108]. A charged droplet is formed that is held by its surface tension [108,110]. 
As the voltage is increased, charge separation occurs and a Taylor cone is formed (Figure 
1-7). When the applied voltage is sufficient to overcome the surface tension of the 
solution, a charged polymer jet is ejected from the Taylor cone [108,110]. The jet 
accelerates towards a grounded electrode and undergoes a whipping and stretching 
action. The solvent evaporates leaving the solution to solidify, forming a fibrous network 
on the grounded electrode target (rotating mandrel or flat metal surface) (Figure 1-7). 
Processing (Section 1.2.1) and solution parameters (Section 1.2.2) involved in the 
electrospinning process are important for the successful conversion of a polymer solution 





Figure 1-7 Schematic representation of a typical electrospinning setup. After the formation of 
the Taylor cone at the needle tip, NF is ejected and collected on the grounded rotating collector 
when the applied voltage overcomes the surface tension [108]. Figure adapted from Sorayani 
Bafqi et al. J. Polymer Res. 2015, 22, 130 [111]. 
 
1.2.1 Electrospinning processing parameters and their effect on the nanofibre 
1.2.1.1 Applied voltage  
The high voltage applied to the polymer solution causes it to form a conical shape and 
charge separation occurs, and at a crucial voltage, a nano-sized fibre will eject from the 
cone as it overcomes the surface tension. This concept was first described by Geoffrey 
Taylor in 1964, hence the term Taylor cone [112]. Applied voltage influences fibre 
diameter, however, the extent of this differs depending on several factors [113,114]. A 
higher voltage applied to the polymer solution results in an increase in repulsive 
electrostatic forces at the Taylor cone and stretching in the fluid jet, resulting in a reduced 
fibre diameter [115–118]. However, increasing the applied voltage can lead to bead 
formation and larger diameter fibres thought to be because more fluid is ejected from the 




1.2.1.2 Flow rate 
For needle-based electrospinning setups (Figure 1-7), the flow rate of the polymer 
solution influences the formation of the Taylor cone and fibre morphology. If the flow 
rate is too slow the Taylor cone cannot be maintained as there is inadequate polymer at 
the capillary tip to replace the solution ejected to form the NF jet [122,123]. Higher flow 




Figure 1-8 A scanning electron micrograph depicting a single NF with ribbon-like morphology 
prepared from polystyrene. Figure adapted from Megelski et al. [122]. Reprinted with 
permission from American Chemical Society: Macromolecules 2002, 35 (22), 8456-8466, 
copyright 2002. 
 
The larger NF diameter and bead formation was attributed to insufficient solvent 
evaporation or drying of the fibres due to the increased flow rate [122,123]. Another 
study demonstrated, when all other parameters were kept constant, poly-(D, L-lactic acid) 
(PDLA) NF diameter was reduced when the solution flow rate was slowed; this is in 
agreement with work by Megelski et al. [124]. 
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1.2.1.3 Distance from needle to the collector 
The NF jet stretches as it ejects from the Taylor cone and traverses the distance between 
the spinneret and the collector. A reduction in fibre diameter by 2-fold, from 19 to 9 μm 
when the distance was lengthened from 1 to 3.5 cm for electrospun poly-(ethylene oxide) 
(PEO) NF has been observed [109]. Matabola and Moutloali (2013) demonstrated that 
the fibre diameter of poly-(vinylidene fluoride) was reduced from 397 nm to 314 nm 
when the electrospinning distance was increased from 15 to 16 cm [125]. In another study 
using poly-(vinyl alcohol) (PVA), when the distance was increased from 8 to 10 cm, the 
bead structures (Figure 1-9) in the NF disappeared to form smooth fibres [126]. 
 
 
Figure 1-9 A scanning electron micrograph demonstrating bead formation along the length of 
the PEO NF after electrospinning. Figure adapted from Fong et al. [127]. Reprinted with 
permission from Elsevier: Polymer 1999, 40, 4585-4592, copyright 1999. 
 
Furthermore, the diameter of the fibres reduced from 266 to 93 nm. When the distance 
was increased to 16 cm, there was a loss in fibre uniformity and cracks in the fibre 
appeared [126]. This was believed to be due to weak electrostatic forces in the fibre 




1.2.1.4 Temperature and humidity 
In general, temperature impacts the polymer solution viscosity, that in turn affects fibre 
diameter [128,129]. Mit-uppatham et al. (2004) demonstrated, that when electrospinning 
nylon-6 at temperatures ranging from 25-60C, the fibre diameter decreased with 
increasing temperature [128]. They suggested this may be due to a lower polymer 
solution viscosity at higher temperatures [128]. Electrospinning cellulose acetate (CA) 
and poly-(vinyl pyrrolidone) (PVP) at elevated temperatures also revealed a similar trend, 
decreased fibre diameter with increasing temperature [129]. Using the same polymer 
systems, the influence of humidity was investigated. It was observed that as the humidity 
was raised, the average fibre diameter for CA increased [129]. However, the opposite 
effect occurred for PVP. The authors stated that the different trends observed between 
the polymer systems were due to different chemical and molecular interactions and the 
solvent evaporation rate at higher humidity [129]. In general increasing humidity results 
in decreased fibre diameter. With an increase in humidity from 4-60% the average NF 
diameter decreased for PVA (667 nm to 161 nm), and PEO (252 nm to 75 nm) [130]. 
The effect of humidity was even more pronounced in a blend NF of poly-
(vinyl)/hyaluronic acid and poly-(ethylene oxide)/chitosan, resulting in a fibre diameter 
reduction of 231 nm to 46 nm and 179 nm to 34 nm, respectively [130]. 
 
1.2.2 Electrospinning solution parameters and their effect on the nanofibre  
1.2.2.1 Concentration of polymer 
The concentration of a polymer solution under constant electrospinning parameters will 
influence the formation of a NF [120]. At a sufficiently low polymer concentration, a 
continuous polymer jet may not form resulting in the formation of micro- or nano-
particles; this process is known as electrospraying [131]. The critical concentration for 
electrospraying or electrospinning to occur is different for each type of polymer solution 
and is related to the polymer chain entanglements. At low polymer concentration, there 
is low chain entanglement and electrospraying occurs instead of electrospinning [131]. 
An increase in the polymer concentration may produce a continuous jet, however, a 
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mixture of beads and fibres can be formed [120]. Fong et al. (1999) demonstrated that by 
increasing the PEO polymer concentration from 1 to 4.5% (w/v), the morphology of the 
NF changed from fibres with intermittent micron-sized beads to fibres with intermittent 
spindle-like structures (Figure 1-10) [132]. By increasing the polymer concentration, the 
bead morphology disappeared to form smooth, bead-free fibres [120,133]. Increasing the 
concentration of PCL also resulted in larger diameter fibres [115]. However, there is a 
limit to how high the concentration of the polymer in solution can be, as the polymer 
solution can become too viscous. At high viscosities, the flow of the polymer solution 
through the spinneret is affected causing beaded fibres to form or the polymer can block 
the spinneret [134]. 
 
 
Figure 1-10 A scanning electron micrograph displaying the spindle-like structures along the 
length of the PEO NF after electrospinning. Figure adapted from Fong et al. [127]. Reprinted 
with permission from Elsevier: Polymer 1999, 40, 4585-4592, copyright 1999. 
 
1.2.2.2 The viscosity of the polymer solution 
In general, altering the solution viscosity will influence the NF size and morphology and 
it is important to note that concentration and viscosity are related, thus changing one will 
alter the other [108]. Reports indicate at low viscosity, fibres are not continuous and break 
up resulting in electrospraying and at higher viscosities, the fluid jet does not eject 
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properly for the needle tip prohibiting fibre formation [120]. For example, 
electrospinning solutions of poly-(carbonate urethane) at a low viscosity (7 Pa.s) 
produced beaded fibres, at an intermediate viscosity (13 Pa.s) uniform fibres were formed 
and large fibres were produced at a high viscosity (23 Pa.s) [135]. The viscosity at which 
one polymer can be electrospun is not the same for all polymers. For PEO to form suitable 
fibres the viscosity range has been determined to be from 0.1-2 Pa.s whereas, CA 
produced fibres within a smaller viscosity range of 0.12-1.02 Pa.s [127,136]. Outside of 
these ranges, either droplets were formed or electrospinning was impossible due to the 
high cohesiveness of the solution [127].  
 
1.2.2.3 The surface tension of the polymer solution 
The surface tension of a polymer solution is mainly attributed to the composition of the 
solvent(s) that it is dissolved in [108]. During the electrospinning process, the surface 
tension of the droplet must be overcome by the applied voltage for a NF to eject from the 
Taylor cone, therefore, a lower surface tension enables electrospinning at a reduced 
applied voltage, because the surface tension is easier to overcome [137]. At a fixed 
concentration of 4% (w/v), PVP dissolved in ethanol produced smooth fibres [138]. 
However, when 4% (w/v) PVP was dissolved in N, N-dimethylformamide (DMF) or 
dichloromethane (DCM), bead-like structures formed in the NF due to the change in 
surface tension of the polymer-solvent solution [138]. 
 
1.2.2.4 Solution conductivity  
To form the Taylor cone, the solution needs to be conductive [117].  If the solution has a 
low conductivity, there will be no charge on the droplet and electrospinning will not 
occur [117]. Insufficient conductivity will cause the Taylor cone to be unstable and 
beaded NF will be produced [108]. On the other hand, a solution with high conductivity 




The conductivity of the polymer solution can be increased by the addition of ionic salts. 
Zong et al. (2002) investigated the effect of the addition of either sodium chloride, 
sodium dihydrogen phosphate or potassium dihydrogen phosphate on PDLA fibre 
diameter and morphology [124]. PDLA produced beaded fibres when electrospun in 
DMF alone, however, when an ionic salt was added to the PDLA/DMF solution, the 
fibres became smooth and bead free [124]. Furthermore, the addition of sodium chloride 
produced the smallest average fibre diameter of 210 nm, followed by sodium dihydrogen 
phosphate with 330 nm, while potassium dihydrogen phosphate produced the largest 
diameter of 1000 nm [124]. In another study, Zang et al. (2005) added sodium chloride 
to increase the conductivity of aqueous PVA solutions, resulting in a reduction of the 
fibre diameter with increasing sodium chloride content [140]. Alternatively, organic 
acids such as formic acid can be used as the solvent to increase conductivity to reduce 
fibre diameter [141].  
 
1.2.2.5 Solvent dielectric constant  
The dielectric constant of a solution indicates its ability to maintain an electric charge in 
the presence of an electric field and is dependent on the solvents used in the 
electrospinning solution [142]. The addition of a solvent with a higher dielectric constant 
to the polymer solution can induce “free” charge in the polymer solution and initiate 
bending instability, leading to smaller diameter fibres [142,143]. It has been shown 
experimentally that the ease of electrospinning a PCL/DCM solution was improved and 
fibre diameter was reduced with the addition of the solvent DMF, which has a dielectric 
constant of 36.7 [144]. The addition of DMF also facilitated the change from 
electrospraying to electrospinning when it was added to PCL/DCM solutions and was 
attributed in part to the solutions higher dielectric constant [145]. Luo et al. (2012) 
studied the dielectric constant of mixed solvent systems for PCL and observed that a 
dielectric constant of ~19 was required to produce fibre diameters of <100 nm [146]. 
Furthermore, a solvent system with a lower dielectric constant resulted in larger fibres 




1.2.2.6 Polymer molecular weight 
The molecular weight of the polymer plays a role in fibre morphology, molecular weight 
is also related to the solution viscosity, as increasing the molecular weight increases 
polymer chain entanglement [108]. Polymers with low chain entanglement produce 
beaded fibres [147]. Increasing the polymer molecular weight produced a smooth fibre 
structure, this was attributed to the increase in polymer chain entanglement [147]. 
Changing the molecular weight of PVA from 13-23 kDa to 31-50- kDa in the electrospun 
solution, caused an increase in fibre diameter and the morphology of the fibres changed 
from circular to flat fibres [148]. 
 
1.2.3 Organic solvents used in electrospun nanofibre drug delivery systems  
Volatile organic solvents are often used in the fabrication of electrospun NF drug delivery 
systems to solubilise hydrophobic active drug or polymers. The solvents used, fall under 
the USP guidelines, which are categorised as Class I, Class II and Class III [86]. The 
classes are classified based on risk assessment [86].   
 
Class I solvents (Table 1-1) should be avoided due to unacceptable toxicities, they are 
known carcinogens and toxic to the environment [86]. Class II solvents (Table 1-2) have 
less severe toxicity than Class I, however, their permitted daily exposure (PDE) to 
patients should be limited to prevent adverse events and should not exceed the limits in 






Table 1-1 Class I residual organic solvents to be avoided during the manufacture of nanofibres 





Benzene 2 Carcinogenic  
Carbon tetrachloride 4 
Toxic and hazardous to the 
environment 
1,2-Dichloroethane 5 Toxic  
1,1-Dichloroethane 8 Toxic  
1,2-Trichloroethane 1500 Hazardous to the environment 
Note: table is not exhaustive  
 
Table 1-2 Class II residual organic solvents that should be limited to patients and should not 
exceed the permitted daily exposure limits.  
Solvent  Concentration limit (ppm) PDE (mg/day) 
Acetonitrile  410 4.1 
Chlorobenzene 360 3.6 
Chloroform 60 0.6 
Cyclohexane 3880 38.8 
N, N-Dimethylacetamide 1090 10.9 
N, N-Dimethylformamide 880 8.8 
Ethylene glycol 620 6.2 
Formamide 220 2.2 
Hexane 290 2.9 
Methanol 3000 30.0 
Methylene chloride 600 6.0 
Pyridine 200 2.0 
Sulfolane 160 1.6 
Tetrahydrofuran 720 7.2 
Toluene 890 8.9 
Trichloroethylene 80 0.8 
Xylene 2170 21.7 




The majority of electrospinning in the literature often incorporates Class II solvents 
because they are common solvents that are known to solubilise the polymers. For 
example, PCL has been electrospun using chloroform, methanol, dichloromethane 
(DCM), N, N-dimethylformamide (DMF), toluene and tetrahydrofuran [149]. The use of 
Class II solvents in an NF drug delivery system adds a safety risk for the patient because 
of the associated toxicities. However, the USP states that residual solvents should be 
removed where possible or to a level that can be supported by safety data because they 
offer no therapeutic benefit [86].  Class II solvents should be identified and quantified as 
part of the process validation as outlined in the USP [86]. The identification, 
quantification and removal of the Class II solvents is a limitation for their use in NF 
production because it is a regulatory barrier.  
 
Class III solvents (List 1-1) are less toxic to humans than Class I and II and the USP 
states they should be used whenever possible [86]. The PDE for Class III solvents is 
5,000 ppm without the need to perform any quantification test, higher amounts are 
possible providing there is justification and good manufacturing practice is followed 
[86]. The use of Class III solvents in the manufacture of NF systems, especially NF drug 
delivery systems formulated for a delicate environment such as the brain, is beneficial to 
the end-user from a safety perspective. It is also of benefit to the manufacturer because 










List 1-1 Class III residual organic solvents should be used whenever possible, their permitted 
daily exposure is 5000 ppm and higher amounts are possible.  
Solvent  Solvent Solvent 
Acetic acid Ethyl acetate Methyl ethyl ketone 
Acetone Ethyl ether Methyl isobutyl ketone 
Anisole Ethyl formate 2-Methyl-1-propanol 
1-Butanol Formic acid  Pentane 
2-Butanol Heptane 1-Pentanol 
Butyl acetate Isobutyl acetate 1-Propanol 
Tert-butyl methyl ether Isopropyl acetate 2-Propanol 
Dimethyl sulfoxide Methyl acetate Propyl acetate 
Ethanol 3-methyl-1-butanol   
Note: table is not exhaustive 
 
1.2.4 Techniques employed to load nanofibre with drug 
Due to the flexibility of the electrospinning process, several methods exist to produce a 
drug-loaded NF. The processes include; co-electrospinning, coaxial electrospinning, 
post-electrospinning modification and emulsion electrospinning (Figure 1-11). The drug 
release profile from the NF depends on the method of drug entrapment and allows for the 













Figure 1-11 The different electrospinning techniques used to load the active drug into the NF 
matrix. a) post-modification of NF with the drug, b) co-electrospinning with polymer and drug, 
c) coaxial electrospinning forming drug core and polymer sheath, d) emulsion electrospinning 
forming drug core and polymer sheath [150]. Figure adapted from Meinel et al. Eur. J. Pharm.  








1.2.4.1 Post-modification of nanofibre for drug loading 
Post-modification of the NF by drug adsorption is a simple drug-loading method to obtain 
a NF drug delivery system (Figure 1-11 a) [151]. However, this approach generally 
results in a burst release of the active drug, as the drug is localised on the surface of the 
NF [151].  Ornidazole, an antibiotic, was absorbed to the surface of PCL NF and an 80% 
burst release of the drug was observed after 3 h [151]. Immobilisation of the active drug 
to the surface can attenuate the burst release and also supports biomolecule adhesion 
[152]. VEGF was immobilised on the surface due to specific interactions with a heparin 
coating, and release of VEGF occurred over 15 days [152]. Immobilisation of the active 
drug avoids harsh conditions as it is often performed under mild aqueous conditions, 
therefore the biological activity of the active drug is not lost [152].  
 
Bioconjugation is a method to produce reliable release rates. In the case of 
bioconjugation, the active drug is chemically bound to the NF by a linker [153]. Cleavage 
of the conjugate is generally by an enzyme, releasing the active drug from the NF [153]. 
Kim and Yoo (2010) investigated the release of linear poly-(ethyleneimine)/DNA 
complexes that were chemically conjugated to PCL/PEG NF via a matrix-
metalloproteinase cleavable peptide [153]. Release of the complex was dependent on 
matrix-metalloproteinase activity and there was an initial burst release of both poly-
(ethyleneimine) and DNA in the first 12 h period [153]. After 72 h, the release had slowly 
increased to 82% and 77% for DNA and poly-(ethyleneimine), respectively [153].  
 
1.2.4.2 Co-electrospinning of polymer and drug  
Co-electrospinning is when the active drug and polymer are mixed and dissolved in the 
same solution before electrospinning [154]. It is the most cost-effective, less time 
consuming and generally, the preferred method to achieve a drug-loading NF delivery 
system (Figure 1-11 b) [154]. This method allows for a homogenous distribution of the 
active drug throughout the NF with a high drug loading [154]. The active drug is released 
by diffusion and polymer degradation, this can lead to a release profile with an initial 
burst followed by a sustained release of the drug [154]. Paclitaxel was electrospun with 
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PLGA 85:15 and PLGA 50:50 [106]. A low initial burst release followed by a sustained 
release for over 80 days in vitro was observed for both NF [106]. Furthermore, release 
from PLGA 50:50 occurred at a faster rate than PLGA 85:15, due to the faster 
degradation of PLGA with a higher glycolic acid (GA) content [106]. Co-electrospinning 
exposes the active drug to organic solvents, exposure to solvents may affect the active 
drug functionality, especially in the case of biomolecules. However, an electrospun 
heparin-loaded NF from a solution of PCL dissolved in DCM and methanol significantly 
reduced vascular smooth muscle cell proliferation in vitro, indicating heparin maintained 
bioactivity when electrospun in the presence of organic solvents [155]. 
 
1.2.4.3 Coaxial electrospinning to form drug core and polymer sheath 
Coaxial electrospinning uses a capillary tube with an inner capillary housed inside an 
outer capillary, to produce core/sheath fibres (Figure 1-11 c) [156]. Generally, a solution 
containing the active drug enters the inner capillary while a polymer solution enters the 
outer capillary [156]. When electrospinning occurs, a core NF (active drug) is 
encapsulated inside an outer sheath (polymer). The sheath layer can protect biomolecules 
from harsh solvents while acting as a diffusion barrier, reducing the initial burst release 
that can occur in conventional electrospun fibres [157]. Fluorescein isothiocyanate-
conjugated bovine serum albumin (FITC-BSA) was encapsulated in a PEG core with a 
PCL sheath [157]. The aqueous conditions of the core solution protected the biomolecule. 
Furthermore, the initial burst release observed in a conventional electrospun fibre of 
PEG/PCL blend containing FITC-BSA was alleviated in FITC-BSA/PEG PCL core-
sheath fibres, when the release was investigated in vitro [157]. 
 
1.2.4.4 Emulsion electrospinning to form drug core and polymer sheath  
Emulsion electrospinning is another technique that produces core/sheath NF, where the 
droplet dispersed in the electrospinning solution forms the core (Figure 1-11 d) [158]. 
The process can produce core/sheath fibres from a single solution and does not need a 
special spinneret like co-axial electrospinning [158]. In general, a water-in-oil (W/O) 
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emulsion is utilised, as this enables the encapsulation of hydrophilic drugs or 
biomolecules in the core of the fibres [158]. Core/sheath fibres of Proteinase K (core) 
and PEG-PLA (sheath) were produced using a W/O emulsion [159]. Although there was 
an uneven distribution of proteinase K in the core, it was stated that this was due to 
uneven droplet size and could be remedied by adjusting the emulsion composition [159]. 
Chew et al. (2005) demonstrated, that nerve growth factor could be encapsulated in the 
core of fibres electrospun from a solution of poly-(caprolactone-co-ethyl-ethylene) 
phosphate dissolved in DCM, that contained bovine serum albumin (BSA) as a stabiliser 
[160]. Nerve growth factor retained at least partial activity when assessed in vitro for its 
ability to induce PC12 cell differentiation [160]. 
 
1.2.4.5 Influence of drug physicochemical characteristics in drug release from 
nanofibre 
The physical and chemical properties of the active drug can influence the release rate 
from the NF. Blakney et al. (2014) assessed the in vitro release of the hydrophilic drug 
tenofovir and the hydrophobic drug levonorgestrel from a PVA NF [161]. The release of 
hydrophilic tenofovir was rapid, with 100% release occurring after only 30 min, in 
contrast, 100% release of the hydrophobic levonorgestrel occurred after 4 h [161]. 
Rujiravanit et al. (2003) reported that the drug release rate and the total amount of drug 
released from a crosslinked chitosan/silk film were largely reliant on the molecular 
weight of the drug [162]. The total amount of the higher MW drug theophylline (MW 
180.164 g/mol) was less than salicylic acid (MW 138.12 g/mol), this was attributed to it 
being harder for the higher MW drug to diffuse through the matrix [162] Expanding on 
this concept, another study found the total amount of drug released from a PVA NF was 
98, 97, 76 and 42% for naproxen, sodium salicylate, sodium diclofenac and 
indomethacin, respectively [163]. The total amount of drug released and the release rate 




1.3 Application of a nanofibre delivery system for stroke 
In New Zealand, approximately 9,000 people suffer a stroke every year, with Māori and 
Pacific Islanders the most at risk due to an increase in risk factors associated with stroke 
including diabetes, obesity, smoking and hypertension [164]. Also at risk are those who 
have high blood pressure, diabetes, high cholesterol, carotid or other artery diseases, heart 
diseases and certain blood disorders, and people who are obese or lead an inactive 
lifestyle [165,166]. The economic impact of stroke cost New Zealand $700 million in 
2018 and this is forecasted to increase as the total number of strokes is estimated to rise 
by 40% by 2028 [4].  
 
A stroke occurs in the brain due to an interruption in the blood supply to the brain, it is 
defined as ‘a sudden neurological deficit caused by impairment in perfusion to the 
brain’[163, pg 1]. The blood supply to the brain is critical for proper bodily function, as 
the brain is the most complex organ in the body and performs as a centralised control 
over the other organs [168,169]. Disruption of the blood supply by a stroke not only 
causes severe damage to the brain but also has major implications on the other organs 
due to the centralised control such as loss of motor function to one side of the body, 
aphasia and visual problems.  
 
1.3.1 Stroke   
Stroke can either be haemorrhagic or ischemic, haemorrhagic strokes are caused by 
bleeding in the brain from a ruptured blood vessel or following trauma to the head and 
account for 13% of all strokes [170–174]. The bleeding leads to a build-up of blood that 
puts pressure on the surrounding brain causing tissue death, resulting in loss of certain 
bodily functions depending on which region of the brain is affected, or, if bleeding is 
severe, loss of life [172,174]. Haemorrhagic strokes are treated with pharmaceutical 
agents such as antihypertensive drugs to reduce blood pressure, diuretics to ease pressure 
in the subarachnoid space and surgery to alleviate swelling or pressure on the brain and 
stem the flow of blood from the ruptured artery when the bleeding is severe [175].  
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1.3.2 Ischemic stroke  
Ischemic stroke (Figure 1-12) is an age-associated disease and is more prevalent in the 
elderly (> 65 years). However, 10% of ischemic strokes occur in people 50 years or 
younger and ischemic strokes account for 87% of all strokes worldwide [171,176–178]. 
Ischemic strokes occur when the blood supply to the brain is impeded by a thrombus or 
embolism. A thrombus is a blood clot that forms and occludes a blood vessel within the 
brain, whereas an embolism is a plaque or a clot that forms elsewhere in the 
cardiovascular system, travelling to the brain until it reaches a small vessel that it is 
unable to pass through (Figure 1-12). Both cause a reduction in blood flow that stems 
the delivery of oxygen and important nutrients such as glucose to the central core of the 
insult causing rapid cell death. This area is known as the ischemic core [179]. Signs and 
symptoms of ischemic stroke include weakness and/or numbness in the face, arms and 
legs especially on one side of the body, loss of balance or coordination, confusion, slurred 
speech, blurred vision and severe headache [180]. 
 
 
Figure 1-12 Schematic illustration outlining how an ischemic stroke develops in the brain. A 
blood clot blocks blood flow to part of the brain causing necrosis. Source: National Heart, 
Lung, and Blood Institute; National Institutes of Health; U.S. Department of Health and Human 




1.3.3 Current clinical treatments for ischemic stroke 
1.3.3.1 Tissue plasminogen activator to promote reperfusion for stroke  
Currently, the only pharmacological treatment for ischemic stroke is the anti-thrombotic 
drug, tissue plasminogen activator (tPA), used to reduce injury and promote blood vessel 
reperfusion. Intravenous administration of recombinant tPA administered within 3 h of 
stroke onset was approved by the FDA in 1996 [181,182]. The therapeutic window has 
now been extended to 4.5 h based on results from further clinical trials [183]. However, 
the number of patients who receive tPA is still limited due to the short therapeutic 
window. Studies have also found that when ischemic stroke patients are administered 
tPA, disability is prevented in only six patients per 1,000 stroke incidents and mortality 
is not improved with its use [170,184,185]. tPA may be less effective in large clots that 
have calcification due to lack of penetration [186]. Administration of tPA after stroke can 
lead to several side effects, including intracerebral haemorrhage, systemic haemorrhage, 
angioedema, disruption to the BBB and neurotoxicity [15,187]. 
 
1.3.3.2 Endovascular mechanical device for clot removal in stroke  
An alternative approach to reperfusion is the physical removal of the occlusion using an 
endovascular mechanical device (EMD) (Figure 1-13). The surgical procedure extracts 
the occluding thrombi from the vessel to restore blood flow [188]. The first EMD for the 
treatment of ischemic stroke was approved by the FDA in 2004, based on the mechanical 
embolus removal in cerebral ischemia trial [173]. Early EMDs produced recanalization 
rates in patients of 48-63% [189,190]. With new generation EMDs, recanalization rates 
have increased to 80-90% and clinical outcomes for patients have improved [190–194]. 
The surgical procedure does come with possible complications. Device failure can occur, 
such as broken wires, intracranial haemorrhaging can occur after reperfusion or the 






Figure 1-13 Illustration of the Solitaire™ FR EMD. The device is deployed at the site of 
occlusion and embedded into the clot, they are then both withdrawn from the vessel restoring 
blood flow. Copyright © 2017 Medtronic. All rights reserved. Reprinted with permission. 
 
1.3.4 A new pharmacological intervention for the treatment of stroke 
Memory and learning are enhanced by long term potentiation through glutamatergic 
synapses however, γ-Aminobutyric acids (GABA) inhibitory response has been shown 
to block this neuroplasticity [195]. Furthermore, recent findings have demonstrated, a 
high concentration of GABA is present in the extracellular space during ischemic stroke 
[196–198]. The GABA activates extrasynaptic α5-GABAA receptors that produce a tonic 
inhibition and suppresses neuroplasticity and the memory and learning pathways, this 
might explain the limited functional recovery observed in stroke patients [196–198]. To 
investigated this, L-655,708 a negative allosteric modulator selective for the α5-GABAA 
was tested in a photothrombotic mouse stroke model by subcutaneously implanting a 
mini pump to achieve slow release [198]. L-655,708 was administered from 3 days post-
stroke for up to 42 days at a dose regime of 200 μg/kg/day. After 7 days, stroked mice 
that received the drug had reduced fore-limb and hind-limb foot faults compared to 
vehicle-treated stroke controls, indicating improved recovery after stroke. When L-
655,708 was administered at stroke onset, a significantly larger stroke volume was 
observed, whereas delaying treatment produced motor recovery without increasing 
stroke size [198]. This indicates stroke treatment with L-655,708 has the potential to 
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increase the therapeutic window to 3 days compared to 4.5 h with the current treatment 
options. The study demonstrates the potential of L-655,708 as a pharmacological 
intervention for functional recovery after stroke. However, L-655,708 has a low 
molecular weight of 341.36 g/mol and a short plasma half-life of only 0.5 h, limiting its 
ability to effectively and efficiently target the site of stroke when administered orally 
[199]. 
 
1.4 Thesis aims and structure  
Delivery of drug to the CNS is difficult with the BBB hindering efficient transport from 
the systemic circulation.  Strategies to overcome this need to be developed to achieve a 
therapeutic dose at the site of action without causing unwanted toxicity to other organs. 
A NF implanted at the site of action will remain there and with sufficient drug-loading 
due to the high surface to volume ratio, allows efficient, localised drug delivery without 
the negative effect of unwanted toxicity to other organs. Therefore, this thesis describes 
the development of NF formulation that could have application in the treatment of some 
neurological disorders. Therefore, the overarching aim of this thesis is to develop and 
characterise implantable NF for drug delivery to treat neurological disorders using low 
toxic solvent systems. 
 
In Chapter 3 a PLGA NF will be developed from a Class III solvent system consisting 
of ACE:EtAc, which is less toxic than a Class II solvent system. The NF will be compared 
to a PLGA NF electrospun from the more toxic Class II solvent system consisting of 
DCM and DMF. Three model drugs (paracetamol, ampicillin, and tetracycline) with 
different molecular weights will be incorporated into the PLGA NFs. The release rate of 
the drugs will be determined from PLGA NFs electrospun from Class II and Class III 
solvent systems.  
 
The aims of chapter 3 are: 
- Develop PLGA NF from less toxic Class III solvent system.  
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- Characterise and compare the physical and chemical properties of PLGA NF 
produced from Class III and Class II solvent systems.  
- Develop drug-loaded PLGA NF from Class II and Class III solvents systems. 
-  Characterise and compare the physical and chemical properties of drug-loaded 
PLGA NF produced from Class II and Class III solvent systems.  
- Investigate and compare the drug release of three drugs with different molecular 
weights from PLGA NF prepared from Class II and Class III solvent systems. 
 
It is hypothesised there will be a difference in fibre diameter size between the NF that 
will lead to differing release rates of model drugs from the NF. The release rate will also 
differ with respect to drug molecular weight, with low MW drug releasing faster than 
high MW drug. 
 
In Chapter 4 PCL will be electrospun with blend polymers, two natural polymers GEL, 
CH and the synthetic polymer PEO using a Class III solvent system consisting of acetic 
acid:formic acid which is less toxic than Class II solvent systems. 
 
The aims of chapter 4 are: 
- Develop PCL NF and PCL/blend NF from less toxic Class III solvent system.  
- Characterise and compare the physical and chemical properties of PCL and 
PCL/blend NF. 
- Investigate and compare the drug release of L-655,708 from PCL and PCL/blend 
NFs. 




- Investigate and compare the in vitro cytotoxicity and immune response to PCL 
and PCL/blend NFs. 
 
It is hypothesised blending PCL with natural and synthetic polymers will improve the 
chemical and physical characteristics of the NF compared to a PCL NF. Drug release 
from PCL/blend NFs will be faster than the PCL NF. The PCL/blend NFs will also show 
a reduced in vitro cytotoxicity and immune response from fibroblast cells compared to 











2 Materials and methods 
2.1 Materials  
Poly-(lactic-co-glycolic acid) (PLGA) with a lactide:glycolide ratio of 75:25, an inherent 
viscosity of 0.55-0.75 dL/g and a density of 1.30 g/mL was purchased from Lactel 
Absorbable Polymers, (Birmingham, AL, USA). Poly-(caprolactone) (PCL) (MW 70-90 
kDa), gelatine (GEL) (Porcine, Type A 300 bloom, chitosan (CH) (low MW, 50-190 
kDa, 75-85% deacetylated), poly-(ethylene oxide) (PEO) (MW 200 kDa), tetracycline, 
ampicillin, formic acid (FA), 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT), lipopolysaccharide (LPS) from Escherichia coli (055:B5), rose bengal 
solution (10 mg/mL in normal saline) and Hoechst 33258 solution (1:1000) were 
obtained from Sigma Aldrich Co. (St. Louis, MO, USA). Paracetamol was purchased 
from BDH Chemicals Ltd. Poole, England. Indomethacin was obtained from FWD 
Chemicals Ltd. Xuhui District, Shanghai, China. Glacial acetic acid (AA), 
dichloromethane (DCM), dimethylformamide (DMF), acetone (ACE), ethyl acetate 
(EtAc) and acetonitrile (ACN) were all of HPLC grade and purchased from Merck 
KGaA, (Darmstadt, Germany). L-655,708 was purchased from Tocris Bioscience, 
(Bristol, United Kingdom). Water was purified using a Millipore Milli-Q Reagent Water 
System (Continental Water Systems, USA). Tryptic soy broth was purchased from 
Becton Dickinson, (Franklin Lakes, NJ, USA). Filter paper membrane (0.45 µm) was 
obtained from Phenomenex, Inc. (Torrence, California, USA). A 100 x 4.6 mm, 3µm 
Hypersil BDS C18 column was purchased from Thermo Fisher Scientific (Waltham, MA, 
USA). Normal human dermal fibroblast (NHDF) cells were kindly supplied by 
McConnell group (Microbiology and Immunology, University of Otago). Dulbecco's 
modified eagle medium, fetal bovine serum (FBS), penicillin-streptomycin, were 
purchased from Gibco/Life Technologies Co. (Carlsbad, CA, USA). A BD cytometric 
bead array mouse inflammation kit was purchased from Becton Dickinson, (Franklin 
Lakes, NJ, USA).  
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2.2 Preparation of nanofibres 
2.2.1 Preparation of nanofibre solutions 
2.2.1.1 PLGA solution 
Poly-(lactic-co-glycolic acid) dichloromethane:dimethylformamide (PLGA DCM:DMF) 
was prepared by dissolving 0.2 g of PLGA at a lactide:glycolide ratio of 75:25 with an 
inherent viscosity 0.55-0.75 dL/g and a density of 1.30 g/mL (Lactel Absorbable 
Polymers, Birmingham, AL, USA) in 1 mL of DCM:DMF (HPLC grade, Merck KGaA, 
Darmstadt, Germany) at a ratio of 70:30 v/v, to give a 20% (w/v) polymer solution. The 
solution was stirred using a magnetic stirring bar (300 rpm) overnight to ensure complete 
dissolution. 
 
Poly-(lactic-co-glycolic acid) acetone:ethyl acetate (PLGA ACE:EtAc) was prepared by 
dissolving 0.2 g in 1 mL of ACE:EtAc (HPLC grade, Merck KGaA, Darmstadt, 
Germany) at a ratio of 70:30 v/v or 80:20 v/v to give a 20% (w/v) polymer solution. The 
solution was stirred at 300 rpm using a magnetic stirring bar overnight. 
 
2.2.1.2 PLGA drug-loaded nanofibre solutions 
Solutions were prepared as outlined in Section 2.2.1.1 with the addition of 20 mg of 
either paracetamol (BDH Chemicals Ltd. Poole, England), ampicillin (Sigma Aldrich Co. 
St. Louis, MO, USA) or tetracycline (Sigma Aldrich Co. St. Louis, MO, USA) to give a 
10% (w/w, drug to polymer ratio) drug concentration.  
 
2.2.1.3 PCL and PCL/blend solutions  
Poly-(caprolactone) (PCL) (MW 70-90 kDa, Sigma Aldrich Co. St. Louis, MO, USA) 
was prepared by dissolving 0.2 g in 2 mL of acetic acid:formic acid (AA:FA) (90:10, 
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v/v) to give a 10% (w/v) solution. Poly-(caprolactone)/gelatine (PCL/GEL) and poly-
(caprolactone)/poly-(ethylene oxide) (PCL/PEO) solutions were prepared by dissolving 
0.1 g of PCL and 0.1 g of either GEL (Porcine, Type A 300 bloom, Sigma Aldrich Co. 
St. Louis, MO, USA) or PEO (MW 200 kDa, Sigma Aldrich Co. St. Louis, MO, USA) 
in AA:FA (90:10, v/v) to give a 20% (w/v) solution. Poly-(caprolactone)/chitosan 
(PCL/CH) was prepared by dissolving 0.1 g of PCL and 0.1 g of chitosan (CH) (low 
molecular weight, 50-190 kDa, 75-85% deacetylated, Sigma Aldrich Co. St. Louis, MO, 
USA) in 1.34 mL of AA:FA (90:10, v/v) to give a 15% (w/v) solution. The ratio of PCL 
to blend polymer for all solutions was 50:50 (w/w) and the solutions were stirred at 300 
rpm using a magnetic stirring bar overnight to ensure complete dissolution.  
 
2.2.1.4 PCL and PCL/blend drug-loaded nanofibre solutions 
Solutions were prepared as outlined in Section 2.2.1.3 with the addition of either 1 mg 
of L-655,708 (Tocris Bioscience, Bristol, United Kingdom) or indomethacin (FWD 
Chemicals Ltd. Xuhui District, Shanghai, China) to give a 0.5% (w/w) drug 
concentration. 
 
2.2.2 Electrospinning nanofibre solutions 
Solutions were electrospun in a fume hood at ambient temperature. A syringe (3 mL), 
with a blunted needle (20 GA) (Table 2-1) was connected to a Fusion 200 syringe pump 
(Chemyx Inc. Stafford, TX, USA) that delivered the solution at a specific flow rate 
(Table 2-1). A voltage (Table 2-1) was applied to the needle using a Bertan HVPS Series 
230 power supply (Spellmann, Hauppauge, NY, USA). Fibres were collected on a 
mandrel rotating at 6 rpm, the distance between the needle and rotating mandrel was 15 
cm. The same conditions were used to electrospin drug-loaded NF from the solutions 
containing drug as described above therefore, the theoretical drug loading was 20 mg 
(100%). The subsequent analysis of the NFs was performed on a single batch of each NF 




Table 2-1 The processing parameters used for the polymer/solvent solutions of poly-(lactic-co-
glycolic acid) acetone:ethyl acetate, poly-(lactic-co-glycolic acid) 
dichloromethane:dimethylformamide, poly-(caprolactone), poly-(caprolactone)/chitosan, poly-
(caprolactone)/gelatine, poly-(caprolactone)/poly-(ethylene oxide) and the associated drugs for 
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2.3 Characterisation of nanofibres 
2.3.1 Field emission-scanning electron microscopy 
The morphology of the NFs was characterised by field emission scanning electron 
microscopy (FE-SEM) and the images were used to determine fibre diameter. A 4 mm 
diameter disc was hole-punched from the NF mat, the disc was mounted on 10 mm 
aluminium stub using double-sided carbon tape. The stub was placed in an Emitech 
K575X Peltier-cooled high-resolution sputter coater with carbon coater attachment (EM 
Technologies Ltd, Kent, England) and coated with 10 nm of gold-palladium alloy. 
Samples were viewed in a JEOL JSM-6700F field emission scanning electron 
microscope (JEOL Ltd, Tokyo, Japan) or a Zeiss Sigma VP scanning electron microscope 
(Carl Zeiss Inc, Oberkocken, Germany) fitted with an HKL INCA Premium Synergy 
Integrated ED/EBSD system (Oxford Instruments, Oxfordshire, UK). The samples were 
analysed at an accelerating voltage of 3-5 kV, using the lower secondary detector (LEI) 
or secondary electron detector (SEI), with a working distance of 2-10 mm. By scanning 
across the NF, 10 fields of view were randomly selected and, from the selected field of 
view, 10 fibres were measured for fibre diameter using the FE-SEM software.  
 
2.3.2 Attenuated total reflectance Fourier-transform infrared spectroscopy  
Chemical analysis of pure polymer, drugs and NFs was performed by attenuated total 
reflectance Fourier-transform infrared (ATR-FTIR) spectroscopy to determine if the 
electrospinning procedure altered the polymer composition or chemical interactions 
occurred. A GladiATRTM (Pike Technologies, Inc. Madison, WI, USA) connected to a 
Varian 3100 FT-IR (Varian, Inc. Walnut Creek, CA, USA) was used to acquire ATR-
FTIR spectra. Samples were placed on the ATR diamond crystal and the pressure arm 
positioned over the sample, FTIR data was collected with 64 scans over a range of 4000-
400 cm-1 at a resolution of 4 cm1 using the % transmission mode. A background spectrum 
without sample was collected before the analysis of each sample (Appendix B) and a 
polystyrene film was used as the standard (Appendix B) using the same instrumental 
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conditions. Varian Resolution Pro software version 4.1.0.101 (Varian, Inc. Walnut 
Creek, CA, USA) was used to collect spectral data and plotted using GraphPad Prism.  
 
2.3.3 Differential scanning calorimetry 
Differential scanning calorimetry (DSC) was performed to determine the solid-state of 
the NF using a DSC Q100 equipped with a refrigerated cooling system (TA Instruments, 
New Castle, DE, USA). Approximately 5 mg of the pure polymer or NF mat was sealed 
in a standard aluminium pan. The sample was placed on the front DSC stage, with a 
reference pan placed on the backstage. The sample and reference pan were then heated 
from -100C to 300C at a rate of 5 C/min under a nitrogen atmosphere (flow rate 50 
mL/min). TA universal 2000 analysis software (Version v. 4.1D) was used to collect the 
data and the DSC thermograms were plotted using Microsoft Excel. Before sample 
analysis, indium (purity > 99.9%) was used as the calibration standard (Appendix B).  
 
2.3.4 Thermogravimetric analysis 
Thermogravimetric analysis (TGA) was performed to investigate the thermal properties 
of the NF. Approximately 5 mg of the pure polymer, drugs or NFs was placed in an open 
platinum TGA sample pan and analysed in ramp heating mode at 5C/min from 25C to 
600C under a nitrogen atmosphere (flow rate 50 mL/min) using a TGA Q50 (TA 
Instruments, New Castle, DE, USA). TA universal 2000 analysis software (Version v. 
4.1D) was used to analyse the percentage weight change and the data was plotted using 
Microsoft Excel. A weight calibration was performed before each sample was analysed 
using weight calibration standards. 
 
2.3.5 X-ray diffraction 
To determine the crystallinity of the NF, X-ray diffraction was employed using an X-ray 
diffractometer (PANalytical X’Pert PRO MPD PW3040/60 XRD, New Zealand) 
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attached with a rapid multi-strip X’Celerator detector. Pure polymer or NF mat was 
loaded into the cavity of the aluminium sample holder. The sample holder was positioned 
in the X-ray goniometer and scanned over a range of 5-50 (2θ) at a scanning speed of 3 
/min using Cu Kα radiation at a current of 40 mA and a voltage of 40 kV. Collection 
and analysis of the data was carried out using PANalytical X’pert data collector 
programme with High Score software. 
 
2.3.6 Hot stage microscopy  
To investigate the thermal phase transitions of the PLGA NF and drug-loaded PLGA 
NFs, hot stage microscopy was employed. The NF mat was mounted on a microscope 
glass slide with a coverslip placed on top. The slide was heated from 30-250C at a rate 
of 5C/min in a Mettler Toledo FP82HT hot stage equipped with a Mettler Toledo FP90 
central processor (Mettler Toledo GmbH, Greifensee, Switzerland). Thermo-
microscopic images were observed using a polarized, phase contrast microscope (Nikon, 
Tokyo, Japan). Images were captured at 1C intervals using an OPTIKAM PRO5 digital 
camera (OPTIKA SRL, Ponteranica, Italy) installed with Image Pro Plus software 
version 2.7 (TWAIN interface SDK, Media Cybernetics, Inc. Bethesda, MD, USA).  
 
2.3.7 Mechanical strength of nanofibre 
Mechanical properties [200–202] of the NF was determined using a TA.HD Plus Texture 
Analyser (Stable Micro Systems Ltd, Surrey, England) equipped with a 5 kg load cell 
[202]. A section of the NF was cut in a rectangular shape with dimensions of 100 mm x 
12 mm x 100 µm (L x W x D) and placed in the upper grip, the weight of the grip and 
NF sample was tared before securing the nanofibre in the lower grip. The grips were set 
at 40 mm apart and the test was conducted at a speed of 1 mm/s. Data was collected and 
analysed using Exponent Connect version 6.1.16.0 software (Stable Micro Systems Ltd, 
Surrey, England). The results presented were plotted in Microsoft excel and are the 




2.3.8 Water contact angle of nanofibre 
The hydrophilicity of the NF was determined by water contact angle [203–205], 
measured by an FTA 200 video system and analysed by FTA32 software (First Ten 
Angstroms Inc, Portsmouth, Va, USA). A flat NF sample measuring 30 mm x 15 mm 
was fixed to the stage using double-sided tape. A sessile drop of purified water (Millipore 
Milli-Q Reagent Water System, Continental Water Systems, USA) (1 µL) was placed on 
the NF using a syringe pump (First Ten Angstroms Inc, Portsmouth, Va, USA) and the 
drop recorded by video camera over a 5 min period. Images were captured at time points 
of 0, 1, 5, 10, 15, 20, 30, 50, 100, 150, 200, 250 and 300 s. The contact angle between 
the droplet and NF was measured using First Ten angstrom software and the results 
presented are the average of three independent samples measured in triplicate.  
 
2.3.9 Mass loss from PCL and PCL/blend nanofibre  
The in vitro degradation was investigated to determine the mass loss of polymer in the 
blend nanofibre. A dry NF disc (14 mm) was weighed and placed in a vial containing 2 
mL of PBS (Appendix A). The vial was incubated at 37C for the duration of the 
experiment. At time points 1, 2, 3 and 4 weeks (n=3) the NF disc was removed, rinsed in 
purified water then dried in a vacuum oven at 25C for 48 h. Dried NF disc was 
reweighed and the mass loss % was calculated by the following formula: 
𝑀𝑡
𝑀𝑖
 𝑥 100%  
where Mi is the initial mass of the dry disc and Mt is the mass of the dry NF disc after 
incubation in PBS. Results presented are the average of three independent samples 
measured in triplicate. 
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2.4 In vitro drug release 
2.4.1 RP-HPLC analysis of L-655,708 
2.4.1.1 Instrumentation  
For analysis of L-655,708, a sample (100 μL) was placed in an HPLC vial with a plastic 
insert and loaded onto a 100 x 4.6 mm, 3 µm Hypersil BDS C18 column (Thermo Fisher 
Scientific, Waltham, MA, USA) equilibrated in mobile phase consisting of 
acetonitrile:H2O (ACN:H2O, 60:40 v/v) prepared by combining separate measured 
volumes of ACN (HPLC grade, Merck KGaA, Darmstadt, Germany) and purified water. 
The mobile phase was passed through a 0.45 µm membrane (Phenomenex, Inc. Torrence, 
California, USA) to filter and then degassed under water vacuum in a sonicating water 
bath. RP-HPLC was carried out on an Agilent HPLC system with an Agilent detector 
and autosampler (Agilent Technologies, Kyoto, Japan) using an injection volume of 20 
µL. The isocratic chromatography was performed at a flow rate of 1 mL/min. The 
detector was set at 254 nm for L-655,708 and the peak area was integrated using Agilent 
software (Agilent Technologies, Kyoto, Japan) [73]. 
 
2.4.1.2 L-655,708 stock preparation and standards  
L-655, 708 was dissolved in DMSO at 1.71 mg/mL (5 mM) then diluted 1:1 with purified 
water to give a concentration of 2.5 mM.  The 2.5 mM L-655,708 solution was then 
diluted with PBS to a final concentration of 2.5 μM (stock). The stock (0.5 mL) was 
transferred into 1.5 mL sample tubes and stored at -20C. 
 
For in vitro drug release standards, stock L-655, 708 (2.5 μM) was diluted 1:100 in PBS 
to give a concentration of 25 nM then diluted in PBS (1 mL) to final concentrations of 
0.125, 0.25, 0 5, 5 and 10 nM. These standards were stored in 1.5 mL sample tubes at -




2.4.2 RP-HPLC analysis of indomethacin 
2.4.2.1 Instrumentation  
For analysis of indomethacin, a sample (100 μL) was placed in an HPLC vial with a 
plastic insert and loaded onto a Luna 150 x 4.6 mm, 5 µm C18 column (Phenomenex, Inc. 
(Torrence, California, USA) equilibrated in mobile phase consisting of ACN:PBS (50:50 
v/v) prepared by combining separate measured volumes of ACN (HPLC grade, Merck 
KGaA, Darmstadt, Germany) and PBS. The mobile phase was passed through a 0.45 µm 
membrane (Phenomenex, Inc. Torrence, California, USA) to filter and then degassed 
under water vacuum in a sonicating water bath. RP-HPLC was carried out on an Agilent 
HPLC system with an Agilent detector and autosampler (Agilent Technologies, Kyoto, 
Japan) using an injection volume of 20 µL. The isocratic chromatography was performed 
at a flow rate of 0.5 mL/min. The detector was set at 220 nm for detection of 
indomethacin. The peak area was integrated using Agilent software (Agilent 
Technologies, Kyoto, Japan). 
 
2.4.2.2 Indomethacin stock preparation and standards  
Indomethacin was dissolved in ACN at 1.71 mg/mL (5 mM) then diluted 1:1 with 
purified water to give a concentration of 2.5 mM.  The 2.5 mM indomethacin solution 
was then diluted with PBS to a final concentration of 2.5 μM (stock). The stock (0.5 mL) 
was transferred into 1.5 mL sample tubes and stored at -20C. 
 
For in vitro drug release standards, stock indomethacin (2.5 μM) was diluted 1:100 in 
PBS to give a concentration of 25 nM then diluted in PBS (1 mL) to final concentrations 
of 0.125, 0.25, 0 5, 5 and 10 nM. These standards were stored in 1.5 mL sample tubes at 




2.4.3 RP-HPLC analysis of paracetamol 
2.4.3.1 Instrumentation  
For analysis of paracetamol, a sample (100 μL) was placed in an HPLC vial with a plastic 
insert and loaded onto a Luna 150 x 4.6 mm, 5 µm C18 column (Phenomenex, Inc. 
(Torrence, California, USA) equilibrated in mobile phase consisting of ACN:H2O (70:30 
v/v) prepared by combining separate measured volumes of ACN (HPLC grade, Merck 
KGaA, Darmstadt, Germany) and purified water. The mobile phase was passed through 
a 0.45 µm membrane (Phenomenex, Inc. Torrence, California, USA) to filter and then 
degassed under water vacuum in a sonicating water bath. RP-HPLC was carried out on 
an Agilent HPLC system with an Agilent detector and autosampler (Agilent 
Technologies, Kyoto, Japan) using an injection volume of 20 µL. The isocratic 
chromatography was performed at a flow rate of 1 mL/min. The detector was set at 243 
nm for detection of paracetamol. The peak area was integrated using Agilent software 
(Agilent Technologies, Kyoto, Japan). 
 
2.4.4 RP-HPLC analysis of ampicillin  
2.4.4.1 Instrumentation  
For analysis of ampicillin, a sample (100 μL) was placed in an HPLC vial with a plastic 
insert and loaded onto a Luna 150 x 4.6 mm, 5 µm C18 column (Phenomenex, Inc. 
(Torrence, California, USA) equilibrated in mobile phase consisting of ACN:H2O (80:20 
v/v) prepared by combining separate measured volumes of ACN (HPLC grade, Merck 
KGaA, Darmstadt, Germany) and purified water. The mobile phase was passed through 
a 0.45 µm membrane (Phenomenex, Inc. Torrence, California, USA) to filter and then 
degassed under water vacuum in a sonicating water bath. RP-HPLC was carried out on 
an Agilent HPLC system with an Agilent detector and autosampler (Agilent 
Technologies, Kyoto, Japan) using an injection volume of 20 µL. The isocratic 
chromatography was performed at a flow rate of 1 mL/min. The detector was set at 204 
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nm for detection of ampicillin. The peak area was integrated using Agilent software 
(Agilent Technologies, Kyoto, Japan). 
 
2.4.5 RP-HPLC analysis of tetracycline  
2.4.5.1 Instrumentation  
For analysis of tetracycline, a sample (100 μL) was placed in an HPLC vial with a plastic 
insert and loaded onto a Luna 150 x 4.6 mm, 5 µm C18 column (Phenomenex, Inc. 
(Torrence, California, USA). Gradient HPLC was used for the analysis of tetracycline, 
the mobile phase consisted of solvent A (0.01 M phosphate buffer, pH 3.0) and solvent 
B (ACN). ACN (HPLC grade, Merck KGaA, Darmstadt, Germany) and phosphate buffer 
were filtered separately through a 0.45 µm membrane (Phenomenex, Inc. Torrence, 
California, USA) and degassed under water vacuum in a sonicating water bath. The initial 
mobile phase composition was maintained at 20% solvent A, 80% solvent B at time 0 
and changed linearly to 80% solvent A, 20% solvent B from 0-2 min, then changed 
linearly back to 20% solvent A, 80% solvent B from 2-5 min and held constant from 5-6 
min. RP-HPLC was carried out on an Agilent HPLC system with an Agilent detector and 
autosampler (Agilent Technologies, Kyoto, Japan) using an injection volume of 20 µL. 
The gradient chromatography was performed at a flow rate of 1 mL/min. The detector 
was set at 269 nm for detection of tetracycline. The peak area was integrated using 
Agilent software (Agilent Technologies, Kyoto, Japan). 
 
2.4.5.2 Tetracycline, ampicillin and paracetamol stock preparation and standards  
Tetracycline, ampicillin and paracetamol were dissolved in ACN at 1.71 mg/mL (5 mM) 
then diluted 1:1 with purified water to give a concentration of 2.5 mM.  The 2.5 mM 
tetracycline, ampicillin and paracetamol solutions were then diluted with PBS to a final 
concentration of 2.5 μM (stock). The stock (0.5 mL) was transferred into 1.5 mL sample 
tubes and stored at -20C. 
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For in vitro drug release standards, stock tetracycline, ampicillin or paracetamol (2.5 μM) 
was diluted 1:100 in PBS to give a concentration of 25 nM then diluted in PBS (1 mL) 
to final concentrations of 0.125, 0.25, 0 5, 5 and 10 nM. These standards were stored in 
1.5 mL sample tubes at -20C overnight. The standard curve was performed in triplicate. 
 
2.4.6 In vitro release of drug from nanofibre 
After preparing the drug-loaded NF (Section 2.2.2), a 14 mm drug-loaded NF disc was 
placed in a 24-well plate and a plastic insert placed on top. PBS (1 mL) was added and 
the plate was incubated at 37C for the duration of the experiment. At each time point, a 
100 µL sample of the release media was collected and the sample was replaced with fresh 
PBS (100 µL). The experiment was performed in triplicate and the mean ± standard 
deviation are reported.  
2.5 In vitro cell studies 
2.5.1 Cell Culture 
2.5.1.1 Normal human dermal fibroblast cell culture 
Normal human dermal fibroblast (NHDF) cells were cultured in T75 flasks with 15 mL 
of complete Dulbecco’s Modified Eagle Medium (Gibco/Life Technologies Co. 
(Carlsbad, CA, USA), supplemented with 10% FBS and 1% penicillin-streptomycin 
(Appendix A). NHDF cells were incubated at 37C, 5% CO2 and the medium was 




2.5.2 Nanofibre cytotoxicity and biocompatibility 
2.5.2.1 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide assay  
A 14 mm NF disc was held in the bottom of a 24 well plate with a plastic insert and 
soaked overnight in culture media at 37C, 5% CO2. The next day the media was replaced 
with fresh media. Cells were added to wells containing the NF mat and control wells at 
a cell density of 5x104 cells/cm2 or 2x104 cells/cm2. After cells were cultured for 24, 48 
or 72 h at 37C, 5% CO2, 120 µL of 3-(4, 5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) (Appendix A, Sigma Aldrich St Louis, MO, USA) 
was added to each well. The plate was incubated at 37C, 5% CO2 for 3.5 h. The 
supernatant was removed and 100 µL of isopropyl containing 4 mM HCl (Appendix A) 
was added to each well. The optical density was read at a wavelength of 540 nm using a 
Polarstar Omega Microplate Reader (BMG Labtech, Ortenberg, Germany). The mean ± 
standard deviation for the triplicate wells of each sample are reported. 
 
2.5.2.2 In vitro cytokine production 
A 14 mm NF disc was held in the bottom of a 24 well plate with a plastic insert and 
soaked overnight in culture media at 37C, 5% CO2. The next day the media was replaced 
with fresh media. NHDF cells were added to wells containing the NF mat and control 
wells at a cell density of 2x104 cells/cm2. LPS from Escherichia coli 055:B5, (1 μL) 
(Appendix A, Sigma Aldrich Co, St. Louis, MO, USA) was added to a well as a positive 
control. Media (100 μL), collected at 24 and 48 h was placed in Eppendorf tubes and 
analysed using a BD Cytometric bead array (CBA) mouse inflammation kit according to 




2.5.2.3 Cytometric bead array  
Wash buffer (100 μL) (Appendix A) was added to each well of a 96 well plate to wet the 
plate. The wells were then aspirated for 10 s to drain and blotted on a paper towel to 
remove excess. To each well, 50 μL of capture beads (Appendix A) were added (vortex 
mixed), followed by 50 μL of the standards (Appendix A), 50 μL of the samples (Section 
2.5.2.2) and 50 μL of mouse inflammation PE detection reagent. The plate was covered 
and placed on a plate shaker for 5 min at 1100 rpm. The plate was then incubated at room 
temperature for 2 h, following the incubation period the wells were aspirated for 10 s and 
blotted on a paper towel to remove excess. Wash buffer (100 μL) was added to each well 
to re-suspend the beads, the plate was placed on a plate shaker for 2 min at 1100 rpm 
before sample acquisition. Flow cytometry analysis was performed using a Gallios flow 
cytometer (Beckman Coulter, Brea, CA, USA) and the data was analysed using 
LEGENDplex™ Data Analysis Software (BioLegend, San Diago, CA, USA).  
 
2.6 Statistical analysis 
GraphPad Prism version 5.01 for Windows (GraphPad Software, La Jolla, CA, USA) 
was used to perform statistical analysis. Analysis of statistical significance using an 
unpaired t-test, two-way ANOVA with Bonferroni’s post hoc test and one-way ANOVA 
with Dunnett’s multiple comparison test was then performed as indicated in the relevant 
figure legends. The level of significance was determined by *p < 0.05 ***p < 0.001. 







Development and characterisation of PLGA 





Parts of this chapter have been submitted as a manuscript to the Journal of Materials 
Science, titled: McLaughlin, A., McDowell, A., Clarkson, A.N., Walker, G.F. 
(submitted). Characterisation of poly-(lactic-co-glycolic acid) nanofibers electrospun 
using a sustainable green chemistry for producing solvents with low toxicity solvent 





3 Development and characterisation of PLGA nanofibres using low 
toxic solvents 
3.1 Introduction 
3.1.1 Poly-(lactic-co-glycolic-acid) (PLGA) 
PLGA (Figure 3-1) emerged in the biomedical field in the early 1970s with the 
development of absorbable medical sutures [206]. PLGA has since gained FDA approval 
for clinical use in humans and has seen an increased interest in the biomedical field due 
to its biocompatibility, biodegradation, tailored degradation rate (due to the availability 




Figure 3-1 Chemical structure of the poly-(lactic-co-glycolic-acid) repeating monomer unit. 
The lactic acid repeating unit is in the square bracket labelled n and the glycolic acid repeating 
unit is in the square bracket labelled m. 
 
PLGA is an aliphatic poly-(ester) due to the ester bond linkage in the carbon backbone 
and is generally synthesised from cyclic lactide and glycolide monomers by a method 
called ring-opening polymerisation [209]. The ratio of lactide to glycolide influences the 
overall composition of PLGA, for example, PLGA 90:10 has a 90% lactic acid (LA) to 
10% glycolic acid (GA) content and the polymer can exist in several different ratios, i.e. 




glass transition temperature (Tg) range from 45-55°C, even though GA is highly 
crystalline [210]. In an aqueous environment, PLGA undergoes hydrolytic degradation 
of the ester bonds. The hydrolytic degradation process occurs by bulk or heterogeneous 
erosion, involving four steps; 1) hydration: water enters the amorphous region, causing 
disorder between hydrogen bonds and van der Waals forces lowering the Tg; 2) initial 
degradation: covalent bonds are cleaved and a decrease in molecular weight occurs; 3) 
constant degradation: covalent bonds on the polymer backbone are cleaved causing 
substantial mass loss; carboxylic end groups on the oligomers auto-catalyse the 
degradation process, oligomers diffuse out of the polymer leading to an influx of water 
that assists the diffusion of the oligomers 4) solubilisation: the fragmented oligomers are 
hydrolysed to monomers and are solubilised by the aqueous environment [208,210,211]. 
LA has a methyl side group that makes it more hydrophobic, therefore, PLGA with a 
higher LA content is less hydrophilic and will absorb less water [212]. This influences 
the degradation rate and PLGA with higher LA content will take longer to degrade. 
Typical degradation rates in physiological conditions are 1-2, 4-5, and 5-6 months for 
PLGA 50:50, 72:25 and 85:15, respectively [208,212]. The LA and GA monomers that 
are produced as by-products of PLGA degradation can be metabolised and excreted by 
normal physiological pathways [213,214]. LA is converted to pyruvic acid, enters the 
citric acid cycle and is excreted by respiration as water and carbon dioxide [213,214]. 
GA is eliminated unchanged by the kidney or it is converted to glycine where it enters 
the citric acid cycle and is eventually eliminated as water and carbon dioxide [213]. 
 
3.1.2 Applications of PLGA and its biocompatibility and toxicity 
PLGA has been investigated for a range biomedical applications including scaffolds, 
films, membranes, microparticles and nano-particles [215–219]. However, the 
biocompatibility and toxicity can vary between the different forms. PLGA scaffolds have 
caused an inflammatory response and induce a foreign body reaction at the scaffold 
interface in vivo, due to a potential build-up of acidic degradation products altering the 
pH in surrounding tissue [220]. In addition, PLGA microparticles have been shown to 




size, shape, and chemical and physical properties of particles [221]. PLGA 75:25 
microcapsules containing leuprorelin implanted subcutaneously in rats displayed low 
inflammation with the formation of a fibrous capsule consisting of macrophages and 
foreign body giant cells (a collection of fused macrophages) with the biodegradation and 
phagocytosis of the microspheres after one month [222]. Stereotaxic implantation in the 
rat brain of PLGA 50:50 microspheres with an average diameter of 22 μm were 
investigated over two months [223]. After only one day the microspheres were 
surrounded by macrophages and activated microglial cells, and by day 10 and 21 foreign 
body giant cells and astrocytes were present [223]. The inflammatory response decreased 
considerably after one month and was almost non-existent by two months following the 
biodegradation of the microspheres [223]. Nanoparticles are more readily phagocytosed 
compared to microparticles due to their smaller size, and therefore, result in a reduced 
immune response. However, nanoparticles readily accumulate in the liver, bone marrow, 
lymph nodes, spleen and peritoneal macrophages and toxicity may result as the PLGA 
nanoparticles degrade [210,224]. 
 
3.1.3 Electrospinning PLGA and the use of alternative, low toxic solvents 
As discussed in Chapter 1, electrospinning is a process that can produce fibres with 
diameters in the nanometre range, which provide a high surface area to volume ratio, 
high porosity and excellent mechanical strength, along with flexibility. Researchers have 
explored the potential to fabricate PLGA NF by using the electrospinning process. In the 
biomedical field, PLGA NF have been investigated for their potential use as drug delivery 
devices, tissue engineering scaffolds and wound healing dressings [225–227]. The 
electrospinning process generally requires dissolving a polymer in solvents, which is a 
key parameter that influences the solution properties for electrospinning. Studies have 
shown that polymer concentration, conductivity, dielectric constant, viscosity and 
surface tension of the solution can affect fibre morphology and diameter (12–17). 
However, the solvents employed are often highly toxic and subsequently, there is a need 
to find alternative electrospinning solvents, which are less hazardous and more 





To date, alternative less toxic solvent systems have been investigated for the 
electrospinning of PLA and PCL [228–232]. PLGA NFs have successfully been 
electrospun (Table 3-1). All of these solvent systems are United States pharmacopoeia 
(USP) Class II solvents that are highly toxic, both to the body and the environment [233]. 
The solvent toxicity concerns highlight the need to develop NFs produced using safer 
organic solvents. Despite the use of toxic solvents for the fabrication of PLGA NFs, 
several studies have not been able to show any evidence of toxicity in vitro or in vivo 
[234–236]. The lack of toxicity may be due to the evaporation of the solvent during the 
electrospinning process and post vacuum drying. However, using a toxic solvent in the 
manufacturing process will be a regulatory barrier for biomedical applications as the 
solvents may promote cancerous tumour growth, and the FDA states, that due to the 
inherent toxicity of Class II solvents, their use should be limited where possible in the 
manufacturing process, and when used, their concentration should not exceed their 
permitted daily exposure limit [233]. 
 
Table 3-1 Common solvent systems used to electrospin PLGA. 
Polymer Solvent system Application Reference 
PLGA (50:50) DCMa:DMFb (80:20) Drug delivery [106] 
PLGA (85:15) DCM:DMF (70:30) Drug delivery [106] 
PLGA (75:25) THFc:DMF (90:10) Tissue engineering [237] 
PLGA (70:20) CHCl3d:DMF (80:20) Tissue scaffold [238] 
PLGA (85:15)/PCL CHCl3:MeOHe (3:1) Neural regeneration [239] 
PLGA (50:50)/chitosan DCM:HFIPf (1:2) Tissue regeneration [240] 
DCMa Dichloromethane, DMFb Dimethylformamide, THFc Tetrahydrofuran, CHCl3d Chloroform, MeOHe 





Alternative solvents with lower toxicity have been shown to be effective substitutes for 
electrospinning polymers and include acetone (ACE), ethyl acetate (EtAc), acetic acid 
(AA) and formic acid (FA). These USP Class III solvents have a substantially higher 
permitted daily exposure limit than Class II solvents [233]. ACE is a common solvent 
used in the pharmaceutical industry and has been reported as a non-toxic, innocuous 
solvent for electrospinning PCL [228]. A benign and non-toxic solvent system consisting 
of ACE and AA was successfully used to electrospin PCL and researchers also used a 
combination of ACE and FA to electrospin a CH/PCL blend NF (8-10). EtAc is found in 
many biological systems, readily biodegradable and is hydrolyzed to ethanol and AA, 
therefore, it has a low risk of toxicity [241]. It has been used with AA diluted in water to 
electrospin gelatin and PCL/GEL blend NF [242,243]. 
 
3.2 Chapter aims 
Using the electrospinning method to produce NFs, the aim of the work presented in this 
chapter was to develop an alternative, less toxic solvent system that is suitable to dissolve 
PLGA using Class III solvents to prepare PLGA and drug-loaded PLGA NFs. The 
chemical and physical properties of the PLGA NF prepared using the Class III solvent 
system were characterised and compared to a Class II solvent system to determine if the 
solvent system influenced NF properties. Three model drugs, the low molecular weight 
paracetamol, medium molecular weight ampicillin and the high molecular weight 
tetracycline were then incorporated into the PLGA NFs. The physical and chemical 
properties of the drug-loaded NFs were investigated to determine if the drugs were 
incorporated into the NFs. The properties of the drug-loaded NFs were compared to 
determine if the drugs influenced the properties of the PLGA NFs. The drug release 
kinetics of the three model drugs was investigated to determine if the molecular weight 





3.3 Methods  
PLGA NFs were prepared using the electrospinning process with either ACE:EtAc or 
DCM: DMF as the solvent system and FE-SEM was employed to determine NF 
morphology. ATR-FTIR, DSC and TGA were used to determine the solid-state 
properties. Mechanical strength was measured using a texture analyser and the 
hydrophobic properties were determined by water contact angle measurements. The NF 
morphology and the solid-state properties of the drug-loaded PLGA NFs were 
characterised using the above methods with the inclusion of hot stage microscopy. The 
drug release kinetics from drug-loaded PLGA NFs was determined by RP-HPLC.   
 




3.4.1 Production and characterisation of PLGA nanofibres 
3.4.1.1 Electrospinning and nanofibre morphology 
The electrospinning process was employed to prepare PLGA 75:25 NF using two 
different solvent systems. ACE has been previously described as a low toxic solvent to 
electrospin PCL and initial attempts to electrospin PLGA employed ACE as the solvent 
[228]. However, in the present studies, the PLGA ACE solution did not form a stable 
Taylor cone under an applied voltage. A possible reason for the lack of suitability of ACE 
to form NFs could be related to differences in the dielectric constant. The dielectric 
constant (ε) is an important parameter when electrospinning and researchers have 
concluded a ε of approximately 19 is required to produce an optimal PCL NF from the 
solution [244]. Below a ε of 19 electrospraying of PCL occurred, or fibres with 
micrometre diameters were produced [244]. The ε of pure ACE is 20.7. To lower the ε, 




[245]. EtAc, a low toxic Class III solvent with a ε of 6 was selected. ACE and EtAc were 
mixed at a ratio of 80:20 and 70:30, to give an additive ε of 17.76 and 16.35, respectively. 
PLGA 75:25 was dissolved in the ACE:EtAc solvent system at a ratio of either 80:20 or 
70:30 at 20% (w/v). For NF production the electrospinning parameters were kept 
constant, with a flow rate of 4 mL/h, a voltage of 18 kV, and needle gauge of 20 with a 
distance from needle tip to the collector of 15 cm (Section 2.2.2). The morphological 
analysis of the spun NF mats by FE-SEM (Section 2.3.1) showed that the 80:20 solvent 
produced beaded NF (Figure 3-2 a) However, electrospinning at a ratio of 70:30 gave 
haphazardly aligned, bead free NF (Figure 3-2 b), hence, ACE:EtAc 70:30 was selected 
for the comparison study. DCM:DMF was selected as the comparative solvent system 
due to it being effectively used in the literature to produce fibres from PLGA 50:50 and 
PLA 85:15 and at a ratio of 70:30, the solvent system has a ε of 17.26 [106]. For a 
comparative study, electrospinning of PLGA 75:25 using DCM:DMF at a ratio of 70:30 
was conducted with similar parameters to ACE:EtAc (Section 2.2.2). The resulting NF 





Figure 3-2 FE-SEM micrographs of PLGA 75:25 electrospun with solvent system (a) 
ACE:EtAc (80:20), (b) ACE:EtAc (70:30) and (c) DCM:DMF (70:30). 
 
For further investigation of the morphological differences between the NF produced from 
the two different solvent systems, the fibres were analysed at higher magnification using 
FE-SEM. The fibre diameter range, distribution and average size was determined by 
measuring 100, haphazardly selected fibres from each NF using imaging software 
(Section 2.3.1). ACE:EtAc produced smooth fibres that ranged in diameter from 0.4-2.8 
µm (Figure 3-3 a, b) and when using DCM:DMF a more narrow distribution of fibre 
diameter range of 0.2-2 µm was observed (Figure 3-3 c, d). There was a large variation 
in fibre diameter distribution that was non-uniform with respect to the ACE:EtAc solvent 
system and in contrast, DCM:DMF had a uniform distribution with a few outliers (Figure 
3-3 b, d). Electrospinning with ACE:EtAc produced an NF with an average fibre 
diameter of 1.1 µm (Figure 3-3 e), which was larger than the fibre diameter of 0.63 µm 







Figure 3-3 FE-SEM micrographs and corresponding graph of fibre diameter distribution, (a, b) 
PLGA ACE:EtAc and (c, d) PLGA DCM:DMF. (e) Mean fibre diameter of each NF (n=100). 





3.4.1.2 Attenuated total reflectance-Fourier transform infra-red spectroscopy  
Chemical analysis of the PLGA polymer composition was performed using ATR-FTIR 
to confirm that the chemical bonds of the polymer, were not affected by the 
electrospinning process, or the solvent systems. ATR-FTIR was performed on PLGA 
DCM:DMF, PLGA ACE:EtAc NF mats and pure PLGA polymer (Section 2.3.2). 
Spectra of pure PLGA and PLGA NF are shown in (Figure 3-4). Pure PLGA has a strong 
carbonyl (-C=O) stretch vibration at 1751 cm-1, the carbonyl stretch is observed in PLGA 
ACE:EtAc at 1747 cm-1 and 1749 cm-1 for PLGA DCM:DMF. Characteristic C-O-C 
bands are observed at 1078 cm-1 and 1174 cm-1 for pure PLGA. The C-O-C bands appear 
for PLGA ACE:EtAc at 1085 cm-1 and 1180 cm-1 and 1085 cm-1 and 1182 cm-1 for PLGA 
DCM:DMF. O-H deformation bands are at 1263 cm-1 for pure PLGA and PLGA 
ACE:EtAc and at 1267 cm-1 for PLGA DCM:DMF. Similarly, for all three samples, C-
H stretch is observed at 1450 cm-1, and C-H2 and C-H3 stretch can be observed at ~2940 
cm-1 and 2987 cm-1, respectively. Because the characteristic bands of pure PLGA were 
observed in the spectra of PLGA NF, the ATR-FTIR comparative analysis indicates that 
neither the electrospinning process nor individual solvent systems affected the chemical 
composition of PLGA polymer. 
 
 
Figure 3-4 ATR-FTIR spectra of pure PLGA (black line), PLGA ACE:EtAc NF (orange line) 





3.4.1.3 Differential scanning calorimetry 
PLGA 75:25 is an amorphous polymer, therefore, after the electrospinning process, the 
NF solid-state was investigated to determine if the solvent system influenced the 
amorphous nature of PLGA, given that the rate of solvent evaporation may have an 
influence. A sample of either pure PLGA 75:25, or a PLGA NF prepared using 
DCM:DMF or, ACE:EtAc was sealed in an aluminium pan and was individually 
analysed using DSC. The analysis took place under a nitrogen atmosphere and against a 
reference pan, to establish the heat flow through the material (Section 2.3.3). The 
endothermic peaks in Figure 3-5 represent the glass transition temperature (Tg), which 
indicates the amorphous nature of the sample. Pure PLGA has a midpoint Tg of 46.32°C, 
while the PLGA NFs have higher Tg of 49.92°C and 50.45°C (midpoints) for PLGA 
DCM:DMF and PLGA ACE:EtAc respectively and were not significantly different. Both 
PLGA NFs had a higher Tg than pure PLGA, which may be attributed to the solvents 
acting as a plasticizer, along with the rapid evaporation of the solvent leading to a lower 
molecular orientation and prohibiting the relaxation of the polymer chains [246,247]. The 
difference in Tg of the PLGA NFs using the different solvent systems may arise because 
of differences in solvent volatility. DCM has a low boiling point of 39.6°C whereas DMF 
has a boiling point of 153°C, compared to ACE and EtAc, which have boiling points of 
56°C and 77.1°C, respectively. Therefore, the lower volatility of DCM:DMF may have 
caused a lower Tg, conversely, the higher volatility of  ACE:EtAc resulted in a higher 






Figure 3-5 DSC thermogram of the glass transition of pure PLGA (black line), PLGA 
ACE:EtAc NF (orange line) and PLGA DCM:DMF NF (blue line) over the temperature range 
of 40-56°C. 
 
3.4.1.4 Thermogravimetric analysis 
TGA has been used as a method to detect if any residual solvents are entrapped within 
the NF mat [247]. A sample of pure PLGA, PLGA DCM:DMF NF or PLGA ACE:EtAc 
NF was placed in an aluminium pan and heated from 35°C to 600°C in a TGA (Section 
2.3.4). Solvent loss is observed in the TGA over the range of 35-120°C for each sample 
(Figure 3-6 a). PLGA DCM:DMF shows a weight loss of ~0.13% over the range of 42-
60°C and ~0.25% from 80-108°C. The first step may be attributed to DCM (boiling point, 
39.6°C) while the latter may be due to DMF, although this has a boiling point of 153°C. 
PLGA ACE:EtAc has a single weight loss step of ~0.22% from 45-80°C. The single 
weight loss step may be a combination of the two solvents, as the boiling points of 56°C 
and 77°C for ACE and EtAc, respectively, could indicate evaporation is occurring at 





TGA was also used to investigate the thermal stability and the maximum degradation 
temperature of the PLGA NFs (Figure 3-6 b). Pure PLGA had an onset temperature of 
~230°C and finished at ~420°C (Figure 3-6 b) and is in agreement with previously 
published PLGA TGA data [248]. Both of the NFs had a higher onset temperature of 
~260°C but also finished decomposition at ~420°C (Figure 3-6 b).  For both PLGA NFs, 
this is consistent with literature values [247,249]. The difference in onset temperature 
may be attributed to the difference in fibre diameter between the two PLGA NFs as 
observed in Section 3.4.1.3 and may also explain why the initial rate after the onset 
temperature is different between PLGA ACE:EtAc and PLGA DCM:DMF. As the larger 
fibre diameter of PLGA ACE:EtAc may reflect a more bulk PLGA structure, therefore 






Figure 3-6 TGA thermograms of pure PLGA and PLGA NFs. (a) Over the range of 35-120°C 
of pure PLGA (black line), PLGA ACE:EtAc NF (orange line) and PLGA DCM:DMF NF 
(blue line). (b) Over the range of 35-600°C of pure PLGA (black line), PLGA ACE:EtAc NF 






3.4.1.5 Mechanical strength 
Due to morphological differences observed in the NF (Section 3.4.1.1), the tensile 
strength was investigated to determine if the different morphology of the fibres 
influenced the tensile properties of the NF. The NF mat was cut into 100 mm x 12 mm 
strips, placed in tensile grips and stretched until breaking at 1 mm/s using a texture 
analyser (Section 2.3.7). Figure 3-7 depicts a typical tensile strength curve of the PLGA 
NF mats. The maximum tensile strength of the PLGA NF electrospun using ACE:EtAc, 
was 1.9 MPa; in contrast DCM:DMF had a higher tensile strength of 4.7 MPa and the 
difference between the two NF was statistically significant.  
 
 
Figure 3-7 Graph showing the measurement of the force applied to the NFs over time of PLGA 
ACE:EtAc (orange line) and PLGA DCM:DMF (blue line) NF. Each line represents the mean 
of three individual experiments. 
 
The PLGA NFs made from different solvent systems undergo different mechanical 
deformation processes. Figure 3-7 identifies the different regions as the fibres go through 




a gross overview of the different failure mechanism of the two NF at the plastic region. 
Necking occurs when the cross-sectional area of the sample decreases creating a “neck” 
[250]. This form of deformation can be observed in the PLGA DCM:DMF NF (Figure 
3-8 A). The PLGA ACE:EtAc NF deforms by a mechanism known as fibril crazing, as 
the NF is put under tension and cracks appear perpendicular to the applied force (Figure 
3-8 B) [251,252].  
 
 
Figure 3-8 Photograph of the deformation at the plastic region (red box) of (A) PLGA 
DCM:DMF NF and (B) PLGA ACE:EtAc NF. 
 
To investigate the different failure mechanism in more detail, FE-SEM images (Section 
2.3.1) were captured before and after the deformation process eat the elastic, plastic and 
fracture regions of the NFs (Figure 3-9). Before tensile testing, both PLGA DCM:DMF 
and PLGA ACE:EtAc show overlaying individual NFs (Figure 3-9 1a, 2b). At the elastic 
stage, the NF appears to be still haphazardly orientated (Figure 3-9 1b, 2b). As PLGA 
DCM:DMF enters the plastic region necking starts to occur and this increases as the 
tension is applied (Figure 3-9 1c). At the fracture point, the edge of the fracture shows 
aligned fibres in the direction of the applied tension (Figure 3-9 1d). Higher 
magnification of fractured fibres shows necking occurring in individual fibres, leading to 




tension starts to occur in the plastic region of the PLGA ACE:EtAc NF mat and is more 
pronounced at the fracture point, where individual fibres span the fracture (Figure 3-9 
2c, 2d). Higher magnification of individual fibres at the fracture point shows the force 
applied has led to fibril crazing, where single fibril has been drawn out from the fibre 













Figure 3-9 FE-SEM images of PLGA DCM:DMF and PLGA ACE:EtAc NF taken at the different regions during the deformation process. The direction of 
tension applied is shown in the figure and is the same for all FE-SEM images. (1a) PLGA DCM:DMF NFs before deformation, (2a) PLGA ACE:EtAc NFs 
before deformation, (1b) PLGA DCM:DMF NFs at the elastic region, (2b) PLGA ACE:EtAc NFs at the elastic region, (1c) PLGA DCM:DMF NFs at the 
plastic region, (2c) PLGA ACE:EtAc NFs at the plastic region, (1d) PLGA DCM:DMF NFs at the fracture point, (2d) PLGA ACE:EtAc NFs at the fracture 
point, (1e) high magnification of PLGA DCM:DMF NFs at the fracture point, (2e) high magnification of  PLGA ACE:EtAc NFs at the fracture point.
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3.4.1.6 Surface hydrophobicity of nanofibre  
The surface hydrophobicity of an NF is dependent on the chemical and physical 
properties, differences in the fibre diameter of the NF may change the physical properties 
and therefore influence the surface hydrophobicity. To investigate the surface 
hydrophobicity of PLGA NF, dynamic water contact angle measurements were 
conducted. The surface of a material is deemed hydrophobic if the angle from where the 
water-surface interface meets is more than 90°, conversely, if the angle is less than 90° 
the surface of the material is considered hydrophilic [253]. To determine this, a 1 μL 
sessile drop of water was placed on the surface of the NF and a camera recorded and 
captured the drop over a 5 min period (Section 2.3.8). Water droplets are observed on 
NF mats in Figure 3-10. PLGA 75:25 ACE:EtAc had a significantly higher water contact 
angle at all three of the time points measured indicating the surface was more 
hydrophobic. The initial water contact angle was 72.6° and after five minutes reduced to 
69.2°, compared to DCM:DMF, which started at 65° and over five minutes had decreased 
to 63° (Figure 3-11). In the present study, the surface of both PLGA NFs are considered 
hydrophilic, due to having a contact angle below 90°. However, as the contact angle is 
influenced by the surface roughness, the difference observed may be due to a non-
uniform fibre diameter distribution, contributing to an increased surface roughness that 
led to an increased contact angle for the PLGA ACE:EtAc NF. Literature values of PLGA 
NF contact angles are higher than the results we obtained here, although there is a large 
variance in the data, from 105° to 139° [254–260]. However, Vasita et al. (2010) did see 
a similar trend for their dynamic contact angle measurements with a decrease of ~4°, 





Figure 3-10 Photograph of the water droplets on (a) PLGA DCM:DMF at 1 s, (b) PLGA 






Figure 3-11 Water contact angles of PLGA ACE:EtAc (blue line) and PLGA DCM:DMF 
(orange line) as a function of time. Each point represents the mean of three individual 
experiments ± SD. Statistical significance was determined by two-way ANOVA with 
Bonferroni’s post hoc test, ***p<0.001 and is the comparison of the two NF. 
 
3.4.2 Production and characterisation of drug-loaded PLGA nanofibres 
3.4.2.1 Electrospinning and drug-loaded nanofibre morphology 
Using the two different solvent systems, drug-loaded PLGA NFs were prepared by the 
co-electrospinning method by dissolving the drug in the polymer/solvent solution, 
followed by electrospinning of the solution. To investigate and compare the fibre 
morphology of the drug-loaded NFs prepared using the different solvent systems, 100 
fibres were selected and analysed by FE-SEM software (Section 2.3.1). All formulations 
were able to be electrospun and formed haphazardly aligned, overlaid fibre mats (Figure 
3-12). Furthermore, FE-SEM images show that the individual fibres appear to have 
irregular structures on the surface of the NFs that may be drug particles bound to the 
surface of the NFs (Figure 3-12). Drug crystals on the surface of NFs have been reported 
by other authors. For example, Zeng et al. (2005) reported doxorubicin hydrochloride 
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crystals on the surface of poly-(L-lactide) and Seif et al. (2015) noted caffeine crystals 
on the surface of PCL NFs [261,262].  
 
 
Figure 3-12 FE-SEM micrographs of (a) PLGA DCM:DMF + tetracycline, (b) PLGA 
ACE:EtAc + tetracycline, (c) PLGA DCM:DMF + ampicillin, (d) PLGA ACE:EtAc + 
ampicillin, (e) PLGA DCM:DMF + paracetamol and (f) PLGA ACE:EtAc + paracetamol NF. 




Overall, PLGA electrospun using ACE:EtAc as the solvent system led to NFs with a 
greater fibre diameter range and distribution (Figure 3-13 b, d, f). Fibre diameter ranged 
from 0.4 – 2 µ PLGA DCM:DMF + tetracycline vs 0.4 – 2.6 µm for PLGA ACE:EtAc + 
tetracycline (Figure 3-13 a, b). PLGA ACE:EtAc + ampicillin ranged from 0.2 – 4 µm 
compared to PLGA DCM:DMF + ampicillin which was 0.4 – 2.4 µm (Figure 3-13 c, d). 
PLGA ACE:EtAc + paracetamol ranged from 0.4 – 4.4 µm, while PLGA DCM:DMF + 
paracetamol had the narrowest range, which was 0.2 – 1 µm (Figure 3-13 e, f). 
 
 
Figure 3-13 Histogram representing the NF diameter range and distribution of (a) PLGA 
DCM:DMF + tetracycline, (b) PLGA ACE:EtAc + tetracycline, (c) PLGA DCM:DMF + 
ampicillin, (d) PLGA ACE:EtAc + ampicillin, (e) PLGA DCM:DMF + paracetamol and (f) 




The average fibre diameter for PLGA DCM:DMF + tetracycline was 0.969 µm while 
PLGA ACE:EtAc + tetracycline was 1.43 µm. There was no statistically significant 
difference between the average fibre diameter of PLGA DCM:DMF + ampicillin (1.16 
µm) and PLGA ACE:EtAc + ampicillin (1.40  µm). The biggest difference was observed 
between the paracetamol loaded NFs. PLGA DCM:DMF + paracetamol had the smallest 
average fibre diameter of 0.625 µm and PLGA ACE:EtAc + paracetamol had the largest 
average fibre diameter of 1.94 µm (p < 0.001) (Figure 3-14). 
 
 
Figure 3-14 The mean fibre diameter of each PLGA drug-loaded NF. PLGA DCM:DMF + 
tetracycline (grey bar), PLGA ACE:EtAc + tetracycline (orange bar), PLGA DCM:DMF + 
ampicillin (yellow bar), PLGA ACE:EtAc + ampicillin (green bar), PLGA DCM:DMF + 
paracetamol (blue bar) and PLGA ACE:EtAc + paracetamol (red bar). Bars represent the mean 
of 100 fibres from each NF ± SD. Statistical significance was determined by one-way ANOVA 





3.4.2.2 Attenuated total reflectance-Fourier transform infra-red spectroscopy of 
drug-loaded NF 
ATR-FTIR (Section 2.3.2) was performed to investigate the incorporation of the drug in 
the NF and to determine if there was a chemical interaction between the polymer and 
drug. ATR-FTIR was performed on a sample of the drug-loaded NF and pure drug to 
obtain and compare the spectra.  
 
Pure tetracycline (Figure 3-15 a) (black line) was observed to have characteristic peaks, 
at 3319 cm-1 N-H stretching occurs and at 3298 cm-1 as an O-H stretch.  The peak at 2983 
cm-1 is attributed to CH3.  A peak is observed at 1672 cm
-1, which is assigned to C=O 
stretching of the amide I band and the peak at 1521 cm-1 is assigned to the amide II band. 
The two peaks observed at 1614 cm-1 and 1581 cm-1 are due to the C=O stretching of the 
two different carbonyl groups. The peak at 1226 cm-1 represents C-N stretch. PLGA 
DCM:DMF + tetracycline (blue line) and PLGA ACE:EtAc + tetracycline (orange line) 
(Figure 3-15 a) have characteristic peaks of PLGA which occur at 2995, 2947, 1751, 
1267, 1180 and 1087 cm-1, which corresponds to CH2 and CH3 stretch, C=O stretch, O-
H deformation and C-O-C stretch, respectively. With respect to tetracycline, the N-H 
peak at 3319 cm-1 and the O-H peak at 3298 cm-1 do not appear in the spectrum of either 
NF, this may be due to hydrogen bonding with the carbonyl group of PLGA. A peak at 
1672 cm-1, which is assigned to the amide I band in tetracycline appears in both NFs 
although, it is weaker in PLGA ACE:EtAc + tetracycline. The two carbonyl stretching 
peaks appear at 1610 and 1579 cm-1 for PLGA DCM:DMF + tetracycline and are weak. 
The same peaks are stronger in PLGA ACE:EtAc + tetracycline and appear at 1614 and 
1579 cm-1. The C-N stretch of tetracycline appears at 1222 cm-1 in the spectrum of both 
NFs. The new peaks that appear in both NF spectrums indicate the incorporation of the 
drug in the NF. Furthermore, the change in peak intensity and shifts may indicate an 





The ATR-FTIR spectrum of pure ampicillin (black line), PLGA DCM:DMF + ampicillin 
NF (blue line) and PLGA ACE:EtAc + ampicillin NF (orange line) are shown in Figure 
3-15 b. In the spectrum of pure ampicillin, a peak is observed at 3331 cm-1 which is 
attributed to N-H stretching, while the peaks at 2974 cm-1 and 2926 cm-1 are due to CH3 
stretching. The peak at 1764 cm-1 is assigned to C=O stretching.  Amide I band is 
assigned to the peak at 1692 cm-1, while the amide II band appears at 1494 cm-1 with a 
shoulder peak at 1514 cm-1. The sharp peak at 642 cm-1 is characteristic of S-C stretching. 
The PLGA NFs appear to have the characteristic peaks of PLGA (Figure 3-15 b), which 
appear at 2987, 2941, 1749, 1267, 1182 and 1085 cm-1 that correspond to CH2 and CH3 
stretch, C=O stretch, O-H deformation and C-O-C stretch, respectively. The N-H peak 
of ampicillin appears weakly at 3332 cm-1 in the spectrum of PLGA DCM:DMF + 
ampicillin and very weakly at 3332 cm-1 in PLGA ACE:EtAc + ampicillin NF, this may 
be due to hydrogen bonding with the carbonyl group of PLGA. The amide I band appears 
weakly at 1693 cm-1 for PLGA DCM:DMF + ampicillin and 1691 cm-1 for PLGA 
ACE:EtAc + ampicillin on the shoulder of the C=O peak of PLGA. The amide II band 
appears very weakly at 1525 cm-1 for PLGA DCM:DMF + ampicillin and 1512 cm-1 for 
PLGA ACE:EtAc + ampicillin and may be due to hydrogen bonding with the carbonyl 
group of PLGA. The S-C stretching peak appears at 644 cm-1 for both NFs. The 
appearance of ampicillin peaks in both NF spectrums indicate the incorporation of the 
drug in the NF. Furthermore, the change in peak intensity and shifts may indicate an 
interaction is occurring between the drug and polymer such as hydrogen bonding. 
 
The ATR-FTIR spectrum of pure paracetamol (black line), PLGA ACE:EtAc + 
paracetamol (orange line) and PLGA DCM:DMF + paracetamol (blue line) are depicted 
in Figure 3-15 c. In the spectrum of pure paracetamol, N-H stretching is observed at 
3321 cm-1 and O-H stretch is seen at 3149-3103 cm-1. The peak at 1651 cm-1 is assigned 
to the amide I band, while the amide II band appears at 1560 cm-1. The peak that appears 
at 1224 cm-1 is C-N stretch. Both PLGA NFs have the characteristic peaks of PLGA 
which appear at 2987, 2941, 1749, 1267, 1182 and 1085 cm-1 which correspond to CH2 
and CH3 stretch, C=O stretch, O-H deformation and C-O-C stretch, respectively. A peak 
at 3321 cm-1 and 3147 cm-1 appears in PLGA DCM:DMF + paracetamol that is assigned 
to N-H stretch and O-H stretch of paracetamol, these peaks do not appear in PLGA 
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ACE:EtAc + paracetamol and maybe due to hydrogen bonding with the carbonyl group 
of PLGA . The amide I and II bands occur at 1654 cm-1 and 1564 cm-1 for PLGA 
DCM:DMF + paracetamol and for PLGA ACE:EtAc + paracetamol at 1660 cm-1 and 
1543 cm-1. The C-N stretch of paracetamol appears at 1222 cm-1 for both NF. All 
paracetamol peaks are weaker for PLGA ACE:EtAc + paracetamol compared to PLGA 
DCM:DMF + paracetamol. The appearance of paracetamol peaks in both NF spectrums 
indicate the incorporation of the drug in the NF. Furthermore, and as suggested for the 
incorporation of the other drugs into the NFs, the change in peak intensity and shifts may 
indicate an interaction is occurring between the drug and polymer such as hydrogen 
bonding or the change in the solid-state of the drug from crystalline to amorphous as 





Figure 3-15 ATR-FTIR spectra of (a) pure tetracycline (black line), PLGA ACE:EtAc + 
tetracycline NF (orange line) and PLGA DCM:DMF + tetracycline NF (blue line), (b) pure 
ampicillin (black line), PLGA ACE:EtAc + ampicillin NF (orange line) and PLGA DCM:DMF 
+ ampicillin NF (blue line) and (c) pure paracetamol (black line), PLGA ACE:EtAc + 




3.4.2.3 Thermogravimetric analysis of drug-loaded nanofibre 
To investigate the thermal stability of the drug-loaded NF and also confirm the 
incorporation of the drug in the NF TGA analysis was employed. Samples of either pure 
drug or drug-loaded NF were placed in a platinum TGA pan and heated in a furnace 
under a nitrogen atmosphere from 20-600°C (Section 2.3.4).  
 
There are three weight loss steps in the TGA curve of pure tetracycline (Figure 3-16 a). 
The initial step occurs from 200°C to 250°C and represents a weight loss of 23%, the 
second step occurs from 250-350°C, with a weight loss of 13%. The first two steps are 
attributed to the thermal degradation of tetracycline with the formation of a carbonaceous 
product [267]. The final step is the decomposition of the carbonaceous product from 350-
600°C. Previous experiments demonstrated there is solvent loss from the PLGA NFs 
(Figure 3-6 a). Solvent loss occurs in the drug-loaded NF however, this is also coupled 
with the decomposition of tetracycline and PLGA and occurs over the range of ~50-
320°C. There is a slight deviation in weight loss between the two NFs over this range 
that may be due to a combination of the volatility of the different solvents as observed in 
Figure 3-6 a, and the loss of surface-bound drug. For example PLGA DCM:DMF may 
contain more surface bound drug compared to PLGA ACE:EtAc, therefore, this surface 
bound drug is degraded faster increasing the rate of weight loss. The larger weight loss 
step from 320°C is the decomposition of the PLGA polymer.  
 
The TGA weight loss curve of pure ampicillin has three weight loss steps (Figure 3-16 
b). The first step results in a 31% weight loss and occurs over the range of 211-243°C. 
The second step occurs from 243-350°C and corresponds to a weight loss of 39%. The 
first two steps are the decomposition of ampicillin, which forms a carbonaceous product. 
The final weight loss step is the decomposition of the carbonaceous product. Solvent loss 
is observed from drug-loaded NFs with the addition of ampicillin decomposition, which 
occurs from 220°C until 270°C and represents a weight loss of ~8%. This is followed by 




The TGA decomposition of pure paracetamol is shown in Figure 3-16 c. There is a 
weight loss step that starts at 167°C and is at a lower temperature compared to the other 
drugs investigated in this study. This is the degradation of paracetamol and results in a 
98% weight loss. A further 2% weight loss occurs from 263-430°C and is the 
decomposition of paracetamol. However, the drug-loaded NFs have a lower onset 
temperature of ~200°C (Figure 3-16 c) compared to the drug-free PLGA NFs (Figure 
3-6 b) therefore, this suggests that paracetamol is incorporated in the drug-loaded NF. 
The large weight loss step observed in Figure 3-16 c from ~200-356°C is, therefore, a 





Figure 3-16 TGA thermogram over the temperature range of 20-600°C of (a) pure tetracycline 
(black line) PLGA ACE:EtAc + tetracycline (orange line) and PLGA DCM:DMF + tetracycline 
(blue line), (b) pure ampicillin (black line) PLGA ACE:EtAc + ampicillin (orange line) and 
PLGA DCM:DMF + ampicillin (blue line) and (c) pure paracetamol (black line) PLGA 




3.4.2.4 Differential scanning calorimetry of drug-loaded nanofibre 
To investigate the solid-state characteristics of the drug-loaded NF, DSC analysis was 
undertaken. The Tg midpoint of PLGA in NFs loaded with tetracycline or ampicillin was 
54°C (Figure 3-17 a, b), this is an increase of ~4°C when compared to non-drug loaded 
PLGA NFs (Figure 3-5) and may be due to the influence of the crystalline drug. 
Melting/degradation of tetracycline occurs at 230-231°C as observed in the TGA 
thermograms and hot stage microscopy data. The DSC thermogram of PLGA NF loaded 
with ampicillin showed a step in the baseline at 102-103°C indicating a phase transition 
and melting/degradation occurs at 117-119°C as evidenced in the hot stage microscopy 
data. (Figure 3-17 b). Paracetamol drug-loaded NFs (Figure 3-17 c) show that the PLGA 
has a similar glass transition to non-drug loaded PLGA NFs (Figure 3-5) with a Tg 
midpoint of 46°C for PLGA DCM:DMF + paracetamol and 44°C for PLGA ACE:EtAc 
+ paracetamol. The thermograms also have an exothermic peak at 88°C for PLGA 
DCM:DMF + paracetamol and 87°C for PLGA ACE:EtAc + paracetamol, which is 
attributed to the crystallisation of paracetamol from the amorphous form [268–270]. The 
exothermic peak might suggest paracetamol is in the amorphous form in the NFs. There 





Figure 3-17 DSC thermogram over the temperature range of 25-250°C of (a) PLGA 
DCM:DMF + tetracycline NF (blue line) and PLGA ACE:EtAc + tetracycline (orange line), (b) 
PLGA DCM:DMF + ampicillin NF (blue line) and PLGA ACE:EtAc + ampicillin (orange line) 
and (c) PLGA DCM:DMF + paracetamol NF (blue line) and PLGA ACE:EtAc + paracetamol 




3.4.2.5 Hot stage microscopy of drug-loaded nanofibres  
To visually examine the thermal phase transitions of the PLGA NFs, hot stage 
microscopy was employed (Section 2.3.6). The hot stage images at 30°C confirm the FE-
SEM images showing drug bound to the NF surface, as being birefringent drug nano-
crystals (Figure 3-18 1a, 2a, Figure 3-19 1a, 2a, Figure 3-20 1a, 2a). Furthermore, 
birefringence is not observed at any temperature point in the hot stage images of non-
drug-loaded PLGA NFs (Figure 3-21). At the Tg midpoint, observed in the DSC data 
and after the Tg of PLGA, relaxation of the polymer chains is observed in the hot stage 
images and confirms the Tg of the PLGA (Figure 3-18 1b, 1c, 2b, 2c, Figure 3-19 1b, 
1c, 2b, 2c, Figure 3-20 1b, 1c, 2b, 2c). Subsequent degradation of the PLGA exposes 
the drug nano-crystals and then degradation of the drug occurs, which is in agreement 
with the TGA and DSC data (Figure 3-18 1d, 1e, 2d, 2e, Figure 3-19 1d, 1e, 2d, 2e, 




















Figure 3-18 Hot stage microscopic images of the thermal transitions and solid-state structure of PLGA DCM:DMF + tetracycline NF at (1a) before the glass 
transition of PLGA at 30°C, (1b) the PLGA glass transition temperature midpoint of 54°C, (1c) after the PLGA glass transition at 75°C, (1d) crystalline 
tetracycline at 99°C and (1e) the degradation of tetracycline at 230°C. PLGA ACE:EtAc + tetracycline NF at (2a) before the glass transition of PLGA at 
30°C, (2b) the PLGA glass transition temperature midpoint of  54°C, (2c) after the PLGA glass transition at 75°C, (2d) crystalline tetracycline at 96°C and 
















Figure 3-19 Hot stage microscopic images of the thermal transitions and solid-state structure of PLGA DCM:DMF + ampicillin NF at (1a) before the glass 
transition of PLGA at 30°C, (1b) the PLGA glass transition temperature midpoint of 54°C, (1c) after the PLGA glass transition temperature at 75°C, (1d) 
crystalline ampicillin at 103°C and (1e) the degradation of ampicillin at 217°C. PLGA ACE:EtAc + ampicillin NF at (2a) before the glass transition of PLGA 
at 30°C, (2b) the PLGA glass transition temperature midpoint of 54°C, (2c) after the PLGA glass transition temperature at 75°C, (2d) crystalline ampicillin at 
















Figure 3-20 Hot stage microscopic images of the thermal transitions and solid-state structure of PLGA DCM:DMF + paracetamol NF at (1a) before the glass 
transition of PLGA at 30°C, (1b) the PLGA glass transition temperature midpoint of 46°C, (1c) after the PLGA glass transition temperature at 70°C, (1d) 
crystalline paracetamol at 88°C and (1e) the degradation of paracetamol at 144°C. PLGA ACE:EtAc + paracetamol NF at (2a) before the glass transition of 
PLGA at 30°C, (2b) the PLGA glass transition temperature midpoint of 44°C, (2c) after the PLGA glass transition temperature at 70°C, (2d) crystalline 















Figure 3-21 Hot stage microscopic images of the thermal transitions in the PLGA DCM:DMF NF at (1a) before the glass transition of PLGA at 30°C, (1b) 
the PLGA glass transition temperature midpoint of 50°C, (1c) after the PLGA glass transition temperature at 75°C, (1d) before the degradation of PLGA at 
100°C and (1e) the degradation of PLGA at 230°C. PLGA ACE:EtAc NF at (2a) before the glass transition of PLGA at 30°C, (2b) the PLGA glass transition 
temperature midpoint of 50°C, (2c) after the PLGA glass transition temperature at 75°C, (2d) before the degradation of PLGA at 100°C and (2e) the 
degradation of PLGA at 230°C
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3.4.2.6 In vitro drug release from drug-loaded nanofibre 
To investigate the release of model drugs with different molecular weights from the NFs, 
tetracycline (MW 480.90 g/mol), ampicillin (MW 349.41 g/mol) or paracetamol (151.17 
g/mol) was dissolved in the polymer/solvent solution at a concentration of 10% w/w and 
incorporated into the PLGA DCM:DMF or PLGA ACE:EtAc NF using the 
electrospinning process (Section 2.2.2). The release of tetracycline occurs in two 
apparent stages, an initial rapid or burst release over the first 1 h, with 52% release of 
tetracycline from PLGA DCM:DMF and 67% release from PLGA ACE:EtAc (Figure 
3-22). The second stage is a gradual release from 1 h-21 days (504 h) where a cumulative 
release of 92% and 95% is observed for PLGA DCM:DMF and PLGA ACE:EtAc, 
respectively. There were significant differences (p < 0.05) in release from PLGA 
DCM:DMF + tetracycline vs PLGA ACE:EtAc + tetracycline at the 2, 6 and 72 h time 
points. The release of paracetamol had a similar profile to tetracycline with an initial 
burst release over the first 1 h followed by a gradual release until 14 days (336 h). The 
burst release of paracetamol from PLGA DCM:DMF was 65% and 53% from PLGA 
ACE:EtAc after 1 h from to14 days (336 h) the release of paracetamol was gradual with 
similar release profiles from both NFs. However, at the 21 day (504 h) time point, the 
release had deviated with a cumulative release of 77% for PLGA DCM:DMF + 
paracetamol and 98% for PLGA ACE:EtAc + paracetamol. The only time point that was 
significantly different (p < 0.001) for PLGA DCM:DMF + paracetamol vs PLGA 
ACE:EtAc + paracetamol was at 21 days (504 h)..  
 
The release of ampicillin had a different release profile to that of tetracycline and 
paracetamol with a slight (20%) burst release after 1 h. Release of ampicillin from PLGA 
DCM:DMF then increased from 1-48 h with 73% released. It plateaued from 48 h-7 days 
(169 h) and then increased over the last period from 7-14 days (168-504 h) with a final 
cumulative release of 93%. Release from PLGA ACE:EtAc was slower than PLGA 
DCM:DMF with only an increase 28% from 1-48 h,then a gradual release from 48 h-7 
days (168 h) with 42% released, thereafter an increase was observed from 7-21 days 
(168-504 h) with the cumulative release of 99% at 21 days (504 h). The release of 




significant difference was observed from 6 h (p < 0.05) to 7 days (168 h) (p < 0.001) 
between the PLGA DCM:DMF and PLGA ACE:EtAc NFs.  
 
 
Figure 3-22 In vitro cumulative release of tetracycline, ampicillin and paracetamol from PLGA 
DCM:DMF and PLGA ACE:EtAc NF (A) over the first 12 h and (B) over 504 h. PLGA 
DCM:DMF + tetracycline (orange dashed line), PLGA ACE:EtAc + tetracycline (orange line), 
PLGA DCM:DMF + ampicillin (green dashed line), PLGA ACE:EtAc + ampicillin (green 
line), PLGA DCM:DMF + paracetamol (blue dashed line) and PLGA ACE:EtAc + paracetamol 





3.5 Discussion  
This chapter has reported the development of an alternative, low toxic solvent system 
composed of ACE and EtAc to electrospin PLGA 75:25. The NFs produced using the 
electrospinning method were physically and chemically characterised. The physical and 
chemical properties of the NF produced using the less toxic solvent system was compared 
to a NF produced using a more toxic solvent system consisting of DCM and DMF, which 
is often described in the literature. Furthermore, drug-loaded PLGA NFs prepared using 
the two solvent systems were characterised and the drug release profiles of a low, 
medium and high molecular weight drugs were investigated and compared for each NF 
produced using the two solvent systems. 
3.5.1 Solvent system development and nanofibre morphology  
Before electrospinning of PLGA could occur, a suitable low toxic solvent system needed 
to be selected. ACE was chosen because it had been previously described as an 
alternative, benign solvent for electrospinning PCL [228]. However, attempts to 
electrospin PLGA using only ACE were unsuccessful because the solution did not form 
a stable Taylor cone under an applied voltage. Based on a report where the investigators 
showed the optimal ε for electrospinning PCL was ~19, it was decided to lower the ε of 
ACE by introducing another USP Class III solvent with a low ε and EtAc fitted the 
criteria [244]. To calculate the ε for the solvent system, the additive approach was 
employed. For ACE:EtAc at ratios of 80:20 and 70:30, the ε was calculated to be 17.76 
and 16.35, respectively, while the toxic solvent system of DCM:DMF had a ε of 17.26 
[245]. Interestingly, FE-SEM analyses of the PLGA NF showed bead free fibres were 
produced using the solvent system with the lower ε, which is in contrast to the literature, 
as solvent systems with a lower ε result in beaded fibres [146]. It is plausible the solution 
viscosity and surface tension are also influencing fibre or bead formation and the 
differences observed between the two systems.  Therefore, future studies that assess 





3.5.2 Physical and chemical properties of PLGA nanofibres 
This study compared the physical and chemical characteristics of a PLGA NF produced 
using an alternative low toxic solvent to a common toxic solvent system used in the 
literature. The electrospinning processing parameters were held constant and compared 
to electrospinning PLGA NF using ACE:EtAc to determine the effect of the solvent 
system of NF formation. Although from FE-SEM analysis it was observed both solvents 
systems produced PLGA fibres, electrospinning using ACE:EtAc produced an NF with 
a broader fibre diameter distribution and a larger average fibre diameter. This is because 
solutions with a lower ε have lower conductivity and therefore, a reduced repulsive force 
within the polymer as it crosses from the electrospinning needle to the collector. This 
causes less stretching of the polymer and, hence a larger fibre diameter [271]. You et al. 
(2006) had similar findings when they electrospun PLGA 50:50 using two different 
solvents [272]. Chloroform (ε = 4.8) produced fibres with an average diameter of 760 nm 
while HFIP (ε = 16.7) produced fibres with an average diameter of 270 nm [272]. 
However, along with the ε, other solution parameters contribute to fibre morphology. 
Solvent-polymer interaction influences the viscosity of the polymer solution and Yang et 
al. (2004) showed that changing the ratio of solvents in the solvent system can alter the 
viscosity [138,244]. Viscosity has been shown to affect fibre morphology, with beaded 
fibres forming at low viscosity (7 Pa.s), uniform fibres at 13 Pa.s and large fibres at high 
viscosity (23 Pa.s) [135]. Similarly, the surface tension of the polymer solution, which is 
mainly derived from the solvents used, can impact fibre morphology with larger fibres 
forming from solutions with higher surface tension [271]. Solution viscosity and surface 
tension were not investigated and future studies should establish the viscosity and surface 
tension of the two solvent systems to further explain the difference in fibre diameter and 
distribution.  
 
Solid-state analysis of the NF is important to determine if an interaction is occurring 
between the polymer and solvent, resulting in an altered chemical structure of the 
polymer and changes in NF properties. By irradiating the polymer with infrared radiation, 
ATR-FTIR spectroscopy can determine if functional groups present within the polymer 




exhibited spectra that were similar to the pure PLGA polymer. Given the fact that no 
additional IR bands appeared in the NF spectra and there were no shifts in the IR bands, 
it can be concluded that the electrospinning process and solvents used did not alter the 
chemical structure of PLGA. Furthermore, the ATR-FTIR spectrum is in agreement with 
previously reported ATR-FTIR data for electrospun PLGA NF [247,273]. PLGA 85:15, 
electrospun in HFIP, gave ATR-FTIR bands with C=O stretching at 1747 cm-1, C-O-C 
bands at 1083 cm-1 and 1181 cm-1, O-H deformation at 1264 cm-1, C-H stretch at 1452 
cm-1 and other methyl groups at 2800-3300 cm-1 [273]. Likewise, PLGA 75:25 
electrospun using a solvent system of tetrahydrofuran (THF) and DMF produced a ATR-
FTIR spectrum with carbonyl stretch at 1747 cm-1, C-O bands in the 1093-1450 cm-1 
regions and C-H2, C-H3 bands around 3000 cm
-1 [247].  
 
Even though the DSC thermograms indicated the NFs were amorphous in nature, the 
rapid evaporation of the solvent during the electrospinning process can influence the 
molecular orientation and relaxation of the polymer chains and, hence alter the extent of 
the amorphic nature of the NF [246]. Giller et al. (2010) demonstrated the solvent 
evaporation rate influenced the formation of either the γ or α crystalline phase of 
electrospun nylon-6 [274]. The solvent can also act as a plasticizer, which leads to a 
decrease in the Tg [273]. The data from TGA analysis suggests there is residual solvent 
present in both of the NF and therefore, it would be expected that this is reflected in the 
DSC results with a lower Tg in the NF than the pure polymer. However, this was not 
observed. It should be noted that the manufacturer states the Tg should be in the range of 
50-55°C for pure PLGA 75:25, which is higher than our result for pure PLGA, but the 
manufacturers' range is in line with the electrospun NF [275]. The difference between 
the Tg of the NF may be due to the variance in the solvent system volatility. It may also 
be attributed to PLGA DCM:DMF having a larger free volume than PLGA ACE:EtAc 
because of the smaller fibre diameter. Having a larger free volume allows the molecular 
chains to move more easily and this results in a lower Tg [276]. The Tg of electrospun 
PLGA NF is variable in the literature.  Fouad et al. (2013) had a similar Tg of 51°C for 
an electrospun NF of PLGA 75:25, which was 3°C lower than the pure PLGA sample 
and they concluded this was because of an improvement in the orientation of the 




Vasita et al. (2010) observed a Tg of 54.9°C, while Liu et al. (2009) observed a Tg of 
45.3°C, a decrease of 8°C from the pure PLGA [256,277]. 
 
The TGA analysis of PLGA electrospun using DCM:DMF showed two weight loss steps.  
The first may be attributed to DCM (boiling point, 39.6°C) while the latter may be due 
to DMF, although this has a boiling point of 153°C. The single weight loss step in PLGA 
electrospun with ACE:EtAc may be a combination of both of the solvents as the boiling 
points are 56°C and 77°C, respectively, and weight loss occurs over this range. There is 
no weight loss step over this range in the pure PLGA polymer only gradual weight loss.  
Therefore, this confirms the presence of residual solvent in the NF. Thermal 
decomposition is higher for the NF compared to the pure polymer, which could be 
attributed to the decrease in the amorphous nature of the NF as measured by DSC. The 
change in thermal stability may also be due to the packing of the sample during the 
analysis, as a solid mass of sample may produce different results to a powder sample and 
therefore a solid mass of PLGA may differ to a PLGA NF mat [278]. This may also 
explain the difference in the onset temperature observed between the two PLGA NFs, as 
the larger fibre diameter of PLGA ACE:EtAc may reflect more of a bulk PLGA structure 
and therefore the onset temperature is decreased slightly.  
 
3.5.3 Tensile strength and deformation process of PLGA nanofibres 
The mechanical strength of randomly orientated NF mats is influenced by fibre size 
distribution, porosity, individual fibre orientation, fibre-fibre fusion and entanglement of 
fibres [279]. Modelling has shown the higher number of fibre-fibre fusion points leads to 
improved mechanical strength [279]. The smaller diameter fibres in DCM:DMF may 
lead to an increase in fibre fusion points, hence higher tensile strength is observed. In 
contrast, ACE:EtAc produced larger diameter fibres with less surface area and therefore, 
fewer fusion points. It has also been reported decreasing the fibre diameter orientates the 
polymer chains along the fibre axis, which leads to an increase in mechanical strength 




the deformation process may also be explained by fusion points where individual fibres 
overlap and fusion to the other fibre. Fusion points are created when wet fibres are 
deposited on the collector due to insufficient evaporation of the solvent. For this to occur, 
the solvents used for electrospinning often have low volatility or the distance from the 
needle to the collector is short [282]. You et al. (2006) demonstrated that PLA NF with 
fewer fusion points were mechanically inferior to NFs that had been thermally bonded to 
create more fusion points [282]. This was also computationally modelled by Wei et al. 
(2009), with the model predicting that NF strength would be significantly increased when 
the fibre fusion points were increased and, fibre-fibre fusion points performed a vital role 
in the deformation and fracture mechanism [283]. A larger fibre diameter may create 
fewer fusion points, which may allow fibres to move more freely and align easily in the 
direction of the applied force. This may explain why fibre alignment is observed earlier 
on in the deformation process for PLGA ACE:EtAc fibres. Because there is no resistance 
to the tension, the fibres are stretched and drawn out, which leads to a single fibril at the 
fracture point and, hence a lower mechanical strength. With smaller diameter fibres and 
an increase in fibre fusion points, alignment in the direction of the applied tension is more 
difficult because of the strength this creates. As the tension is applied past the elastic 
threshold, the fibres enter the plastic region where they start to stretch and necking starts 
to occur leading to a clean break of the fibres at the fracture point, as seen with PLGA 
DCM:DMF. The tensile strength reported here for PLGA 75:25 electrospun using 
DCM:DMF is comparable to Shin et al. (2006) who electrospun a NF of PLGA 75:25 
using DMF and THF with an average fibre diameter of 550 ± 150 nm and tensile strength 
of 4.67 ± 0.31 MPa [284]. Due to the lower mechanical strength of PLGA ACE:EtAc, its 
ability to be used in the biomedical field as a drug delivery device is compromised. 
 
3.5.4 Hydrophobic characteristics of PLGA nanofibres 
PLGA 75:25 is considered a hydrophobic polymer, however, with increasing GA content 
it becomes more hydrophilic [208]. The hydrophilicity of the NF is not only governed by 
the polymers chemical composition but also the surface topography. Generally, smaller 
diameter fibres lead to an increase in contact angle, which would lead to PLGA 




The surface roughness due to wrinkles, grooves and pits in the NF affects the contact 
angle [287]. These features can be caused by the solvent employed, the volatility of the 
solvent and how it interacts with the polymer. Miyauchi et al. (2006) demonstrated that 
by changing the ratio of THF and DMF in a polystyrene electrospinning solution, they 
were able to produce NF with different surface topography and roughness [287]. By 
increasing the surface roughness the hydrophobicity of the NF was increased [287]. 
Therefore, the different solvent systems may be influencing the surface roughness of 
PLGA NF and, hence why different contact angles are observed. Literature values of 
PLGA NF contact angles are higher than the results we obtained here, although there is 
a large variance in the data, from 105° to 139° [254–260]. However, Vasita et al. (2010) 
did see a similar trend for their dynamic contact angle measurements with a decrease of 
~4°, from ~122° to 118° [256]. 
 
3.5.5 Physical and chemical properties of drug-loaded PLGA nanofibres 
To investigate the drug release kinetics of the NFs, three model drugs with different 
molecular weights were incorporated into the NF, to achieve this the simple method of 
co-electrospinning was used (Section 1.2.4.2). Morphology of the drug-loaded NFs was 
investigated using FE-SEM. The fibre diameter of drug-loaded NFs displayed a similar 
trend to non drug-loaded NFs, where electrospinning using ACE:EtAc produced larger 
fibre diamters. Paracetamol PLGA NFs produced the largest difference, with PLGA 
ACE:EtAc + paracetamol having an average fibre diameter 1.94 µm compared to PLGA 
DCM:DMF + paracetamol which was 0.625 µm. This may have arisen because of the 
difference in the viscosity’s of the electrospinning solutions. The PLGA ACE:EtAc + 
paracetamol solution may have had a higher viscosity which resulted in larger fibre 
diameters. The drug-loaded NFs were characterised to determine if the co-
electrospinning method had indeed been successful with incorporating the drug in the 
NF.  ATR-FTIR spectroscopy is a simple, rapid analytical tool to identify the molecular 
make-up of the sample in question. By comparing the spectra of the pure drug to the 
spectra of the drug-loaded NFs, it is possible to deduce if the drug has been incorporated 




paracetamol were able to be observed in the spectra of PLGA DCM:DMF NF and PLGA 
ACE:EtAc NF indicating that the co-electrospinning method was successful. 
Furthermore, peak shifts, changes in peak intensity or broadening of peaks, indicate that 
chemical interactions are occurring between the drug and polymer, which are generally 
the indication of hydrogen bonding. If hydrogen bonding is occurring between the drug 
and polymer, it may influence the release profile of the drug.   
 
The presence of the drugs in the PLGA NFs does not affect the thermal degradation of 
PLGA and all initial weight loss steps in the TGA thermograms of the drug-loaded PLGA 
NFs appear to be that of the drug themselves. The onset temperature of degradation of 
ampicillin and paracetamol is at a higher temperature to that of bulk drug and the cause 
of this may be due to the solid-state of the drug in the NF and the amount of drug bound 
to the surface of the NF. Conversely, tetracycline appears to start degrading at a lower 
onset temperature and this may be because a larger amount of drug is exposed at the 
surface of the NFs, not concentrated in the NFs or bulk drug. The initial weight loss step 
observed in the thermogram of the tetracycline PLGA NFs may also be coupled with the 
loss of solvent. 
 
The DSC data suggests both tetracycline and ampicillin are in the crystalline form, as a 
step in the base line (indicating a Tg)  does not appear in their respective thermograms. 
The melting/degradation of tetracycline occurs at ~230°C and  for ampicillin at ~ 217°C.  
The crystalline nature of both tetracycline and ampicillin may have also influenced the 
Tg of the PLGA as the Tg has been increased by ~4°C compared to non-drug loaded 
PLGA NFs. Although the ATR-FTIR data suggested there was no chemical interaction, 
the increase in Tg may have occurred due to the structure of the crystalline drug 
physically interfering with the molecular orientation and relaxation of the polymer 
backbone in PLGA. The thermogram of ampicillin loaded PLGA NFs appeared to have 
a step in the baseline, which may have been caused by a Tg of a low amount of amorphous 
ampicillin or it was a solid-solid phase transition such as a polymorph. Further studies 
such as XRD would be needed to confirm this. In contrast, a crystallisation peak was 




paracetamol is in the amorphous state in the NFs. The paracetamol has not influenced the 
Tg of PLGA like tetracycline and ampicillin, this may be because it is amorphous like 
PLGA and therefore has no crystal structure that physically interferes with the PLGA.  
 
The hot stage microscopy images confirm that the irregular structures observed on the 
NFs in the FE-SEM images are drug particles, as birefringent nano-crystals can be 
observed on the NFs before heating is applied. The presence of birefringence nano-
crystals is in agreement with the DSC data and suggests tetracycline and ampicillin are 
in the crystalline form. Paracetamol shows little birefringence at 30°C however, upon 
heating, crystallisation of paracetamol occurs and there is an increase in birefringence. 
Although there is an increase in birefringence in the images of tetracycline and 
ampicillin, the PLGA is degrading and exposes more crystalline tetracycline and 
ampicillin, which may be entrapped in the NF. Subsequent melting/degradation of the 
drugs is observed and confirms the TGA and DSC data.  
 
3.5.6 Drug release kinetics and mechanism of release from drug-loaded PLGA 
nanofibres 
The drug release kinetics from a NF is typically controlled by the degradation of the NF 
polymer and drug diffusion from the NF [288,289]. The larger the fibre diameter, the 
further a drug has to travel to diffuse out of the NF, therefore, the slower the release rate 
will be. However, an initial rapid release of drug is often observed and this is generally 
attributed to the drug that is bound to the surface of the NF as this comes in to contact 
with the release media first and has a short diffusion path. In the present study, it can be 
concluded that there is likely to be paracetamol and tetracycline present at the surface of 
both PLGA DCM:DMF and PLGA ACE:EtAc NF as an initial rapid release over the first 
hour is observed. This is also confirmed by the FE-SEM and hot stage microscopy 
analysis as irregular deposits and birefringent nano-crystals on the surface of the NFs are 
observed which can be attributed to the drug at the surface. The initial rapid release is 




Interestingly, there is no statistically significant difference over the first 2 h of drug 
release between paracetamol and tetracycline from both PLGA NFs indicating molecular 
weight was not a factor in the release rate. From 1 h- 21 days (504 h), there was a gradual 
release of paracetamol and tetracycline from both NFs, while the release rate fluctuated 
over this period for both drugs and from both NFs there was no statistically difference 
between the two drugs at the end of the release period from 14-21 days (336-504 h). The 
decrease in drug release after 72 h observed for PLGA ACE:EtAc + tetracycline and 
PLGA DCM:DMF + paracetamol may be attributed to the dilution of the drug by the 
replacement media that was added after each subsequent sample was taken. If the 
molecular weight influenced the release rate we would expect a low molecular weight 
drug to have a fast release and a high molecular weight drug to have a slow-release. 
However, the findings from this study indicate that paracetamol, the low molecular 
weight drug does not release faster than tetracycline, the high molecular weight drug or 
vice versa.  
 
The similar release rates of paracetamol and tetracycline may also be explained by the 
DSC data. The crystalline peak in the DSC thermogram of PLGA NF + paracetamol 
suggests paracetamol is in the amorphous phase when electrospun. The amorphous 
paracetamol will have increased solubility and therefore the release rate will be faster 
compared to the crystalline drug. However, tetracycline that appears to be in the 
crystalline form released at a similar rate, therefore, the high molecular weight of 
tetracycline may lead to an increased amount of drug at the surface of the NFs and the 
surface-bound drug results in a fast release that is similar to a drug in the amorphous 
form. Similarly, fibre diameter did not alter the release rate of the drugs either even 
though producing a NF using ACE:EtAc resulted in a broader fibre diameter range and 
a larger average fibre diameter. If in fact, fibre diameter altered the release rate of drug 
we would expect to see a slower drug release for larger diameter fibres in the case of 
PLGA ACE:EtAc NF, as the diffusion path is longer.  
 
If fibre diameter or molecular weight do not alter the drug release rate, what is influencing 




DCM:DMF + ampicillin and PLGA ACE:EtAc + ampicillin have a similar average fibre 
diameter that is not statistically different, yet the release of ampicillin from both NFs was 
slower than paracetamol and tetracycline with less of an initial rapid release. 
Furthermore, the release of ampicillin from PLGA ACE:EtAc was slower compared to 
release from PLGA DCM:DMF and from 6 h-14 days (336 h) there was a statistically 
significant difference between the two NFs although, drug molecular weight is the same 
and the fibre diameter was similar. The difference in release rate is not due to fibre 
diameter or drug molecular weight. The different release profiles of ampicillin from the 
two NFs suggests there is another mechanism influencing the release profile. The point 
of difference between the two NFs is the solvent system. So is the solvent system 
influencing the release of the drug, and if so, how?  
 
To form a drug-loaded NF, the electrospinning process reported here requires the 
polymer and drug to be dissolved in an organic solvent forming a solution, the solution 
is electrospun and deposited on a collector in the form of a NF, it is through this process 
that the drug becomes dispersed in the NF matrix. Therefore, the solubility of the drug in 
the organic solvent will influence the dispersion of the drug in the NF. Furthermore, the 
solubility of the drug will be different depending on the organic solvent used, if the drug 
has poor solubility in the solvent system this may lead to the drug being dispersed on the 
surface of the NF resulting in a burst release as observed with paracetamol and 
tetracycline. However, if the drug has good solubility in the solvent system the drug will 
be evenly distributed throughout the NF matrix, with no burst release such as the case 
with ampicillin. Therefore, it can be concluded that drug release is not only controlled by 
diffusion from the NF matrix and degradation of the NF matrix but is also influenced by 
how the drug is dispersed in the NF matrix and in particular, the solubility of the drug in 





3.5.7 Conclusion  
In this study, PLGA 75:25 was electrospun using ACE:EtAc as the solvent system, which 
has reduced toxicity to human health and environment. The NF properties were 
characterised and compared to a PLGA NF prepared using DCM:DMF, a common 
solvent system found in the literature. NF diameter uniformity was decreased and the 
surface hydrophobicity was increased when electrospinning was conducted with 
ACE:EtAc. When mechanical performance is required, we have shown the new solvent 
system has major implications on the mechanical strength and deformation process and 
mechanical performance was inferior to PLGA electrospun using DCM:DMF. Although 
ACE and EtAc are less hazardous solvents, this demonstrates that the solvent system 
affects the NF properties and selecting the correct one is critical to achieving success for 
the intended purpose. However, the electrospinning process using a solvent system 
consisting of ACE:EtAc requires further optimization to produce a PLGA NF with 
smaller diameter fibres and unimodal size distribution. The mechanical deformation 
process of the PLGA ACE:EtAc NF compromises its use as a drug delivery device and 
further optimisation of the electrospinning parameters may result in similar or superior 
mechanical properties to DCM:DMF. This study demonstrated that molecular weight nor 
fibre diameter influenced drug release but rather, drug release was influenced by how the 
drug was dispersed in the NF matrix, which was determined by the solubility of the drug 
in the solvent system. Therefore, the selection of the electrospinning solvent system 
needs to be considered when a desired release profile is required. The following chapter 
focuses on the development and characterisation of PCL and PCL/blend NF, electrospun 
using low toxic solvents AA and FA to establish if the chemical and physical properties 






Development and characterisation of PCL and 




Aspects of this chapter have been published in the manuscript titled: Smith, G. P. S., 
McLaughlin, A., Clarkson, A. N., Gordon, K. C., & Walker, G. F. (2017). Raman 
microscopic imaging of electrospun fibers made from a polycaprolactone and 





4 Development and characterisation of PCL and PCL/blend 
nanofibres using low toxic solvents 
4.1 Introduction  
4.1.1 Poly-(caprolactone) (PCL) 
PCL (Figure 4-1), like PLGA, is a poly-(ester), however, the repeating unit is hexanoate 
and is generally synthesised by ring-opening polymerisation of ε-caprolactone [290]. 
PCL is an FDA approved polymer that has been engineered as a co-polymer with glycolic 
acid for use in medical sutures [291–293]. PCL has attracted considerable attention in 
the biomedical field in applications such as tissue engineering scaffolds and drug delivery 
devices due to its excellent mechanical strength and tailorable release kinetics [294–299]. 
 
 
Figure 4-1 Chemical structure of the poly-(caprolactone) repeating monomer unit. 
 
PCL is a hydrophobic polymer that is soluble in an extensive range of organic solvents, 
is semi-crystalline (50%) with a low melting point of ~60C  and a Tg of -60C [299]. 
PCL has ester bonds in the backbone that are hydrolysed in an aqueous environment. 
Water enters the amorphous region where hydrolytic cleavage of the ester bond occurs, 
resulting in the loss of monomers and oligomers. Degradation of PCL is auto-catalysed 
by carboxyl end groups and the crystalline region of the polymer is degraded. The by-
products of the degradation process, 6-hydroxyl caproic acid and acetyl coenzyme A, are 




hydrophobic nature of PCL, it slowly degrades over months to years depending on the 
molecular weight [291].  
 
4.1.1.1 Electrospinning of poly-(caprolactone) 
With an increased interest in electrospinning, researchers have started to investigated 
NFs as either a standalone drug delivery device, a tissue engineering scaffold or 
combination of both [301–303]. The processing capabilities and relatively low cost of 
PCL allow it to be an effective polymer for the production of NFs using electrospinning. 
Generally, for electrospinning, PCL with an average molecular weight of 80 kDa is used 
and concentrations range from 5-40% (w/v) [292]. Electrospinning has been conducted 
at voltages ranging from 9-25 kV, with flow rates varying from 0.4-24 mL/h and distance 
from the spinneret to the collector between 7.5 cm and 48 cm. The NFs produced ranged 
in size, with the smallest having a diameter of 100 nm and the largest with a diameter of 
10 μm [292].  
 
The variability in diameter size highlights the importance of physically characterising the 
NFs after they are produced.  The most frequently utilised solvents used during 
electrospinning of PCL are outlined in Table 4-1 [292]. The solvents are classified as 
USP Class II residual solvents. The USP assessment of solvents identifies Class II 
residual solvents, as nongenotoxic animal carcinogens, with the possibility of causing 
other irreversible toxicities such as neurotoxicity, Class II residual solvents are also 
suspected of other significant but reversible toxicities such as anxiolytic, narcotic and 
anaesthetic effects [86,304]. Due to the classification and assessment of Class II solvents, 
the USP has set permitted daily exposure (PDE) limits and concentration limits for each 
solvent (Table 4-1) that are ‘used or produced in the manufacture of drug substances or 
excipients, or the preparation of drug products’ [86]. Therefore, it is a requirement to 
determine exposure limits when using Class II residual solvents and testing of residual 
solvent levels should be undertaken when the manufacturing process of a drug product 




Table 4-1 USP Class II solvents frequently used to electrospin PCL. USP exposure limits and 
assessments of Class II solvents are given. Adapted from USP 40, Residual Solvents [86]. 




Chloroform 4.1 410 
Dichloromethane 6.0 600 
N-N-dimethylformamide 8.8 880 
Methanol 30.0 3000 
Tetrahydrofuran 7.2 720 
Assessment  
Solvents to be limited. Non-genotoxic animal carcinogens or possible causative agents of 
other irreversible toxicity such as neurotoxicity or teratoxicity. Solvents suspected of other 
significant but reversible toxicities 
 
In addition to using Class II solvents to electrospin PCL, Class III solvents are starting 
to emerge as suitable solvents to electrospin PCL (Table 4-2) [292]. USP Class III 
solvents are considered to be less toxic and of less risk to human health than Class II 
solvents [86]. When Class III solvents are used, the PDE can be up to 50 mg per day or 
5000 ppm without justification. Higher quantities may also be accepted as long as they 
are within reason of manufacturing capability and good practice. If the residual solvent 
content is higher than 50 mg per day, it should be quantified [86]. Due to Class III 
solvents being less toxic, and having less restrictive control around exposure limits, it is 
more beneficial to electrospin PCL from solvent systems composed from this Class of 
solvent. PCL has only been previously electrospun using the Class III solvent acetone, 
but this involves the additional step of heating the solution to 40C to completely 





Table 4-2 USP Class III solvents used to electrospin PCL and assessment. Adapted from USP 
40, Residual Solvents [86]. 
Solvent Assessment 
Acetic acid Solvents with low toxic potential to humans; 
no health-based exposure limit is needed (note 
– Class III residual solvents have PDEs of 50 





Recently, acetic acid and formic acid, which are both USP Class III solvents and safer to 
use, have emerged as suitable solvents to electrospin PCL. Ferreira et al. (2014) 
electrospun PCL dissolved in glacial acetic acid at concentrations ranging from 14-26% 
(w/v) and these authors concluded that acetic acid concentrations between 20-23% (w/v) 
yielded the most regular NFs. NF size was also smaller compared to a PCL NFs 
electrospun using chloroform [306]. Van der Schueren et al. (2011) investigated the 
electrospinning of PCL dissolved in a solvent system consisting of acetic acid and formic 
acid [307]. The solvent system produced NFs with a diameter of 266 nm ± 39, which was 
10 times smaller than PCL NFs electrospun from a chloroform solution. They determined 
that a solvent system consisting of acetic acid and formic acid was suitable to produce 
nanoscale PCL fibres [307]. 
 
4.1.2 Polymer blend nanofibres for devices 
Although biomedical devices, which are typically fabricated from only one polymer, 
have properties that are necessary for the intended application, the polymer may also 




PCL has a slow degradation rate from months to years, which may be desired for a device 
that needs to be active over a long time frame. However, the hydrophobicity of PCL may 
lead to non-specific protein binding resulting in a fibrous capsule forming around the 
device in vivo, rendering it ineffective for releasing drugs in the desired manner [291]. 
To overcome the limitations of a single component NF, the use of block copolymers is 
an approach that researchers have employed with electrospinning. To increase the 
degradation rate of a PCL NF, Chew et al. (2005) increased the hydrophilicity of the PCL 
by synthesising and electrospinning a copolymer of PCL and ethyl ethylene phosphate 
(PCLEEP) [308]. Although no water contact angle studies were performed to assess the 
NF hydrophobicity, degradation studies showed an increase in degradation of the 
PCLEEP NF after 6 months, compared to a PCL film [308]. Combining a block 
copolymer of PEG with PCL and electrospinning the copolymer into a NF resulted a 
water contact angle of 30.9 ± 1.85, which was lower than the water contact angle of a 
PCL NF (119.5 ± 0.7)  [309]. It has been suggested that the inclusion of PEG chains 
into the PCL polymer was responsible for the lower hydrophobicity observed and 
therefore the hydrophobic properties of the PCL NF were improved [309,310].  
 
Another approach to overcome the limitations of a single polymer NF is to functionalise 
or modify the surface of the NF, which can be done post electrospinning. For example, 
to retard the burst release of bovine serum albumin (BSA) from PVA NF, Zeng et al. 
(2005) coated the PVA NF with poly-(p-xylylene) by chemical vapour deposition [311]. 
The coated PVA NF reduced the burst release of BSA in the range of 2.5 μg/mL to 6.5 
μg/mL and was dependent on the thickness of the poly-(p-xylylene) coating, with a 
thicker coating having a smaller burst release [311]. A poly-(lactic acid)-co-poly-
(caprolactone) NF was air plasma treated to increase the NF hydrophilicity and a collagen 
solution was subsequently coated onto the NF. The researchers observed an increase in 
cell viability, attachment and spreading of human coronary artery endothelial cells when 
cultured on the collagen-coated NF [312]. A disadvantage of these approaches is that it 
can be complex to fabricate the copolymer and usually involves additional steps in the 





An alternative approach to achieve improved NF properties is to simply incorporate 
another polymer into the NF by electrospinning a solution composing of two polymers 
producing a polymer blend NF. Kenawy et al. (2002) used this approach to prepare a 
blend solution of PLA and PEVA at a ratio of 50:50 and electrospun a NF to entrap 
tetracycline hydrochloride [313]. They showed the burst release of tetracycline 
hydrochloride was reduced by 15% from the blend NF and a more sustained, controlled 
release over 120 h was achieved compared to the release of tetracycline hydrochloride 
from a NF produced using only PEVA [313]. Carson et al. (2016) electrospun a blend 
solution of PCL and PLGA and assessed the release rate of tenofovir [314]. They reported 
that there was less of a burst release of tenofovir from the blend NF compared to a PCL 
NF, and increasing the PLGA content led to a more sustained release of drug [314]. 
Incorporation of a block copolymer has also been shown to increase the biocompatibility 
of PCL by electrospinning PCL with the amphiphilic block copolymer poly-(N-
vinylpyrrolidone)-b-PCL. Increasing the surface hydrophilicity of the blend NF was 
enhanced, which increased fibroblast cell viability and adhesion compared to the PCL 
NF [315].  
 
4.1.2.1 Poly-(ethylene oxide) – a synthetic polymer for electrospinning 
Poly-(ethylene oxide) (PEO) (Figure 4-2) is a synthetic poly-(ether) comprised of 
repeating ethylene oxide units, it is hydrophilic in nature and synthesised by 
polymerisation of ethylene oxide. PEO is available commercially in a vast array of 
molecular weights. Typically low molecular weight (MW) polymers (MW <50,000 Da) 
are often referred to as PEG and PEO is the term used for high MW material (MW 
>50,000 Da) [316]. PEG is often used as a coating for biomedical implants due to it being 
biologically inert and anti-fouling [317]. PEGylation is a term used to describe the 
coating of a surface with PEG and has been shown to enhance the circulating time of 
particulate delivery systems in vivo, reduce phagocytosis and allow the passage of 
particulate delivery systems through membranes more rapidly [318–321]. PEO is often 
used as a copolymer for drug delivery devices to offer better degradation kinetics, 






Figure 4-2 Chemical structure of the PEO repeating monomer unit. 
 
Degradation of PEO does not occur readily by hydrolysis, but rather because it is 
hydrophilic, the polymer chains dissociate in water and are eliminated unchanged by 
renal or biliary excretion [317,323]. The alcohol functional group on the PEO polymer 
can be metabolised by oxidation to carboxylic acid, diacids and hydroxyl acids [317,323]. 
 
PEO is a relatively bio-inert polymer with low protein and cell adherence and so is a 
desirable material to use for implants.  Researchers have demonstrated PEO coupled to 
amine-modified glass reduced the adhesion of human macrophage cells and the 
formation of foreign body giant cells in vitro [322,325]. Because of its inert nature and 
anti-fouling properties, PEG has been utilised for coating biomedical devices to reduce 
infection and improve biocompatibility [326,327]. The biocompatibility of PEG-based 
hydrogels implanted in the rat brain has been investigated by determining the microglial 
and astrocyte response over a 56-day time course [328]. At all-time points assessed, a 
needle injected into the brain as a sham induced a greater astrocyte response than the 
hydrogel [328]. The initial hydrogel implant produced a lower microglial response 
compared to sham, which peaked after 7 days [328]. However, assessment at 56-days 
revealed sham controls as having low microglial cell activity compared to hydrogel 
animals [328]. These results lead the researchers to conclude PEG-based hydrogels were 





PEO is relatively easy to electrospin because it is readily soluble in a wide variety of 
solvents including water, organic solvents and acids [109,124,130,147]. For this reason, 
researchers have used PEO to investigate the influence processing and solution 
parameters have on electrospinning and NF production [109,120,124,130,147]. PEO is 
often blended with other polymers, in particular, natural polymers because of its ease for 
electrospinning, as it facilitates fibre formation of the natural polymer [329–331]. Fibre 
fabrication of PEO blends with other synthetic polymers is limited in the literature, 
however, there are reports of it being electrospun with PLGA, PLA and PCL using 
chloroform, ethanol, DCM and DMF as solvents [332–334]. Nein et al. (2013) reported 
electrospinning a 12 wt. % solution of PCL/PEO at ratios of 75:25, 50:50 and 25:75 
PCL/PEO, in DCM. A beaded NF was produced with a ratio of 75:25 PCL to PEO 
whereas 50:50 and 25:75 both produced bead-free fibres [335]. The fabrication of 
PCL/PEO nanoscale fibres has been reported by Gao et al. (2014) using a total polymer 
concentration of 7.5, 5 and 3.75 wt. % of PCL and PEO. The authors prepared the 
solutions at ratios of 2:1, 1:1 and 1:2, PCL to PEO using DCM:DMF (1:1 ratio v/v).  
Electrospinning of a 7.5 wt. % at a ratio of 2:1 produced large fibres with an average 
diameter of 1048 nm [336]. Whereas decreasing polymer blend concentrations decreased 
the fibre diameter with, 5 wt. % at a ratio of 1:1 producing fibres with a diameter of 455 
nm and 3.75 wt. % (1:2) producing a fibre diameter of 248 nm [336]. 
 
4.1.2.2 Chitosan – a natural polymer for electrospinning 
Chitosan (CH) is a linear, poly-cationic, polysaccharide derived from the partial 
deacetylation of chitin under alkaline conditions, a natural polysaccharide found in the 
exoskeleton of arthropods [337]. CH is composed of repeating units of D-glucosamine 
and N-acetyl-glucosamine that are joined by β-(1-4) glycosidic bonds and is semi-
crystalline in the solid-state form [337]. CH has been investigated extensively in the 
biomedical field for wound dressings, drug delivery and tissue engineering scaffolds 





CH degradation in vivo occurs by non-enzymatic and enzymatic hydrolysis, the former 
is very slow and is negligible in vivo [338]. Lysozyme is the primary enzyme responsible 
for the biodegradation of chitosan in humans and is found in many bodily fluids, 
including serum, tears, saliva, breast milk, urine and cerebrospinal fluid [339,340]. 
Lysozyme is also produced by neutrophils and macrophage cells of the immune system 
[338]. Lysozyme catalyses the hydrolysis of the β-(1-4) glycosidic bonds that link D-
glucosamine and N-acetyl-glucosamine of chitosan. The degradation kinetics are related 
to the degree of deacetylation, the higher the deacetylation of CH the slower the 
degradation rate [341,342]. After in vivo enzymatic hydrolysis, CH is further degraded 
to oligosaccharides of various lengths. The oligosaccharides are generally soluble in an 
aqueous environment and are either eliminated unchanged in the urine or metabolised in 
the glycosaminoglycan and glycoprotein pathways [341–345]. Therefore, CH is easily 
biodegraded which makes it appealing for biomedical applications.  
 
An electrospun NF composed of a natural polymer, such as CH, may be beneficial due 
to increased biocompatibility. However, natural polymers are generally more challenging 
to electrospin compared to synthetic ones due to difficulty dissolving the polymers, high 
viscosity of polymer solutions and the formation of hydrogen bonds in aqueous 
environments [346–349]. Electrospinning of pure CH is difficult because, in the presence 
of the high electric field, the repulsive interaction between the ionic groups on the 
polymer backbone hinders continuous fibre formation [350]. PEO has been employed as 
a blend polymer with acetic acid as the solvent to aid in the formation of continuous CH 
NFs. It is thought that PEO forms strong hydrogen bonds with CH, which enables 
electrospinning to occur [329–331,351,352].  
 
Research surrounding the electrospinning of CH in PCL/CH NF blends has been limited 
due to the lack of common solvent systems. However, the recent interest of 
electrospinning with alternative solvent systems has seen an increase in publications of 
PCL/CH NF blends [353]. Semnani et al. (2017) dissolved 5 wt. % chitosan (1000 kDa 
MW) in trifluoroacetic acid and 10 wt. % PCL in trifluoroethanol and the solutions were 




rate of 0.5 mL/h with an applied voltage of 22 kV and the distance from the needle (23 
gauge) to the collector was 15 cm. The subsequent NF had slightly beaded morphology 
with an average fibre diameter of 243 ± nm [354]. An alternative solvent system for the 
electrospinning of PCL/CH blends consisting of acetic acid:formic acid (AA:FA) at 
ratios of 1:9, 3:7 and 5:5 (v/v) was employed to electrospin an 8 wt. % PCL and 10 wt. 
% CH blend [355]. Fibre formation was possible for all solutions, however, only 3:7 and 
5:5 AA:FA produced a stable Taylor cone, and the average fibre diameter for the NF was 
203 ± 44 nm and 367 ± 118 nm, respectively [355]. Roozbahani et al. (2015) used the 
same solvent system to fabricate blends of PCL at 8 wt. % and CH at 0.2, 0.4, 0.6, 0.8 
and 1 wt. %. At lower CH concentrations (0.2, 0.4 wt. %) beads were present alongside 
the NF [353]. As the concentration of CH increased so did the average fibre diameter 
from 82.39 to 131.85 nm for 0.2-0.8 wt. % CH. The exception was 1 wt. % CH, which 
had an average diameter of 109.01 nm and a ribbon-like morphology [353]. The studies 
outlined above demonstrate that it is feasible to electrospin blends of PCL/CH using 
alternative solvent systems to produce NFs. 
 
4.1.2.3 Gelatine – a natural polymer for electrospinning  
Gelatine (GEL) is a hydrophilic, protein polymer consisting of single-stranded 
molecules, and is prepared by partial hydrolysis and thermal denaturation of collagen, 
which is generally isolated from bovine or porcine skin. When the hydrolysis is 
performed under acidic conditions the GEL is called type A and when done under basic 
conditions it is type B [356–359]. GEL was first produced in Holland on a commercial 
scale in 1685 and GEL solutions were first used in humans in 1915 for the resuscitation 
of moribund hypovolemia patients [360]. Since then it has been used extensively in the 
pharmaceutical industry in the form of nanoparticles, hydrogels and fibres for drug 
delivery application and the FDA regard it as generally recognised as safe [358,360].  
 
GEL is a protein composed of amino acids and so it is generally highly biodegradable.  




utilised by cells [361]. GEL is also generally biocompatible and produces a low immune 
response and is non-antigenic, plus has also been shown to be pro-angiogenic [362,363]. 
It is often coated on the surface of biomaterials to improve cell adherence, hydrophobic 
properties and biocompatibility [364]. The fast degradation rate, low solubility and 
mechanical properties of GEL limit it as a standalone biomedical device.  However, GEL 
can be cross-linked with agents or incorporated with other polymers to improve the 
properties of GEL or the overall properties of the device [358,365,366]. 
 
GEL is insoluble in most organic solvents due to its polarity and along with the highly 
viscous or gel-like structure of GEL in solution, it makes it challenging to electrospin 
[367,368]. To improve the ‘electrospinnability’ of GEL and improve the properties of 
synthetic polymers, GEL has been blended with the synthetic polymers PVA, PLA, 
PLGA, and PCL for electrospinning NF [369–371]. The difficulty electrospinning GEL 
blends is finding a suitable solvent system that dissolves both polymers, and often 
fluorinated solvents are used which are highly toxic [369–371]. With research suggesting 
GEL is stable in FA, Yang et al. (2007) prepared a 17% (wt. %) solution of GEL in FA. 
The GEL solution was mixed with a 10% (wt. %) aqueous solution of PVA at ratios of 
7:3, 5:5, 3:7 and 1:9 [372]. The average fibre diameters ranged from 133 ± 28 nm to 447 
± 129 nm and the fibre diameter increased with increasing PVA concentration [372]. To 
electrospin a blend of PCL and GEL, Denis et al. (2015) investigated an alternative 
solvent system consisting of AA and FA. PCL and GEL were prepared in separate 
solutions of AA:FA at a ratio of 90:10 (w/w) [373]. The solutions were then mixed at 
ratios of 90:10, 85:15, 80:20 and 75:25 (PCL to GEL, w/w) for a total polymer 
concentration of 15% (w/w). All the ratios produced bead-free fibres with the average 
fibre diameter ranging from 614 nm to 877 nm as the GEL content increased [373]. 
 
4.1.3 In vitro degradation and drug release mechanisms for nanofibres 
The simplest method to encapsulate a drug into NFs is by co-electrospinning (Section 




the drug being dispersed homogenously throughout the polymer fibre network [374]. 
Drug release is controlled by diffusion of the drug through the polymer network and 
degradation of the polymer. The drug can diffuse by two means (1) by passing through 
pores in the polymer network or (2) by passing between polymer chains [288]. Diffusion 
can lead to a burst release and the rate of release is not constant because as time 
progresses the release rate decreases due to it taking longer for the drug to diffuse from 
the core of the polymer network [289]. 
 
Generally, biodegradable polymers erode by surface or bulk erosion through random 
hydrolytic chain scission degradation (Figure 4-3). For most biodegradable polymers, 
surface and bulk processes will occur, but the level of degradation will vary depending 
on the chemical composition of the polymer backbone [375]. The process of surface 
erosion occurs when hydrolysis of the polymer bonds is faster than the diffusion of water 
into the bulk of the polymer allowing hydrolysis to proceed at the surface [376]. In an 
ideal scenario, the rate of erosion would be proportional to the surface area and drug 
release can be zero-order as long as the polymer network shape remains constant and 
diffusion of the drug is minimised [375]. Bulk erosion is the converse, water penetrates 
into the bulk of the polymer faster than the hydrolysis of the polymer bonds, the polymer 
degrades uniformly and the volume of the material remains the same while the mass 
reduces [377]. Diffusion controlled release will occur in delivery devices that undergo 
bulk erosion and initially drug diffusion proceeds rapidly (burst release) due to surface-






Figure 4-3 Schematic representation of polymer erosion of (a) surface erosion, when 
hydrolysis of the polymer bonds is faster than the diffusion of water into the bulk of the 
polymer and degradation proceeds at the surface. (b) Bulk erosion, when the polymer degrades 
equally throughout the whole material, the volume of the material remains the same while the 
mass reduces. Figure adapted from Rohman G. Biodegradable polymers: recent developments 
and new perspectives. Rohman G, editor. Zagreb, Croatia: IAPC Publishing; 2017, pp.108-140 
[380]. 
 
PCL is a biodegradable poly-(ester) that undergoes bulk erosion. The PCL monomer has 
a 5 hydrocarbon chain that increases its hydrophobicity and slows the degradation rate 
compared to other poly-(esters) such as PGA and PLA and therefore, PCL can be used 
as a long term drug delivery device [381–383]. Because bulk erosion is the main 
mechanism, drug release from PCL is generally biphasic, with the initial release by 
diffusion-controlled mechanism proceeded by degradation controlled facilitated by bulk 
erosion. NF composed of PCL is no exception. Tetracycline hydrochloride was 
encapsulated in a PCL NF, an initial burst release of the surface-bound drug over the first 
hour was observed, followed by a sustained release over an 8 h period [384]. Similarly, 
a 30-45% burst release of rifampicin over 1-2 h, with a sustained period of release for 8 
h thereafter was observed from a PCL NF [385]. However, complete release of drug was 




rifampicin, and suggest conducting the experiment in dynamic conditions to alter release 
kinetics [385]. 
 
Blending PCL with other polymers can increase the degradation and bulk erosion of the 
NF and therefore this can increase the total amount of drug released from the NF. When 
blending chitosan with PCL (ratio 1:1 v/v) to form an NF, 100% release was achieved 
for rifampicin [386]. The NF produced an initial burst release of ~72% after 1 h, with the 
complete release by of rifampicin by 24 h [386]. Kim et al. (2007) showed that by 
increasing the PEO content in PCL/PEO blend NF the total amount of lysozyme released 
from the NF increased. At a ratio of 50:50 (w/w) PCL/PEO, only 32% release occurred 
over 12-days compared to 87% release of lysozyme during the same period for PCL/PEO 
at a ratio of 10:90 (w/w) [387]. When GEL was incorporated into a PCL NF (50:50, w/w), 
almost 100% release of metronidazole was achieved over 3-weeks. The mechanism of 
drug release was considered to be dependent on drug diffusion and GEL degradation, 
hence almost 100% of the payload was released [388]. 
 
4.1.4 Biocompatibility and immune response to nanofibres  
The hydrophobic nature of PCL leads to poor water absorption and it lacks bioactive 
functional groups that limit its ability for cells to attach. However, researchers have 
investigated mice fibroblast cell adhesion to PCL films and the cytotoxicity of the films 
in vitro [389]. The researchers found cell proliferation was slower on PCL films 
compared to controls during the first 48 h, however, after 96 h cell proliferation had 
increased [389]. Cytotoxicity was examined using the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide (MTT) assay and analysing lactate dehydrogenase (LDH) 
levels [389]. There was no significant difference between LDH levels between PCL films 
and controls over the 96 h period and after 168 h control levels were higher than PCL 
films, indicating the films had good cell viability. Cell viability was similar for PCL films 





The introduction of the polymers PEO, GEL and CH into the NF to add functional side 
chains may enhance the biocompatibility and reduce the cytotoxicity of the PCL NF. 
PEO is a biologically inert polymer, however, it is hydrophilic and may increase the 
wettability of the PCL NF and improve cell adhesion [322]. CH has amine, hydroxyl and 
acetamido functional groups, which promote cell adhesion and GEL possesses the 
tripeptide arginine-glycine-aspartic acid-like-sequence, which is known to promote cell 
adhesion and migration [390,391]. 
 
Another aspect to consider is the inflammatory response after implantation, especially in 
the brain where the environment is particularly fragile.  An implant is observed as a 
foreign body and immediately following implantation blood/biomaterial interactions 
occur. Proteins such as fibrinogen, albumin, fibronectin, vitronectin, γ globulin along 
with others bind to the biomaterial surface [392–395].  The proteins modulate host 
inflammatory cell interactions and adhesion, the cells secrete cytokines, growth factors 
and chemo-attractants, to further attract more cells [392,396]. To investigate the in vitro 
inflammatory response of an NF vascular scaffold prepared from PCL, PLA and 
collagen, Haghjooy Javanmard et al. cultured macrophages on the NF and determined 
the release of the pro-inflammatory cytokine IL-6 [397]. The electrospun scaffold 
showed a significant decrease in IL-6 release compared to a poly-(tetrafluoroethylene) 
graft and a glass graft [397]. Saino et al. used a similar approach to investigate the in 
vitro inflammatory response from macrophages to PLA NF alignment and diameter 
[398]. They reported the release of cytokines indicating a pro-inflammatory response to 
the PLA NF, however, a greater inflammatory response was observed from the PLA film 
control [398]. With regard to drug delivery devices, it is important to establish if they 
provoke an immune response because if the foreign body reaction is activated in vivo it 
can ultimately lead to foreign body giant cell formation and a fibrous capsule surrounding 





4.1.5 Chapter aims 
The aim of the work presented in this chapter is to develop a low toxic solvent system 
that is suitable to dissolve PCL, CH, GEL and PEO to prepare a NF from PCL and 
PCL/blend polymers for the use as a drug delivery system. The chemical and physical 
properties of the NF were characterised and compared, to determine if the polymer blend 
NF enhanced the chemical and physical properties of PCL and provided an improved 
system for drug delivery. The drug release profile of L-655,708 was investigated from 
PCL and PCL/blend NFs and indomethacin release was investigated from PCL/CH NF 
to determine if a charge interaction between CH and L-655,708 was influencing the drug 
release. Furthermore, the NFs were investigated in vitro, for mass loss, sterility, 
cytotoxicity and to establish if the NFs produced an immune response. PCL/CH and 
PCL/GEL NF have been prepared before in AA:FA. However, to the best of our 
knowledge, the fabrication of PCL/PEO NF prepared using AA:FA has not been reported 
in the literature. 
 
4.2 Methods 
PCL and PCL/blend NFs were prepared using the electrospinning process using AA:FA 
as the solvent system and FE-SEM was employed to determine NF morphology. ATR-
FTIR, DSC, TGA and XRD were used to determine the solid-state properties. 
Mechanical strength was measured using a texture analyser and the hydrophobic 
properties were determined by water contact angle measurements. In vitro degradation 
studies were conducted and drug release kinetics from the drug-loaded PCL and 
PCL/blend NFs was determined by RP-HPLC. In vitro cell culture studies included 
cytotoxicity and immune response assays.  
 






4.3 Results  
4.3.1 Production and characterisation of PCL and PCL/blend nanofibres 
4.3.1.1 Electrospinning and scanning electron microscopy  
Based on previous reports for electrospinning PCL/CH and PCL/GEL, AA and FA were 
selected as suitable low toxic solvents [355,373,400]. A ratio of 90:10 AA to FA was 
found to dissolve PCL and the other blend polymers. PCL and PCL/blend NF were 
prepared by the electrospinning method using AA and FA as the solvent system at a ratio 
of 90:10 (Section 2.2.2). The overall polymer concentration of each solution was 10%, 
15%, 20% and 20% w/v for PCL, PCL/CH, PCL/GEL and PCL/PEO, respectively. The 
ratio of the polymers in the blend solutions were 50:50 and 2 g of each polymer solution 
was electrospun on to the rotating collector at a flow rate of 0.6 mL/h for PCL and 0.3 
mL/h for PCL/CH, PCL/GEL and PCL/PEO (Table 4-3). The morphological analysis 
was conducted by field emission-scanning electron microscopy (FE-SEM) (Section 
2.3.1) and showed smooth, bead-free fibres were produced for all four NF formulations 
(Figure 4-4). 
 
Table 4-3 Electrospinning parameters for nanofibre formation. 
Polymer Polymer 
concentration 



























Figure 4-4 FE-SEM micrographs of electrospun PCL and PCL/blend NFs. (a) PCL, (b) 
PCL/CH, (c) PCL/GEL and (d) PCL/PEO NF. 
 
To investigate and compare the morphology of the NF, 100 fibres were randomly selected 
and analysed by FE-SEM software (Figure 4-5 and Figure 4-6). For PCL NFs the fibre 
diameter ranged from to 90-270 nm, with an average diameter of 133 nm (Figure 4-5 a, 
Figure 4-6). PCL/CH NF had the smallest average fibre diameter of 84 nm and fibre 
diameter ranged from 50-150 nm, however, the average fibre diameter was not 
significantly different to the PCL NF (Figure 4-5 b, Figure 4-6). PCL/GEL NF fibres 
were the largest with an average diameter of 779 nm and this was significantly different 
to PCL NFs (p < 0.001), with fibre diameter ranging from 200 nm to 1600 nm (Figure 
4-5 c, Figure 4-6). PCL/PEO NF fibres ranged from 50-370 nm, with an average 
diameter of 199 nm, which was significantly different to PCL alone (p < 0.05) (Figure 






Figure 4-5 Diameter range and distribution histogram of electrospun PCL and PCL/blend NFs: 






Figure 4-6 The mean fibre diameter of electrospun PCL and PL/blend NFs. Bars represent the 
mean of 100 fibres from each NF ±SD. Statistical significance was determined by one-way 
ANOVA with Dunnett’s multiple comparison test, *p < 0.05, ***p <0.001 and is the 
comparison of the PCL NF to blend NF groups. 
 
4.3.1.2 Attenuated total reflective-Fourier transformed infra-red spectroscopy 
During electrospinning, polymers are exposed to solvents and high electric fields that 
may alter their chemical composition. Therefore, attenuated total reflective-Fourier 
transformed infra-red spectroscopy (ATR-FTIR) (Section 2.3.2) was performed on PCL 
and PCL/blend NFs to determine if the chemical structure of the polymers had changed 
after electrospinning. 
 
Asymmetric CH2 stretching and symmetric CH2 stretching bands are observed at 2935-
2941 cm-1 and 2866 cm-1 for pure PCL and the PCL NF (Figure 4-7). The strong, sharp 
band at 1724 cm-1 is associated with carbonyl stretch. The fingerprint region shows C-O 
and C-C stretching bands of the crystalline phase at 1296 cm-1. C-O and C-C stretching 
bands of the amorphous phase overlap in the pure PCL spectrum (1159 cm-1), the two 
peaks are slightly separated in the PCL NF spectrum with the peak at 1159cm-1 having a 




amorphous nature of the PCL NF. Furthermore, the change in relative peak intensities 
may be due to the change in the crystalline/amorphous state of the PCL NF. 
 
Pure CH has a weak broad band at 3302 cm-1 that is attributed to O-H and N-H stretching 
(Figure 4-8). This band can also be seen in the PCL/CH NF spectra at 3273 cm-1. The 
amide I band (C=O stretch) at 1633 cm-1 and amide II band (N-H bending) at 1531 cm-1 
are more pronounced in the PCL/CH NF sample compared to pure CH, this may indicate 
an interaction is occurring between CH and PCL and could be a result of hydrogen 
bonding reducing the amorphous nature of CH. The carbonyl stretching band at 1724 cm-
1 in pure PCL is observed at 1726 cm-1 in PCL/CH NF. The ATR-FTIR spectrum 
indicates CH is incorporated in the NF  
 
Pure PCL has characteristic peaks that are also observed in the PCL/GEL NF with a 
weaker transmittance (Figure 4-9). Pure GEL has a weak broad band at ~3250 cm-1 that 
corresponds to O-H and N-H stretching, and this is also observed in the PCL/GEL NF. 
Protein bands appear in both spectra, the amide I band (C=O stretch) occurs at 1616 cm-
1 in pure GEL and 1637 cm-1 for PCL/GEL NF. The amide II band (N-H bending) is 
observed at 1512 cm-1 and 1527 cm-1 for pure GEL and PCL/GEL NF, respectively. The 
shift to a higher wavelength may indicate a shortening of the amide I and II bond due to 
the interaction with PCL. From the spectra, the presence of GEL in the NF can be 
confirmed.  
 
Asymmetric and symmetric CH2
 stretching bands are observed at 2924 cm-1 and 2875 
cm-1 for pure PEO (Figure 4-10). There is a coalescence of these bands in the PCL/PEO 
NF, with asymmetric and symmetric stretching bands of CH2
 in PCL at 2941 cm-1 and 
2866 cm-1. The characteristic band at 842 cm-1 attributed to CH2 in pure PEO is observed 
in the PCL/PEO NF at 844 cm-1. The semi-crystalline C-O-C triplet band at 1122, 1093 
and 1060 cm-1 in pure PEO can also be seen in the spectra of PCL/PEO NF. The carbonyl 
stretching band at 1724 cm-1 in pure PCL is not seen in the spectra of pure PEO but is 





Figure 4-7 ATR-FTIR spectra of pure PCL (grey line) and PCL NF (blue line). Each line 
represents the mean of three independent experiments. 
 
 
Figure 4-8 ATR-FTIR spectra of pure PCL (grey line), pure chitosan (black line) and PCL/CH 





Figure 4-9 ATR-FTIR spectra of pure PCL (grey line), pure GEL (black line) and PCL/GEL 
NF (yellow line). Each line represents the mean of three independent experiments.  
 
 
Figure 4-10 ATR-FTIR spectra of pure PCL (grey line), pure PEO (black line) and PCL/PEO 





4.3.1.3 Thermogravimetric analysis 
Thermogravimetric analysis (TGA) is used to determine the thermal stability of a 
polymer, the loss of volatile solvents or water content and also confirms the incorporation 
of the blend polymers into the NF. Samples were placed in a TGA pan and heated in a 
furnace in a nitrogen atmosphere from 25-600C (Section 2.3.4). 
 
PCL has low thermal stability with a melting point of 60C, the TGA curve of pure PCL 
(Figure 4-11 a) shows a one-step decomposition process [401]. Pure PCL had an onset 
temperature of ~250C and decomposition occurred over the range of ~250-510C. The 
PCL NF had a higher onset temperature of ~280C and decomposition occurred over the 
range of ~280-510C.  
 
There are three weight loss steps in the TGA curve of pure CH (Figure 4-11 b). The 
initial loss occurs from 0-10% (Figure 4-11 b). The main weight loss is observed over 
the range of ~250C to ~400C. The PCL/CH NF DSC curve shows a similar trend with 
a ~5% water weight loss over the 150C temperature range (Figure 4-11 b). This 5% 
weight loss is half of the pure CH due to the polymers in the NF being at a ratio of 50:50. 
PCL major decomposition onset temperature occurs at ~280C and proceeds until 470C.  
 
Initial weight loss for pure GEL is from 35-200C and is ~10% of the total weight of the 
sample (Figure 4-11 c). PCL/GEL NF has an initial weight loss of ~5% from 35-150C. 
The major decomposition step for pure GEL and PCL/GEL occurs at an onset 
temperature of 260C and continues to ~400C where decomposition of the polymer 
backbone occurs. 
 
The TGA curve for pure PEO (Figure 4-11 d) is a single step decomposition, the onset 
temperature is at 200C and decomposition occurs over the range of ~200-400C. The 




occurred. However, the rate of decomposition was less than pure PEO (Figure 4-11 d). 
The TGA curve of the NF was a combination of the two polymers. It was more thermally 
stable than PEO but less stable than PCL.  
 
 
Figure 4-11 TGA curves of pure polymers and electrospun PCL and PCL/blend NFs. (a) pure 
PCL (grey line) and PCL NF (blue line), (b) pure CH (black line), PCL/CH NF (orange line) 
and PCL NF (blue line), (c) pure GEL (black line), PCL/GEL NF (yellow line) and PCL NF 
(blue line) and (d) pure PEO (black line), PCL/PEO NF (green line) and PCL NF (blue line).  
 
4.3.1.4 X-ray diffraction 
XRD is a technique used to analyse the phase of a material and can rapidly determine if 
a polymer is in the amorphous or crystalline state. Pure polymer or NF were loaded into 
the X-ray diffractometer and scanned over a range 5-50 (2θ) with Cu Kα radiation 
(Section 2.3.5). Pure PCL has two distinct diffraction peaks at positions 21 and 24 (2θ 
(Figure 4-12 a). The peaks indicate the polymer is semi-crystalline with crystalline and 




indicating PCL is still semi-crystalline after the electrospinning process. The XRD 
pattern of pure CH shows a broad peak confirming the amorphous nature of CH (Figure 
4-12 b). After electrospinning CH with PCL into a NF, the CH is still in the amorphous 
state as no new peaks appear and the peaks that are present correspond to those for PCL 
(Figure 4-12 b). Pure GEL is also amorphous and remains in this state after 
electrospinning as confirmed by the broad XRD pattern (Figure 4-12 c). Pure PEO has 
two characteristic x-ray diffraction peaks at 19 and 23 (2θ) (Figure 4-12 d). Three 
peaks are observed in the PCL/PEO NF at diffraction positions of 19, 21, and 23 (2θ), 
these are associated with the crystalline peaks observed in pure PEO and pure PCL 




Figure 4-12 XRD patterns of pure polymers and electrospun PCL and PCL/blend NFs. (a) pure 
PCL (grey line) and electrospun PCL NF (blue line), (b) pure CH (black line), PCL/CH NF 
(orange line) and PCL NF (blue line), (c) pure GEL (black line), PCL/GEL NF (yellow line) 






4.3.1.5 Differential scanning calorimetry 
DSC is a powerful tool to determine the solid-state of polymers. Samples are sealed in 
an aluminium pan and heated at a controlled rate under a nitrogen atmosphere (Section 
2.3.3).  Figure 4-13 shows the DSC thermogram of pure PCL and electrospun PCL NF. 
An endothermic peak occurs at 59.6C for pure PCL and at 58.2C for the PCL NF, this 
is the melting temperature (Tm). The enthalpy of fusion is calculated from the area under 
the Tm curve and relates to the degree of crystallinity. For 100% crystalline PCL the 
reported enthalpy of fusion is 135 J/g [335]. The area under the curve for pure PCL was 
calculated to be 78.9 J/g and therefore the degree of crystallinity is 58.4% (Table 4-4). 
PCL NF had an area under the curve of 68.8 J/g and a degree of crystallinity of 50.9% 
(Table 4-4). The Tg occurs at -67C in the pure PCL and -64C for PCL NF.  
 
The DSC thermogram of pure CH, PCL/CH NF and PCL NF are shown in Figure 4-14. 
For pure CH a large endothermic peak occurs over a wide temperature range with a centre 
at 112C. The Tm of PCL in the PCL/CH NF is 59.1C with an enthalpy of fusion of 37 
J/g that corresponds to a 27% degree of crystallinity (Table 4-4). The inset of the Tg 
shows it has increased from -67C (PCL NF) to -28C (PCL/CH NF).  
 
Pure GEL, PCL/GEL NF and PCL NF DSC curves are shown in Figure 4-15. Pure GEL 
as a similar endothermic peak to pure chitosan centred at ~111C. PCL in the PCL/GEL 
NF has a Tm of 56.6C and enthalpy of fusion of 23.7 J/g, which corresponds to a degree 
of crystallinity of 18% (Table 4-4). The inset shows the Tg of PCL NF is -64C this has 
increased to -30C in the PCL/GEL NF (Figure 4-15). 
 
Pure PEO has a Tm of 68.8C and enthalpy of fusion of 192.5 J/g. Reports state the 
enthalpy of fusion for 100% crystalline PEO is 203 J/g, therefore, the degree of 
crystallinity is 96% (Table 4-4) [335]. PCL/PEO NF has a Tm of 64.7C and enthalpy 




fusion (192.5 J/g) but, higher than PCL NF Tm (58.2C and enthalpy of fusion (68.8 J/g). 
The enthalpy of fusion of the NF indicates it is a blend of the two polymers. The Tg has 
also changed from -64C (PCL NF) to -58C. Pure PEO did not appear to have a Tg in 
the DSC thermogram (Figure 4-16). 
 
Table 4-4 Enthalpy of fusion and crystallinity as determined from DSC data of polymers and 
electrospun PCL and PCL/blend nanofibres. 
Polymer 
 





Pure PCL 18.9 58.4 
 
PCL NF 68.8 58.4 
 
PCL/CH NF 37 27 
 
PCL/GEL NF 23.7 18 
 
Pure PEO 192.5 96 
 






Figure 4-13 DSC thermogram over the range of -80-160C of pure PCL (grey line), PCL NF 




Figure 4-14 DSC thermogram over the range of -80-160C of pure CH (black line), PCL/CH 
NF (orange line) and PCL NF (blue line). Inset of (a) PCL NF glass transition temperature and 





Figure 4-15 DSC thermogram over the range of -80-160C of pure GEL (black line), 
PCL/GEL NF (yellow line) and PCL NF (blue line). Inset of PCL NF glass transition 
temperature (blue line) and PCL/GEL NF glass transition temperature (yellow line). 
 
 
Figure 4-16 DSC thermogram over the range of -80-160C of pure PEO (black line), PCL/PEO 
NF (green line) and PCL NF (blue line). Inset of PCL NF glass transition temperature (blue 





4.3.1.6 Mechanical strength of nanofibres  
In order to be used for drug delivery, the NF must be strong enough to withstand external 
forces such as handling and surgical implantation, and must also be able to endure the 
environment within the brain. To determine the mechanical properties of the NF and to 
investigate if producing blend NFs influenced changes in the mechanical properties of 
PCL, tensile testing was performed. A length of NF with dimensions of 100 mm x 12 
mm was placed in tensile grips and put under tension until the fibre fractured (Section 
2.3.7).  
 
PCL/CH had the lowest tensile strength of 0.64 MPa and Young’s modulus of 3.65 MPa 
followed by PCL with a tensile strength of 1.43 MPa and Young’s modulus of 7.25MPa 
(Figure 4-17). PCL/GEL had a tensile strength of 3.27 MPa and the highest Young’s 
modulus of 295.17 MPa, which was significantly higher than PCL NF (p < 0.05). 
PCL/PEO had the highest tensile strength of 7.58 MPa, significantly higher (p < 0.001) 
compared to PCL and a Young’s modulus of 78.90 MPa (Figure 4-17). 
 
 
Figure 4-17 The maximum tensile strength of PCL and PCL/blend NFs. Bars represent the 
mean of three independent experiment ±SD. Statistical significance was determined by one-
way ANOVA with Dunnett’s multiple comparison test, *p < 0.05, ***p < 0.001 and is the 




4.3.1.7 Hydrophobicity of nanofibres  
The hydrophobicity of a NF may influence protein adsorption and cell adhesion 
therefore, effecting the biocompatibility and drug release in vivo. PCL is a hydrophobic 
polymer, and by introducing different polymers into the electrospinning blend solution, 
such as CH, GEL or PEO, the resulting NF hydrophobic properties can be altered. To 
determine whether PCL hydrophobicity was altered when electrospun with CH, GEL or 
PEO, water contact angle measurements were conducted by placing a drop of water on 
the NF and recording the contact angle for 300 s (Section 2.3.8). The general trend of the 
contact angles over the 300 s period is displayed in (Figure 4-18) and the water droplets 
are depicted on the NF in Figure 4-19. PCL and PCL/CH have similar initial contact 
angles of 71.8° and 73.5°. PCL/PEO has an initial contact angle of 64.1° and PCL/GEL 
is significantly lower at 43.4°. PCL and PCL/CH also show a similar rate of decrease 
with PCL decreasing to 67.4° and PCL/CH reducing to 70.1°. PCL/PEO contact angle 
drops to 57.5° over the 300 s period. PCL/GEL shows the most significant decrease after 
30 s it has reduced to 7.2° and is completely absorbed by the surface after 50 s. 
 
 
Figure 4-18 Kinetics of water contact angles on the surface of PCL and PCL/blend NFs over a 
300 s period. PCL (blue line), PCH/CH (orange line), PCL/GEL (yellow line) and PCL/PEO 
(green line). Each line represents the mean of three individual experiments ± SD. Statistical 
significance was determined by two-way ANOVA with Bonferroni’s post hoc test, ***p < 






Figure 4-19 Water droplets on the surface of PCL and PCL/blend NFs at 1 and 300 s. (a) PCL 
NF at 1 s, (b) PCL NF at 300 s, (c) PCL/CH NF at 1 s, (d) PCL/CH NF at 300 s, (e) PCL/GEL 





4.3.2 In vitro mass loss of nanofibres 
The NF are prepared from biodegradable polymers that degrade primarily by hydrolysis 
when placed in an aqueous environment. The degradation time for each polymer is 
different and is dependent on the physical and chemical properties of the polymer. To 
investigate the in vitro mass loss, NF were weighed then placed in PBS (pH 7.4) and 
incubated at 37°C to mimic the physiological conditions of in vivo hydrolysis (Section 
2.3.9). The mass loss of the NF is shown in Figure 4-20.  
 
Over the 4-week time course, PCL and PCL/CH NF had a mass loss of ~3 and ~4%, 
respectively. This is in contrast to PCL/GEL and PCL/PEO, as both NF lost significant 
mass after 1 week (35% and 42%, respectively) and by the end of the 4 weeks, PCL/GEL 
had 62% mass remaining and PCL/PEO had 56% mass remaining (Figure 4-20). The 
mass loss from PCL/GEL and PCL/PEO indicates ~40% of GEL and PEO were degraded 
from the fibre and the remaining weight in the NF is most likely to be PCL, as the ratio 
of the polymer blend NF was 50:50. 
 
 
Figure 4-20 Mass loss from PCL and PCL/blend NFs over a 4-week time period in phosphate 
buffered saline (pH 7.4) at 37°C. PCL (blue line), PCL/CH (orange line), PCL/GEL (yellow 
line) and PCL/PEO (green line). Straight lines have been used between the points and each 




4.3.3 In vitro drug release from nanofibres 
L-655,708 was dissolved in the polymer/solvent solutions at a concentration of 0.1% 
w/w, based on our previous work and incorporated into the PCL and PCL/blend NF by 
the electrospinning process (Section 2.2.1.4) [73]. The release of L-655,708 from the NF 
was monitored by validated RP-HPLC assay (Section 2.4.1) [73].  
 
The release of L-655,708 from the NFs showed an initial burst release for the first 
approximately 48 h, followed by no further release over the remaining 4-weeks of 
assessment (Figure 4-21). PCL had the lowest initial release of 47% after 48 h followed 
by PCL/GEL which had an initial release of 81% after 48 h. PCL/PEO showed a release 
of 87% in the initial phase and release over the initial phase from PCL/CH was the fastest 
with 100% over a 24 h period. After 48 h, the release curve levelled off and there was no 
further release over the 4-weeks for all of the NFs. Furthermore, the decrease 72 h may 
be due to the release of drug being complete and the concentration diluted by the 







Figure 4-21 In vitro cumulative release of L-655,708 from PCL and PCL/blend NFs in 
phosphate buffer saline (pH 7.4) at 37°C, (A) over the first 12 h and (B) over 504 h. PCL 






4.3.4 The effect of charge interaction between the drug and chitosan on in vitro 
release 
To investigate if a charge interaction between CH and L-655,708 was responsible for a 
faster release rate of L-655,708 compared to the other PCL/blend formulations, drug-
loaded PCL/CH NF were electrospun with a drug that had no net charge. Indomethacin 
was selected as the drug of choice due to having a similar molecular weight (357.787 
g/mol) to L-655,708 and because it is hydrophobic like L-655,708. Indomethacin was 
dissolved in the polymer/solvent solution at a concentration of 0.5% w/w and 
incorporated into the PCL/CH NF using the electrospinning process (Section 2.2.1.4). 
The release of indomethacin from the PCL/CH NF was monitored by RP-HPLC (Section 
2.4.2). The cumulative percent release of L-655,708 and indomethacin from the PCL/CH 
NFs is shown in Figure 4-22. The release profiles of L-655,708 and indomethacin from 
the PCL/CH NFs are not statistically different and have an apparent biphasic release, 
with an initial burst release, followed by a plateau where there was no change in drug 
release. For L-655,708 the burst release occurs over the first 24 h where it reaches over 
100% cumulative release and is followed by a period of no further drug release up to 21 
days (504 h). The burst release of indomethacin is extended to 48 h where a cumulative 






Figure 4-22 In vitro cumulative drug release from PCL/CH NF in phosphate buffered saline 
(pH 7.4) at 37°C, (A) over the first 8 h and (B) over 504 h. Indomethacin (blue line), L-655,708 





4.3.5 In vitro cell culture studies  
4.3.5.1 Nanofibre in vitro cytotoxicity 
Cell viability and proliferation was investigated to determine the in vitro cytotoxicity and 
biocompatibility of the NFs. Normal human-derived fibroblast (NHDF) cells were 
cultured on the NF over a 72 h period (Section 2.5.1.1). Cell viability was determined 
using the MTT assay (Section 2.5.2.1).  
 
After 24 h, PCL/GEL had the greatest cell viability and proliferation followed by 
PCL/PEO and both were statistically higher than non-fibre controls (cells grown on cell 
culture well) (Figure 4-23). PCL/CH cell viability after 24 h was not as high as PCL/GEL 
and PCL/PEO, but was statistically higher than the non-fibre controls, while cell viability 
in the presence of PCL showed no difference to the non-fibre controls (Figure 4-23). At 
the 48 h time period, cell viability and proliferation for PCL had increased to the same 
level as PCL/CH although both were not significantly higher than the non-fibre controls, 
whilst PCL/GEL and PCL/PEO remained at a similar level and were still significantly 
higher than non-fibre controls. After 72 h there was a decrease in proliferation and cell 
viability for all the NF treatments groups, with PCL/PEO having the greatest decrease 
from the 48 h time point. This may have arisen due to the cells becoming too confluent. 
The result shows all NFs were not cytotoxic and can support cell growth, with PCL/GEL 






Figure 4-23 Cell viability of fibroblast cells after incubation of the cells on the NF surface. 
NHDF cells were seeded on NF for a) 24, b) 48 and c) 72 h at 37°C 5% CO2. Cell viability was 
determined using the MTT assay. Bars represent the mean of three independent experiments 
±SD. Statistical significance was determined by two-way ANOVA with Bonferroni’s post hoc 
test, *p < 0.05, ***p < 0.001 and is the comparison of the control (cells grown on cell culture 
well) to treatment groups. 
 
4.3.5.2  Immune response to nanofibres  
The concentration of cytokines present in the media at 24 h and 48 h post-incubation with 
NFs is observed in Figure 4-24. Lipopolysaccharide (LPS) stimulated a significant 
increase in TNF-α, IL-6, IL-12p70 and MCP-1 pro-inflammatory markers expressions at 
24 h and 48 h compared with non-LPS control. After 24 h and 48 h, there was no 





IL-10 is an anti-inflammatory cytokine marker and is up-regulated in response to the 
release of pro-inflammatory cytokines [403]. IL-10 is released from the NHDF cells 
when stimulated with LPS and the response is statistically different at 24 h and 48 h 
compared to non-LPS control, indicating an inflammatory response.  PCL/GEL showed 
a slight increase for IL-10 at 24 h, however, this was not significantly different to the 
control. The control, PCL, PCL/CH and PCL/GEL showed elevated IL-10 levels, but this 






Figure 4-24 Secretion of pro-inflammatory cytokines from NHDF cells when incubated on NFs 
at 37°C 5% CO2. a) TNF-α, b) IL-6, c) IL-10, d) IL 12p70 and e) MCP-1. Media was collected 
after 24 and 48 h, cytokine concentrations were determined by flow cytometry and LPS was 
used as the positive control. Bars represent the mean of three independent experiments ±SD. 
Statistical significance was determined by two-way ANOVA with Bonferroni’s post hoc test, 





4.4 Discussion  
4.4.1 Electrospinning and nanofibre morphology 
To produce NFs the electrospinning method was employed because it is a fast, effective 
technique to produce nanometre diameter fibres. A drawback to this method, however, 
is the process typically uses organic solvents that are highly toxic. To overcome this, 
electrospinning was conducted using AA and FA as the solvent system. AA was selected 
because it is a USP Class III solvent and it has been previously used to electrospin PCL 
and GEL [86,373]. However, it has been reported that neat AA does not sufficiently 
dissolve CH for electrospinning and therefore, FA was incorporated into the solvent 
system to achieve complete solubility of CH [404]. The electrospinning parameters were 
kept constant to remove any variables that may have influenced the resulting NF and to 
achieve a direct comparison of the NF. However, the flow rate for PCL NF was increased 
from 0.3 mL/h to 0.6 mL/h to successfully electrospin the solution.  
 
The electrospinning process produced smooth, randomly aligned, bead-free fibres for 
PCL and the polymer blend solutions. The only difference observed was the fibre 
diameter size. PCL/GEL and PCL/PEO produced a larger average fibre diameter with 
the former being significantly larger. This increase in fibre diameter may be attributed to 
a higher polymer concentration of 20% compared to 10% used in the electrospinning 
solution, as it has been shown when the concentration of PCL/GEL solution was 
increased from 12% to 18%, the average fibre diameter increased from 15.9 nm to 547.6 
nm [405]. This was not the case for PCL/CH as a smaller average fibre diameter was 
observed compared to PCL. Researchers have observed ultrafine fibres ~30 nm in 
diameter when CH is electrospun with PCL [355]. It was concluded that the positive 
charge on CH leads to an increase in charge separation at the Taylor cone and causes an 
increase in polymer jet instability resulting in polymer jet elongation and jet splitting 
[355]. A similar result was observed for a polymer blend of CH/PEO when the 




4.4.2 Solid-state properties of electrospun PCL and PCL/blend nanofibres 
In blend solutions, chemical interactions with functional groups present on the polymers 
may take place and alter the chemical composition of the NF and its properties. The 
exposure to solvents during the electrospinning process may also cause changes in the 
polymer structure and NF properties. ATR-FTIR spectroscopy allows rapid analytical 
identification of the molecular make-up of the polymers present in the NF [407,408]. 
When the NF is irradiated with infrared radiation the molecules absorb the energy at 
specific wavelengths, this absorption corresponds to specific chemical bonds and the 
resulting spectra is the characteristic functional groups present in the NF. In the present 
study, the spectra of the NFs were similar to the individual polymers therefore, each 
polymer was successfully electrospun into a NF or NF blend. Crystalline regions of PCL 
and PEO are observed in the NF spectra and were not transformed into the amorphous 
state after electrospinning [409–411]. Similarly, for the natural polymers, the amide I and 
II bands of CH and GEL are present in their respective NF spectra and were not 
influenced by the solvent or electrospinning process [405,412,413]. The lack of 
additional IR bands in the spectra indicates the composition of each polymer was not 
affected by the solvents or the electrospinning process. The decrease in transmittance 
intensity observed in the NF may simply be attributed to the amount of polymer present 
in the NF. Slight shifts in band positions to the right for polymer blend NFs may be due 
to an increase in hydrogen bonds between the blend polymer with PCL, especially in the 
case of CH and GEL where the amide groups can form hydrogen bonds [414]. Shifts to 
the left resulting in a higher wavelength may indicate a shortening of the amide I and II 
bond due to the interaction with PCL. The spectra for each NF is in agreement with 
previously published spectra [335,415–417]. 
 
At elevated temperatures (>150°C), polymers are known to undergo thermal 
decomposition [418]. Sivalingam et al. (2003) investigated the thermal degradation of 
PCL in detail [419]. Under non-isothermal heating, the process proceeds by random chain 
scission in the polymer backbone and specific chain end scission. Initially, random chain 
scission dominates and over longer periods specific chain end scission dominates where 




is in agreement with Sivalingam et al. (2003), indicating the mechanism of thermal 
degradation is by random chain scission and specific chain end scission. The thermal 
degradation of PEO is well established and occurs by random chain scission between C-
O bonds with cleavage of C-C bonds proceeding at elevated temperatures (pyrolysis) 
[420–424]. The thermal decomposition of GEL and CH is more complex than PCL and 
PEO as it is not a single-step process. The presence of hydrogen bonding groups allows 
water to bind to the macromolecules, and the initial weight loss step in the TGA data for 
both GEL and CH is the loss of bound water [425–427]. Chitosan has a second weight-
loss step that corresponds to the degradation of N-acetyl-D-glucosamine and D-
glucosamine units [428]. It has been proposed cross-linking reaction occurs during the 
decomposition of amino groups forming new cross-linked material and the final 
degradation step is associated with this [429,430]. The second degradation step for GEL 
is associated with the breaking of intra- and inter-molecular bonds, protein and amino 
acid degradation [427,431,432]. The final step has been reported as the decomposition of 
the amino acid glycine [431]. While the TGA data obtained for GEL and CH reported 
here shows three decomposition steps, it should be noted that the thermal decomposition 
of GEL and CH are dependent on many factors including, their natural origin, purity, 
composition and processing, and therefore, differences may arise to the literature [433]. 
The incorporation of CH, GEL or PEO in PCL NFs decreased the thermal stability of the 
PCL NF. However, in contrast, PCL increased the thermal stability of the blend 
polymers. The shift in thermal stability of the polymers has been described by 
Lewandowska and is attributed to interactions between the two polymers at the molecular 
level [434]. This supports the hydrogen bonding between the polymers observed in the 
ATR-FTIR results (Section 4.3.1.2) [434]. Furthermore, similar shifts in thermal stability 
have been observed for PCL/GEL NF, with GEL thermal stability increasing and PCL 
decreasing [414,435]. TGA did not detect the loss of residual solvent from NFs, and this 
may suggest there is no residual solvent present in the NFs after electrospinning. 
 
Polymers exist in different phase states. They can be crystalline, amorphous or semi-
crystalline (crystalline regions and amorphous regions). Crystalline polymers tend to 
have a highly ordered structure with densely packed molecular chains, which are stiff 




loosely packed molecular chains and are considered to be in the glassy or rubbery state 
depending on the Tg of the polymer [436–438]. PCL is a semi-crystalline polymer, it has 
highly ordered crystalline regions as well as rubbery amorphous regions [402]. During 
the electrospinning process, rapid evaporation of the solvent can inhibit the formation of 
the crystalline phase, when it is converted from liquid state (solvent/polymer solution) to 
a solid-state (NF form) [439]. ATR-FTIR results indicated the PCL and PCL/blend NF 
had crystalline regions. To investigate this further and confirm the semi-crystalline 
structure of PCL was responsible, XRD was employed. PCL has been reported to have 
two crystalline peaks at angles of 2θ = 21.4° and 23.8°, which are associated with the 
crystallographic planes of (110) and (200) [402]. The crystalline peaks of PCL were 
observed in all the NFs indicating the semi-crystalline structure of PCL was not 
influenced by blend polymers [402]. However, there was a decrease in the PCL peak 
intensity for all NFs, which suggests the degree of crystallinity was reduced. Gautam et 
al. (2013) observed a similar result in a PCL/GEL NF and proposed the decrease in 
crystalline peak intensity may be due to interactions between PCL and GEL on a 
molecular level [435]. A more probable cause is that the degree of crystallisation is 
hindered by the electrospinning process because the solvent evaporates rapidly and 
therefore the PCL molecular chains are unable to reorganise, nucleate and crystallise 
[440]. 
 
In order to establish and confirm if the electrospinning process influenced the degree of 
crystallinity of PCL in the NF, DSC analysis was undertaken. The enthalpy of fusion of 
135 J/g for 100% crystalline PCL was used to calculate the enthalpy of fusion and, hence 
determine the degree of crystallinity from the melting peak of the DSC thermogram for 
the NF [335]. Pure PCL had a crystallinity of 58.4%. When the PCL was electrospun the 
resulting PCL NF had a reduced crystallinity of 50.9%, confirming the XRD results. The 
values indicate the electrospinning process affected the crystalline state of PCL, however, 
the degree of crystallinity of the PCL NF is higher than reported by Nien et al. (2013) 
who calculated a degree of crystallinity of 39.5% for a PCL NF [335]. The difference in 
the degree of crystallinity may be due to the parameters used for the electrospinning 




support the reduction of the crystalline phase, the Tg of PCL NF showed an increase of 
3°C, which illustrates the amorphous phase increased.  
CH is a semi-crystalline polymer, however, there were no well-defined peaks in the XRD 
and it appears to be amorphous. It has been reported that CH crystalline phase is hard to 
determine due to its hygroscopicity [433]. The DSC data shows a Tg for CH at 112°C 
because of the hygroscopicity of CH. Reports on DSC for CH in the literature are varied 
and range from 50°C  to 170°C  [441–443]. In the study conducted here, it appears CH 
is in the amorphous phase in the NF.  
 
GEL is amorphous in nature and this was identified by the broad peak in the XRD data. 
DSC analysis showed a Tg of 111°C and this is in agreement with Staroszczyk et al. 
(2012) who showed type A GEL had a Tg of 109-118°C [444]. With the introduction of 
CH and GEL into the blend NFs, the crystallinity of PCL reduced and the Tg increased 
in both NF blends compared to the PCL NFs. The changes in crystallinity and Tg 
indicates there is some interaction between the polymers and may be associated with 
hydrogen bonding, which is supported by the ATR-FTIR and XRD data. The PEO used 
in this study had crystalline regions as observed in ATR-FTIR and XRD data and DSC 
confirmed it was 96% crystalline. Literature states a Tg for PEO of -67°C. This was not 
observed in the DSC of pure PEO, which may be because of the high crystallinity of the 
PEO [445,446]. When PEO was electrospun with PCL the enthalpy of fusion of the NF 
was 105.6 J/g because of the higher enthalpy of fusion of PEO. However, the degree of 
crystallinity of each polymer could not be calculated because the melting point of each 
polymer overlapped and was one peak [335]. Based on the XRD data it would appear, 
with the reduced peak intensities of PCL and PEO in the NF blend, the crystallinity had 
decreased and the Tg of PCL/PEO NF increased compared to the PCL NF indicating 
there was a slight increase in the amorphous regions in the DSC thermogram. The results 
suggest NFs produced using CH and GEL influence the crystallinity the most and 
therefore may be better for drug delivery applications. The increase in amorphous regions 
of PCL in the blend polymer NF may provide an increase biodegradation time as water 





4.4.3 Tensile strength of PCL and PCL/blend nanofibres 
To establish whether the blend NFs had similar mechanical strength properties to the 
PCL NF, uniaxial tensile testing was performed. The tensile strength of electrospun NFs 
tends to be inferior to the bulk polymer or textile fibres [447,448]. Bulk PCL has a 
reported tensile strength of 10.6-16.1 MPa, but the tensile strength of the PCL NF 
reported here was considerably less at 1.43 MPa [449]. However, the tensile strength of 
PCL NF in the literature is varied and studies have investigated how the processing 
parameter of electrospinning influences the tensile strength. Bölgen et al. (2005) reported 
a 4% PCL solution, electrospun to form a NF had an average fibre diameter of 52 nm and 
tensile strength of 4.6 MPa. Each time the polymer concentration was increased the 
resulting NF produced larger diameter fibres and higher tensile strength [205]. Gaumer 
et al. (2009) investigated what effect the source to ground distance had on the tensile 
strength of PCL NF. They discovered an increased source to ground distance can increase 
the tensile strength of a PCL NF [450]. A comprehensive study that investigated what 
effect the independent processing parameters; polymer concentration, flow rate, applied 
voltage and needle to collect distance had on the tensile strength of PCL NF was 
conducted by Asvar et al. (2017). Asvar and colleagues observed a range of tensile 
strengths from 0.5-3.0 MPa when each processing parameter was adjusted, although it 
was noted the needle to collector distance had little effect on the tensile strength [451]. 
They concluded the processing parameters alter the morphology of the NFs, which in 
turn influences the NF tensile strength and therefore, tensile strength can be optimised 
by adjusting the parameters [451]. Without altering the electrospinning processing 
parameters, PCL tensile strength can also be improved by adding another polymer [448]. 
However, in this study when CH was blended with PCL, the PCL/CH NF had a lower 
tensile strength of 0.64 MPa compared to PCL NF. CH has been reported to be a weak 
and brittle polymer and therefore, the mechanical integrity of the PCL/CH NF may have 
been compromised with the addition of CH [203,452]. The average diameter fibre of 
PCL/CH NF was smaller than the PCL NF fibre diameter and this may have also 
contributed to the decrease in tensile strength. Prabhakaran et al. (2008) reported similar 
tensile strength results of 1.31 MPa for PCL NF and 0.87 MPa for PCL/CH NF [452]. 
Tensile strength of 4.53 MPa for a PCL/GEL NF has been reported in the literature, 




however, this was statistically greater than the tensile strength of the PCL NF reported in 
this study [453].  
 
Although GEL polymer has poor mechanical properties, the PCL/GEL NF had the largest 
average fibre diameter and this may have contributed to the higher tensile strength [202]. 
The mechanical properties of a PEO NF are limited in the literature because it is often 
added to a solution as a carrier polymer to aid in NF formation of poorly electrospun 
polymers and is generally leached out of the NF post electrospinning [454,455]. For 
example, a dual electrospinning approach has been used to produce a porous PCL NF 
after the leaching out the PEO [454]. They tested the tensile strength of the NF before 
and after PEO was leached out of the NF, which was ~3.9 MPa and 3.2 MPa, respectively 
[454]. The blending of PCL with PEO and fabrication of PCL/PEO NF reported here had 
a significantly increased tensile strength of 7.58 MPa compared to the PCL NF. This may 
have been because of the blend solution creating more polymer chain entanglements 
between the two polymers and subsequently a stronger fibre. This also may explain why 
the PCL/PEO NF produced a higher tensile strength than the other PCL/blend NF. Given 
that the Young’s modulus of brain tissue is typically in the range of a few hundred Pa to 
kPa, the NFs would withstand the environment in the brain [456].  
 
4.4.4 Hydrophobic characteristics of PCL and PCL/blend nanofibres 
A limitation of PCL is its hydrophobic nature, this affects its performance as a biomedical 
device because it can lead to a decrease in biocompatibility and effect drug release in 
vivo. With regard to NF drug delivery, a hydrophobic NF may result in a slower drug 
release due to the time it takes for the NF to become hydrated [457]. To assess the 
hydrophilicity of the NF water contact angle, measurements were conducted. This was 
dynamic and therefore the wettability of the NF was also determined. The study presented 
here shows the PCL NFs with an initial contact angle of 71.8°. The PCL NF is considered 
to be hydrophilic because generally if the water contact angle is larger than 90°, the 




surface is considered hydrophilic [253]. Although previously stated PCL NF contact 
angles in the literature are varied, they are higher than the contact angle reported here 
and are above 90° indicating a hydrophobic surface of the PCL NFs [200,458–460]. The 
lower contact angle reported here may be due to fibre diameter and surface topography 
of the PCL NFs. The contact angle decreased by 4.4°, and this indicated the water droplet 
was poorly absorbed by the NFs and, hence it has low wettability.  
 
CH, GEL and PEO are hydrophilic polymers, by blending each of these polymers with 
PCL the contact angle of the PCL/blend NF should reduce in comparison to the PCL NF. 
Incorporating a hydrophilic polymer produces a NF with an increase in hydrophilicity 
and wettability. However, this was not observed for the PCL/CH NF. The initial contact 
angle was higher at 73.5° with the addition of CH compared to PCL and only decreased 
to 70.1°. Although this was not significantly different to PCL NF, it was in contrast to 
what was expected, as CH is a hydrophilic polymer and therefore it was expected that 
the contact angle would decrease. This result is not dissimilar to previously published 
literature, as a contact angle of 95.3° has been reported for a PCL/CH NF at a ratio of 
70:30 [354]. 
 
A PEO NF has a reported water contact angle of ~20° and PCL/PEO NF has been 
reported to be 35° [461,462]. The inclusion of PEO in the PCL/blend NF in this study 
reduced the initial contact angle from 71.8° (PCL NF) to 64.1°. This is because the water 
interacts with hydrophilic side chains of PEO. The wettability also increased with a 6.6° 
reduction of the contact angle over the time course.  
 
With the introduction of GEL to the NF, the initial contact angle of PCL/GEL NF was 
significantly less at 43.4°. A range of contact angles (57.7°, 32.7°, 54°) have been 
reported in the literature for a 50:50 ratio of PCL/GEL NF and the result reported here is 
within the range [463–465]. The water droplet on the PCL/GEL NF decreased to a 




wettability. A similar trend regarding the decrease in the contact angle of the PCL/GEL 
NF was observed by Zheng et al. (2014) [465]. The lower contact angle of PCL/GEL NF 
is in part due to the amine and carboxyl functional groups of GEL [466]. The contact 
angle is also influenced by surface roughness, which is governed on the nanoscale by 
fibre diameter and porosity, therefore the results reported are only an indication of NF 
hydrophilicity [462]. This also may explain why there are differences to the contact 
angles reported here and the ones stated in the literature. 
 
The in vitro degradation studies of NFs presented in this study were assessed by placing 
the NFs in a solution of PBS (pH 7.4) at 37°C to mimic in vivo conditions, which is the 
most common method used in the literature [467]. However, a limitation with this 
approach is that it does not assess enzymatic degradation. The degradation of PCL is 
reported to take place in a two-step process. The first being the absorption and penetration 
of water into the amorphous regions of the polymer, followed by autocatalysis of the 
carboxylic end groups in the crystalline region [291]. The hydrophobic nature of PCL 
limited the ability of water to penetrate the NF matrix given the mass loss was only 3% 
and the mass loss most likely occurred in the amorphous region given water penetrates 
this region first in the degradation process [291]. Similar results with mass loss of ~ 4% 
after 4 weeks and ~6% after 6 weeks from a PCL NF have been observed [468]. 
 
The slow in vitro degradation due to the hydrophobicity of PCL is consistent with the 
high water contact angle and low wettability of the PCL NF. PCL/CH NFs showed a 
similar degradation rate to PCL NFs, with a reduction of weight of ~4%. Fukunishi et al. 
(2016) observed a similar finding with negligible mass loss of a PCL/CH NF over 4-
weeks. They noted the degradation rate of CH is dependent on molecular weight and 
degree of deacetylation [469]. However, CH degradation is reported to primarily occur 
in humans by enzymatic degradation [338]. Non-enzymatic hydrolysis does occur but its 





A point to note is that the in vitro model used here may not be appropriate to gauge the 
degradation kinetics of the PCL/CH NF in vivo as it is based solely on non-enzymatic 
hydrolysis and therefore further studies based on an enzymatic hydrolysis model would 
be advantageous. The mass loss was significantly increased when GEL was blended with 
PCL, ~35% mass was lost over the first week and after 4-weeks 62% mass was 
remaining. Given the low mass loss value from the PCL NF, the majority of the loss is 
attributed to GEL. A similar trend was observed with a NF composed of PCL/GEL at a 
ratio of 70:30 (w/w) [470]. They concluded mass loss was from leaching of GEL by 
surface erosion followed by bulk erosion due to the mass loss rate being faster at the 
beginning and slowly decreasing [470]. With the addition of PEO, the electrospun 
PCL/PEO NF was the blend that showed the most mass loss over the 4-week period, 
which is attributed to the PEO leaching out of the NFs [454,455]. PEO is added to 
electrospinning solutions to aid in fibre formation or to create porous NFs and is leached 
out of the NFs post-electrospinning. The fact PEO is employed to do this is evident the 
majority of the mass loss observed here is PEO. In all cases, the data presented here 
showed initial weight loss of the blend polymers, however, a further longer study needs 
to be conducted to establish if the degradation of the blend polymers increases the 
degradation rate of PCL, as loss of the blend polymers may facilitate the penetration of 
water into the PCL regions of the NFs. 
 
4.4.5 Drug release characteristics of PCL and PCL/blend nanofibres 
Drug release kinetics from NFs is generally controlled by drug diffusion and degradation 
of the NF polymer [471]. A simple method to alter the kinetics is by introducing another 
polymer into the NF. This can change the surface erosion and degradation profile and 
will influence the drug release profile since erosion and degradation are a factor in drug 
release. In the present study, drug release from PCL NF was altered by electrospinning 
PCL with CH, GEL or PEO to form NF blends. The polymer blend approach has been 
used to alter the release of tetracycline hydrochloride from a PEVA and PLA NF and 
their blends [472]. In the present study, the drug loading concentration was based on a 
previous study that investigated the release of L-655,708 from a hydrogel [73]. Drug 




over 48 h, followed by a period out to 4-weeks where no further cumulative release is 
observed. The initial release may be beneficial for a therapeutic response. However, the 
second stage, of which no increase in drug release occurred may be due to the degradation 
of the PCL component of the NFs therefore, drug release is slower and may be 
insufficient to achieve a level of drug concentration that will produce a therapeutic 
response. Furthermore, the apparent slight decrease in drug release after 72 h may be due 
to the release of drug being complete, however, the concentration is diluted by the 
replacement media that was added after each subsequent sample was taken. PCL NF 
showed the slowest release of L-655,708. This is because PCL NF is hydrophobic, it has 
low wettability and a slow degradation rate. Because the NF has a large surface area to 
volume ratio, the initial 47% drug release over 48 h was from the diffusion of L-655,798 
dispersed on the surface of the PCL NF.  
 
In general, semi-crystalline polymers like PCL tend to have a burst release due to the 
surface-bound drug, which is in the crystalline state and bound to semi-crystalline regions 
of PCL [473]. The low water uptake into semi-crystalline regions hindering the release 
of drug explains why there was limited drug release after 48 h [472,473]. PCL/GEL and 
PCL/PEO NF had similar release kinetics, with PCL/PEO being slightly faster. The drug 
release from these NF is related to the release of surface-bound drug and drug diffusion, 
the hydrophilic nature and wettability of the polymers and the mass loss of GEL and 
PEO. The fast hydration of the NF allows water to penetrate the hydrophilic regions of 
the NF leaching out the polymer, which in turn facilitates the release of L-655,708. Xue 
et al. (2014) observed similar results with a burst release of metronidazole from a 
PCL/GEL NF followed by a sustained release and concluded the mechanism of release 
was related to drug diffusion and the degradation of GEL [388]. An increased in the rate 
of release of dexamethasone from a PCL/PEO microfiber was due to faster wetting 
because of the hydrophilic PEO [474]. Similarly, chloramphenicol showed a faster 
release from PCL/PEO compared to a PCL NF, which was attributed to the PCL/PEO 





PCL/CH NFs would be expected to have a similar drug release profile to the PCL NFs 
since it had similar wettability and in vitro mass loss profile (Figure 4-20). However, 
this was not the case and in fact, it showed the fastest rate of release of L-655,708, with 
100% being released within 24 h. This suggests L-655,708 was not encapsulated in the 
fibres but bound to the surface and most likely in the crystalline form, allowing for the 
immediate release with no sustained delivery. The release rate of L-655,708 from the 
PCL/CH NF limits this formulation as a drug delivery system because a sustained, 
controlled drug release is desired to produce a sufficient therapeutic response. The release 
from PCL/CH may cause local toxicity as the majority of the drug is released over a short 
period. The release of the drug was also highly varied and over the theoretical drug 
loading total which again limits its application as the drug release is unpredictable.  
 
In comparison to the hydrogel delivery system we previously investigated for the 
controlled release of L-655,708, which showed an 80% release over 8 h, all NFs 
demonstrated an improved drug release profile [73]. With a large surface area to volume 
ratio of NF, there is a significant advantage to increase the drug loading amount and 
therefore this should be investigated [73]. However, further in vivo studies will need to 
be conducted to establish if the degradation rate of the PCL component of the NF is 
increased and if this leads to an increase in the total amount of drug release after 48 h. 
 
The drug release of L-655,708 from PCL/CH was further investigated to understand if a 
different mechanism was taking place that influenced drug release. There was no 
significant difference in mass loss between PCL and PCL/CH NF because CH is poorly 
soluble at physiological pH or higher, therefore there is no reduction in the weight of the 
NF as observed for PCL/GEL and PCL/PEO NFs (Section 4.3.2). However, PCL/CH 
released 100% of L-655,708 over a 24 h period compared to a slower release for the PCL 
and PCL/blend NFs. This may be explained by the interaction between the CH and L-
655,708. Under acidic conditions as occurs in the electrospinning solvent system, the 
amines present in CH become protonated giving CH a positive charge, similarly, the 
nitrogen in the imidazo structure of the L-655,708 can too be protonated, creating a 




interaction between CH and the drug forces the drug to the surface or close to the surface 
of the NF, the drug at the surface is released when it comes in to contact with the release 
medium and the drug close to the surface has only a small diffusion path leading to 100% 
of drug release over a 24 h period. To determine if a charge interaction was influencing 
the drug release from the PCL/CH NF, indomethacin a molecule neutrally charged in the 
electrospinning solution, with similar physicochemical properties to L-655,708 was 
incorporated into the PCL/NF and the release investigated. It was hypothesised that 
without a charge interaction, indomethacin would be evenly distributed throughout the 
NF and not distributed near the surface and would result in an extended drug release 
period. It was observed that the release profile of L-655,708 and indomethacin was 
similar from the PCL/CH NF. Therefore, it appears that while a charge interaction 
between CH and the drug may occur, when the neutrally charged indomethacin was 
incorporated into the PCL/CH NF, the release profile remained unchanged (i.e. was not 
statistically different to the release of L-655,708), indicating that the charge interaction 
between CH and L-655,708 is not influencing the drug release profile.  
 
The question remains as to why the complete release of both drugs is observed from the 
PCL/CH NF.  One possibility may be due to phase separation of PCL and CH, along with 
the hydrophobic drugs, favouring the lesser hydrophobic interaction with CH. Phase 
separation may occur in the electrospinning needle as the polymer solution is no longer 
under constant stirring. Upon electrospinning, two distinct fibres may form, a PCL NF 
and a CH/drug NF resulting in the drug diffusing out of the CH NF. Alternatively, a 
core/sheath NF may occur where the CH/drug complex may form a sheath around the 
PCL, resulting in the drug being distributed on the surface of the NF and complete release 
from the NF. 
 
Another theory that may explain why the complete release of drug is observed over a 24-
48 h period could be due to the morphology of the individual fibres. The structure of the 
individual fibres may have nano-pores that facilitate the diffusion of the drugs from the 
NF. Phase separation and breathe figures (nano-pores) have been proposed to explain the 




water is introduced into the electrospinning jet, which creates polymer-rich and polymer-
poor regions and this may facilitate the formation of porous fibres [122]. If the relative 
humidity is high, breathe figures may form on the fibre surface from the condensation of 
water droplets creating pores after the evaporation of the water [476]. A volatile solvent, 
a non-water-soluble material and high humidity are needed to produce porous NFs 
[122,476,477]. Given that the other NF blends did not release 100% of the drug and all 
three conditions required to produce porous NF were not present, it is unlikely that 
breathe figures or vapour induced phase separation could have been responsible for 
producing a porous PCL/CH NF. However, it has been demonstrated that pore formation 
occurs on the surface of NF when using volatile solvents such as DCM [478]. Celebioglu 
and Uyar (2011) theorised that the fast vaporisation of DCM led to local phase separation, 
which produced pores [478]. Cooper et al. (2018) postulated that the formation of pores 
occurred in regions with relatively high solvent content that evaporated faster than the 
surrounding region [479].  Furthermore, a smaller fibre diameter with a larger specific 
surface area will increase the rate of solvent evaporation [480]. Therefore, it is proposed 
that the PCL/CH NFs may have nano-pores on the surface of the NF due to a culmination 
of smaller diameter fibres and a larger surface area giving fast solvent evaporation, 
coupled with phase separation from the fast evaporation and evaporation of the solvents 
in regions with high solvent content.   
 
4.4.6  In vitro biocompatibility of PCL and PCL/blend nanofibres 
The biocompatibility of the NFs needs to be established in vitro before the NF can be 
implanted for assessment in vivo. NFs have a porous architecture and similar 
characteristics, which mimic that of the extracellular matrix. This increases the likelihood 
of biocompatibility in vitro as the unique structure promotes cell-matric and cell-cell 
interactions [481]. However, the properties of the polymer used such as chemical 
functional side groups also influence the adhesion, growth and proliferation of the cells 
on the NFs. Initial attempts to determine the biocompatibility by cell culture experiments 
were conducted with PC12 cells. These cells were difficult to work with because they 
detached from the cell culture plate and NF very easily, which led to inconsistent results. 




extensively used to investigate the biocompatibility of NF in tissue engineering 
applications [482–484]. NHDF cells were cultured on the surface of the NFs for three 
days and cell viability was determined using the MTT assay [485]. The assay is reliant 
on metabolically active cells and therefore is proportional to the number of viable cells, 
which is commonly used for in vitro biocompatibility investigations [481]. From the 
MTT assay, it was revealed the NHDF cells were viable on the PCL NF, however, over 
the 72 h period NHDF cells did not significantly proliferate. Studies presented here 
showed that the PCL NF had an initial contact angle of 71.8°, and it was also shown that 
it had low wettability with poor water absorption (Section 4.4.4), which may have limited 
the attachment and proliferation of cells on the NF. The chemical composition of PCL 
also hinders the adherence and proliferation as it lacks functional groups that act as 
chemical and biological recognition sites [201]. Therefore, the PCL NF could not 
sufficiently support cell growth and cell viability was compromised. 
 
With the introduction of CH to the NFs, there was an increase in cell viability on PCL/CH 
NFs after 24 h. This increase may be attributed to the amine, hydroxyl and acetamido 
functional groups present on CH providing adhesion sites for cell attachment [391]. Cell 
proliferation was not observed over the 72 h period and this may have been due to the 
low wettability of the PCL/CH. PCL/GEL had the highest cell viability and proliferation 
which was maintained over the 72 h period, this is related to GELs high hydrophilicity 
and wettability. GEL is denatured collagen, a constituent of the extracellular matrix and 
possesses the tripeptide arginine-glycine-aspartic acid-like-sequence, which is known to 
promote cell adhesion and migration, and may have significantly contributed to the 
increase in cell viability and fast initial proliferation observed [390]. However, the reason 
for no more proliferation at the 48 h and 72 h assessments may be due to the cells reaching 
their confluence. Cell viability and proliferation was sustained for 48 h on the PCL/PEO 
NF, however, this had decreased at the 72 h time point. The decrease may have been due 
to the cells reaching their confluence or, the cells adhering initially to the hydrophilic 
surface but unable to proliferate on the NF because of the biologically inert PEO [322]. 
The increased viability of cells cultured on PCL/GEL and PCL/PEO over the 48 h period 
may also have been due to the leaching of GEL and PEO from the fibre (Section 4.3.2), 




described in the literature [486,487]. Additionally, the lack of proliferation on PCL, 
PCL/CH may also be related to the surface topography of the NF. The diameter of these 
fibres was small, (Section 4.3.1.1) which creates a rougher surface and studies have 
shown initial cell adhesion is not affected but proliferation is hindered or even decreased 
on a rough surface. This is also supported by the higher water contact angles observed in 
these fibres (Section 4.3.1.7) [488–492].  
 
To further assess the in vitro biocompatibility of the NFs, pro-inflammatory cytokine 
production was determined to establish if the presence of the NFs or the degradation 
products of the polymers produced an immune response. NHDF cells were cultured on 
NFs for 48 h, the medium was collected and cytokine levels were analysed by flow 
cytometry. When NHDF cells were exposed to LPS a pro-inflammatory response was 
triggered however, there was no statistically significant pro-inflammatory response to 
cells cultured on NFs when compared to the control. Given the degradation of the NFs 
would have been occurring over the 48 h period, (Section 4.3.2) the degradation products 
from CH, GEL and PEO did not cause an immune response. The slow degradation of 
PCL may have also prevented the build-up of acidic by-products [493]. A similar finding 
was reported by Sundaramurthi et al. (2013), the researches cultured lymphocytes on 
poly-(3-hydroxybutyrate-co-3-hydroxyvalerate) NFs and after 72 h the NFs did not 
induce pro-inflammatory cytokine production [494]. The secretion of pro-inflammatory 
cytokines from macrophages cultured on PLA NF has been reported, however, the 
immune response was lower compared to a PLA film [398]. It was concluded NFs were 
more biocompatible than microfibers based on the immune response to each by 
macrophages [398]. The results from the cell culture studies suggest the NFs do not cause 
a cytotoxic or pro-inflammatory response when NHDF cells are cultured on them in vitro. 
However, macrophages are considered to be main cell type involved in the immune 
response at the implant surface in vivo, and therefore it may be advantageous to conduct 






In summary, PCL and PCL blend NF of CH, GEL and PEO were successfully prepared 
by the electrospinning process. The NFs were physically and chemically characterised, 
in vitro studies were also conducted, including mass loss, drug release and 
biocompatibility. Each NF showed better attributes in different experiments. Introducing 
the charged polymer CH reduced fibre diameter, which may be desired for drug delivery 
because a higher drug loading can be achieved due to a high surface to volume ratio, 
while the large globular GEL increased the average fibre diameter. Chemical analysis 
showed the polymers were unaffected by the electrospinning and none of the NFs 
appeared to have residual solvent present. The PCL/PEO NF showed better thermal 
stability compared to the NFs produced using natural polymers, however, CH and GEL 
reduced the crystallinity of PCL in the NFs. The solid-state analysis also indicated there 
was an interaction between PCL and the blend polymers on the molecular level and was 
most likely due to hydrogen bonding. PCL and PCL/CH had poor mechanical properties 
and were brittle, compared to PCL/GEL and PCL/PEO, while PCL/PEO produced the 
highest tensile strength. The PCL/GEL NFs possessed the lowest contact angle and had 
the highest wettability. PCL/GEL and PCL/PEO had the highest mass loss over 4-weeks, 
whereas PCL and PCL/CH showed a negligible loss. PCL/CH showed the fastest release 
of L-655,708, followed by PCL/PEO, then PCL/GEL and finally PCL. The release profile 
of indomethacin from PCL/CHG was similar to L-655,708 suggesting a repulsive charge 
interaction was not the reason why 100% release of L-655,708 from PCL/CH was 
observed. It is proposed that nano-pores on the surface of the PCL/CH NF created by 
phase evaporation the solvent and phase separation led to 100% release of both L-
655,708 and indomethacin. PCL/GEL had the best cell viability and proliferation 










5 General discussion and future directions 
Neurological disorders such as dementia, Parkinson’s, epilepsy and stroke are diseases 
that impair everyday living for thousands of New Zealanders every year. Systemic 
delivery of drugs with the sole purpose of targeting the brain to assist in recovery / 
alleviate symptoms from these neurological disorders is difficult due to the BBB, and 
approximately 98% of small molecules fail to cross the BBB [495]. Local implantation 
of drug delivery systems is an alternative approach to by-pass the BBB. However, drug 
delivery systems like nano/micro-particles and hydrogels have limitations. For example, 
they can be easily cleared from the target region in the brain and the disintegration of 
hydrogels can result in a high concentration of the drug being released as a burst, which 
may produce local toxicity and death that is undesirable [63,74,85].  
 
In this thesis, NFs were developed as an alternative to overcome the limitations of 
nano/micro-particles and hydrogels for delivery of bioactive compounds to the brain. 
NFs made from two different polymers (PLGA and PCL) were produced using the 
technique of electrospinning, but more importantly utilised less toxic, USP Class III 
solvents. An important criterion for any new delivery system is to not have any toxic 
effects for the patient. PLGA has been traditionally electrospun using solvents that are 
USP Class II, and are highly toxic to the body [106,233,237–240]. This presents a 
challenge for regulatory approval of a NF system, due to the requirement that any residual 
solvent in the NF must be determined, as to not exceed the permitted daily exposure limit 
(PDE). To overcome this, the electrospinning of PLGA using a less toxic solvent system 
consisting of the USP Class III solvents ACE and EtAc in different ratios were 
investigated as part of this thesis.   
 
NFs with a uniform diameter distribution and free of bead defects are the desired NF 
morphology [496–500]. However, the viscosity and surface tension of the 
polymer/solvent solution are also known to influence fibre morphology. For example, 
electrospinning a solution of poly-(carbonate urethane) with a low viscosity produced 
beaded fibres, whilst high viscosity solutions produced large fibres [135]. Altering the 
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ratio of solvents may also influence the surface tension of the polymer/solvent solutions 
enough to create bead defects in the NF [276]. Electrospinning PLGA using ACE:EtAc 
with a dielectric constant (ε) of 16.35, at a ratio of 70:30 v/v, produced bead free NFs. 
However, electrospinning PLGA with ACE:EtAc at 80:20 v/v (ε = 17.76), produced 
beaded NFs. This is not what we had initially thought would be the case, as it has been 
observed that a ε of ~19 is optimal for electrospinning PCL into a NF [244]. Further, the 
NF solvent system that had a higher ε, is closer to the previously used DCM:DMF (ε = 
17.26), whereas we observed a beaded NF [244]. It is suggested viscosity and surface 
tension measurements of the polymer/solvent systems be carried out to establish why the 
solvent system with a lower ε produced a bead free PLGA NF. 
 
Having developed the new, less toxic solvent system consisting of ACE and EtAc that 
produced a PLGA NF, the subsequent work investigated if PLGA ACE:EtAc NFs were 
suitable as a drug delivery system, and compared to a PLGA NF produced using Class II 
solvents, DCM and DMF. To undertake a direct comparison between NFs, the 
electrospinning parameters (polymer concentration, flow rate, voltage, needle gauge and 
the distance from the needle tip to the collector) were held constant. By doing this, it 
limited the ability to optimise the electrospinning parameters to produce smaller diameter 
PLGA ACE:EtAc NFs with a uniform diameter distribution, as large non-uniform NF 
were observed. Future work should involve optimising the processing and solution 
parameters by decreasing the flow rate or by reducing the concentration of the polymer 
in solution or a combination of both, may be required to achieve the desired 
characteristics of smaller diameter NFs with a uniform diameter distribution 
[115,120,122,124]. Furthermore, the thesis only investigated the analysis and 
characterisation on a single batch of each NF. Therefore, after optimisation studies are 
complete, multiple batches of the NFs should be produced and analysed for 
reproducibility and variation between batches. 
 
In an in vivo environment, there will be stresses and strains exerted on the NF and it 
should also hold up to the handling and manipulation during the process of being placed 
in vivo therefore, the mechanical strength of the NFs was assessed. It was discovered that 
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when comparing the two PLGA NFs, there was a difference in the mechanical strength 
and the deformation process. The mechanical strength test was performed on the macro 
scale and it was found that PLGA NFs electrospun with ACE:EtAc had an inferior 
mechanical strength and underwent a fibril crazing deformation process, where the 
formation of a fibril is drawn out from a fibre. Larger fibre diameter and fewer fibre-fibre 
fusion points were hypothesised as one of the possible reasons fibril crazing and lower 
mechanical strength was observed. Several research groups have investigated the 
mechanical properties of single-stranded NFs using specialised equipment [501–504]. 
Applying this approach to an individual fibre of PLGA ACE:EtAc and DCM:DMF may 
provide insight into the mechanism of deformation to determine if fibre diameter and 
fibre-fibre fusion points are in fact contributing factors. Understanding this deformation 
process may lead to the development of a NF with increased mechanical strength that 
will be useful for in vivo application in patients.  
 
To assess the hydrophilic/hydrophobic surface properties of the NFs in vitro cell culture 
studies were performed, this is important because it provides details on how the cells will 
interact with the NF in vitro and in vivo. PLGA ACE:EtAc had a higher water contact 
angle than PLGA DCM:DMF, which is not desired because it demonstrates the surface 
is more hydrophobic. It is postulated that this may have occurred due to the non-uniform 
fibre diameter of PLGA ACE:EtAc, creating an increase in surface roughness. Scanning 
white light interferometry and atomic force microscopy (AFM) are two techniques that 
are used to analyse the topography of a surface [505–507]. Applying the techniques in 
combination could provide further details on the surface roughness of the NFs. Because 
the two techniques are non-invasive and non-destructive due to not having to prepare or 
modify the sample, the techniques allow for the same sample to be tested for water 
contact angle measurements [505,508]. This would provide a more accurate, in-depth 
understanding of the hydrophilic/hydrophobic surface properties and allow for fine-
tuning of the surface properties to increase the biocompatibility.  
 
It was hypothesised that the diameter of the NF fibres and the molecular weight of the 
incorporated drug would influence the drug release kinetics however, this was found to 
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not be the case. It was suggested drug release was influenced not only by drug diffusion 
and NF polymer degradation but also by the solubility of the drugs in the solvent systems 
and how the drugs were dispersed in the NF matrix after electrospinning. Therefore, to 
better understand the drug release kinetics from the NFs it would be beneficial to confirm 
that the drugs are present at the surface of the NFs and determine how the drugs are 
dispersed in the NF matrix. Further, investigating the solubility of the drugs in each 
solvent system would be useful to help interpret distribution patterns observed in the NFs. 
Hall Barrientos et al. (2017) used AFM to visualise crystalline levofloxacin on the 
surface of PCL NFs [509]. Therefore, AFM could further enhance the argument that 
crystalline drug is present at the surface of the NFs and the technique also has the 
advantage of being non-invasive and non-destructive. However, FE-SEM, AFM and hot 
stage microscopy only provide an image of the drug on the surface and although irregular 
structures and birefringence may be observed in the images, it is not conclusive enough 
to confirm it is in fact drug. X-ray photoelectron spectroscopy (XPS) is a method that 
can be used to determine the surface composition of a material, this method may provide 
the chemical composition of the irregular structures and therefore, provide conclusive 
evidence of the drug at the surface of the NFs [510]. XPS analysis has been used to 
estimate the percentage of paclitaxel on the surface of PLGA micro- and NFs [511]. 
Furthermore, time of flight-secondary ion mass spectrometry (ToF-SIMS) could be used 
to better understand the distribution of the drug in the NF matrix. ToF-SIMS has been 
used to produce 2D and 3D images showing the distribution of levofloxacin and irgasan 
in PCL NFs and this could be applied to the NF systems developed here [509].  
 
Drugs in the amorphous or crystalline state will be incorporated differently into the NF 
matrix and release at different rates, for example, crystalline drugs tend to be at the 
surface of the NF and result in a burst release. Due to the limited supply of the neuro-
active drug L-655,708, further analysis could not be conducted to establish the solid-state 
of the drug in the NFs and to confirm if drug crystallinity influenced the release rate for 
this compound. Therefore, it would be beneficial to examine the chemical and physical 
properties of L-655,708-loaded NF to determine the solid-state of the drug and if there is 
a drug/polymer interaction. To achieve this, the drug concentration will have to be 
increased significantly, to be detected by the instruments such as FTIR, DSC, XRD, XPS 
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and ToF-SIMS. The NFs have a large surface to volume ratio and there is potential to 
increase the drug loading significantly, and studies have shown drug loading of up to 60 
wt% [161,500,512–514]. If the loading dose of L-655,708 was increased it would be 
predicted that this would affect the NF morphology and the solid-state, as it has been 
reported that increasing the loading of poorly water-soluble drugs can lead to larger 
diameter fibres [515]. PCL crystallinity was also shown to be reduced with increased 
drug loading, which may suggest a drug-polymer interaction is occurring, this could be 
determined using the techniques outlined above [515]. 
 
When utilising drug delivery systems, it is important to characterise the degradation 
products of the delivery systems as they can potentially cause an acidic micro-
environment resulting in cell toxicity [220]. In an aqueous environment, PLGA degrades 
to lactic acid and glycolic acid, however, the in vitro cytotoxicity of NF degradation 
products were not established in this thesis [220]. Further studies could investigate the in 
vitro degradation of and determine if the degradation products produce a cytotoxic 
response in neuronal cells. This could then be extended to animal studies to examine if 
the acidic micro-environment promotes a pro-inflammatory response by measuring 
circulating blood cytokine levels to determine if the PLGA NFs are safe for use in vivo.  
 
Degradation of the PCL and PCL/blend polymers were established because the 
degradation of the polymers influences the drug release kinetics. As PCL degradation is 
known to be slow, the blend polymers were incorporated to increase the degradation rate 
of the NF. In vitro degradation studies showed the greatest loss was from PCL/GEL and 
PCL/PEO, which was attributed to the hydrophilic nature of PEO and GEL. From the in 
vitro degradation results, it was expected that PCL/GEL and PCL/PEO would have the 
fastest release of L-655,708. However, PCL/CH showed the fastest release with 100% 
after 24 h, which indicated the drug was not encapsulated in the fibre. It was hypothesised 
a repulsive charge interaction may be occurring between the CH and L-655,708 causing 
the drug to be dispersed on the surface of the fibre and most likely in the crystalline form, 
resulting in a faster release. To investigate if a repulsive charge was the cause, PCL/CH 
was electrospun with the neutral drug indomethacin but, a similar release profile was 
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observed, and so not providing support for the proposed hypothesis of charge repulsion 
driving drug release. Two theories were presented in the thesis as to why a faster release 
was observed from the PCL/CH NF. One suggested phase separation was occurring 
resulting in two distinct fibres with the drug bound to the CH fibre and the other 
suggested nano-pores were formed in the NFs during electrospinning that facilitated the 
release of the drug. Therefore, further investigation is needed to determine if the proposed 
theories are the mechanisms that influence the release from the PCL/CH. Transmission 
electron microscopy (TEM) could be employed to determine if core/shell NFs are 
formed, TEM is a well-established method to examine core/shell NFs [516–519]. 
However, it can cause destruction of the sample and requires single NFs to be deposited 
on a carbon-coated copper grid, which can be difficult to achieve depending on the 
electrospinning equipment and the density of the NF [516–519]. XPS has previously been 
employed to determine the phase separation of polymers in a core/shell NF therefore, this 
technique could be applied to identify the formation of two separate polymer NFs [520]. 
To investigate if nano-pores are present on the surface of the NFs, higher magnification 
FE-SEM images of the NF surface could be obtained [478]. Furthermore, ToF-SIMS and 
XPS may provide an insight into how the drug is distributed in the NF matrix, to 
determine if the drug is localised at the surface of the NF [509,511]. 
 
The cytotoxic and immune response to NFs was assessed in fibroblast cells, however, to 
advance the NF drug delivery system further, it would be advantageous to assess the 
effect of drug release in an in vitro setting before in vivo studies are conducted. The in 
vitro drug release assessment could be achieved by conducting whole cell patch clamp 
recordings. In particular, the assessment of L-655,708 in post stroked mouse brain slices 
could be investigated in a similar nature to Clarkson et al. (2010) to determine if the 
release of L-655,708 from the NF is sufficient to reduce GABA-mediated tonic inhibition 
[201]. Conducting this experiment would then form the basis to lead into in vivo 
assessment of drug release from the NF. 
 
NFs possess an advantage over other implantable biomaterials since they have a similar 
structure to the native tissue extracellular matrix, therefore, the NF composition is 
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‘familiar’ to cells. Because of the NF structure, when it is implanted into the body, it may 
elicit less of a foreign body response resulting in the NF drug-eluting system having 
improved performance and desired outcome. In the CNS the foreign body response 
occurs when activated microglia cells migrate to the implant site releasing cytokines, 
reactive oxygen species and promote extracellular matrix deposition [521–523]. For 
implants that cannot be phagocytosed, microglia cells form multi-nucleated cell bodies, 
not unlike foreign body giant cells [524]. Activated astrocytes are recruited, expressing 
glial fibrillary acidic protein (GFAP) [523,525,526]. Astrocytes secrete excessive 
extracellular matrix proteins such as proteoglycan NG2, neurocan and collagen, which 
are the building blocks required to form a glial scar [527,528]. A NF blend composed of 
three polymers, PLGA, PLA and PCL was investigated as a potential drug delivery 
system for the treatment of glioblastoma multiforme [529]. In vivo biocompatibility was 
assessed in a rat model and after 3 months implantation, the NF was found to be 
compatible with no sign of inflammation adjacent to the implant-tissue interface. Minor 
inflammation was observed at the implant-brain interface with the infiltration of immune 
cells and thickening of tissue. Pro-inflammatory cytokine levels were slightly elevated at 
the 72 h time point. However, overall levels remained within the normal limits and the 
researchers concluded the implant caused no serious pathological changes or adverse 
immune response [529]. Another study investigated a NF composed of the copolymer 
poly-(L-lactide-co-caprolactone) as a wound dressing for injured brain parenchyma 
[530]. The researchers observed a massive increase in astrogliosis in rats that were 
surgically injured, but this was not observed in rats who received a surgical injury and 
were treated using NFs. A glial scar did form in animals that had surgery + NF, however, 
this was thinner and more orderly in structure compared to the surgically injured animals. 
The researchers deemed that the NF was biocompatible and concluded that the NF may 
protect against the cascade of uncontrolled damage caused by excessive proliferation of 
astrocytes and inflammation [530].  
 
A recent study examined a PCL NF scaffold as an implant for neuronal tissue repair in a 
rat brain [531]. Inflammation peaked after 7 days and was restored to normal levels after 
60 days, neurite infiltration and axonal growth were observed within the implant [531]. 
Therefore, to advance the NF as a drug delivery system for neurological disorders and in 
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particular stroke, it would be advantages to investigate the foreign body response in vivo. 
Studies should focus initially on the biocompatibility of the NFs and investigate 
circulating blood cytokine levels and the presence of activated astrocytes cells around the 
NFs. Cytokine levels can be assessed by collecting blood samples at specific times points 
and quantified by using an inflammatory cytokine multiplexed flow cytometric assay. To 
determine the infiltration and presence of activated astrocytes, at specific time points the 
brain would be removed and sliced, GFAP expression could then be detected 
immunohistochemically. Furthermore, to advance the NF drug delivery system to the 
clinic, in vivo drug release studies need to be conducted to determine if the drug release 
is sufficient to improve recovery after a neurological event. To assess the in vivo drug 
release, the brain would have to be removed at specific time points and homogenised, an 
assay would then have to be developed that involved the extract of the drug from the 
brain homogenate for analysis of the drug by RP-HPLC. In the case of stroke, to assess 
recovery, the volume of the stroke infarct could be analysed. This could be done by 
placing a drug-loaded NF into the stroke cavity, then at specific time points removing the 
brain and processing brain slices histologically and measuring infarct volume [198]. 
Furthermore, behavioural studies such as the grid-walking task and cylinder task could 
be conducted on stroked mice to assess if there is functional recovery after implantation 
of a drug-loaded NF [198]. 
 
In conclusion, the research conducted in this thesis has developed and characterised NFs 
composed of PLGA, PCL and PCL/blends using low toxic solvent systems for the first 
time. The drug release kinetics of three model drugs was assessed from NFs and it was 
discovered that molecular weight and fibre diameter did not influence drug release. It 
was proposed drug release was influenced by the solubility of the drug in the solvent 
system and how it was dispersed in the NF matrix. Blending the hydrophobic PCL 
polymer with hydrophilic polymers improved the properties of the PCL NF. PCL/CH NF 
showed a different release mechanism was responsible for drug release compared to the 
PCL and PCL/blend NFs. Two mechanisms of drug release were proposed; (1) phase 
separation of the polymers occurred during electrospinning, forming two distinct fibres 
with the hydrophobic drugs favouring the lesser hydrophobic interaction with CH 
resulting in drug diffusion out of the CH NF. Alternatively, a core/sheath NF occurred 
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where the drug was located in the CH sheath around a PCL core resulting in drug 
distributed at the surface of the NF. (2) During the electrospinning process, nano-pores 
were created on the surface of the NF that facilitated the diffusion of the drugs from the 
NF. Experiments were then recommended that could investigate and determine the 
mechanism of drug release. The PCL/GEL NF demonstrated the desired chemical and 
physical properties, along with a suitable in vitro degradation profile and an improved 
drug release profile compared to the other PCL/blend NFs and supports the need to 
investigate the PCL/GEL NF in vivo. With further investigation, NFs may show potential 
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Phosphate buffered saline 
Sodium chloride     8 g 
Potassium chloride     0.2 g 
Di-sodium hydrogen phosphate   1.15 g 
Potassium dihydrogen phosphate   0.2 g 
Purified water      1000 mL 
pH adjusted to 7.4 
 
Complete DMEM media  
Penicillin/Streptomycin solution   5.0 mL 
FBS       50 mL 
DMEM to       500 mL 
 
MTT solution  
MTT        2.5 mg 
DMEM                            5 mL 
The solutions were filtered through a 0.22 μm syringe filter and sterilised by autoclave 




Isopropyl containing 4 mM HCl 
Isoproyl       49.984 mL 
HCl 37%      16 μL 
 
Lipopolysaccharide (LPS) solution 
LPS        1 mg 
PBS       1 mL 
 
Capture beads  
Each capture bead suspension was vigorously vortex mixed for 5 s before mixing.  50 μL 
of each capture beads were placed in a single tube labelled ‘mixed capture brads’, the 
mixed beads were vortex thoroughly. 
 
Mouse inflammatory standards  
Lyophilized mouse inflammatory standard spheres were transferred to a 15 mL conical 
flask and reconstituted in 2 mL assay diluent. The standard was allowed to equilibrate 
for 15 min at room temperature, then gently pipetted to mix. Assay diluent (300 μL) was 
added to 8 tubes and a serial dilution was performed to give dilutions of 1:2, 1:4, 1:8, 
1:16, 1:32, 1:64, 1:128 and 1:256. Assay diluent was used as the negative control. 
 
Wash Buffer (1x) 
Wash buffer (20x) was equilibrated at room temperature, then 25 mL of 20x wash buffer 








Figure B-1 Example of ATR-FTIR background scan. Over a range of 4000-400 cm-1 at a 
resolution of 4 cm1, 64 scans were collected. The scan was conducted before the analysis of 
each sample. 
 
Polystyrene film standard 
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L-655,708 standard curve linearity 
 
Figure B-4 RP-HPLC Standard curve for L-655,708, peak area vs concentration of L-655,708. 
L-655,708 was linear in the range 0.125-10 nM (R2 = 0.99). Points represent the mean of three 
independent experiments ±SD. 
 
Paracetamol standard curve linearity 
 
Figure B-5 RP-HPLC Standard curve for paracetamol, peak area vs concentration of 
paracetamol. Paracetamol was linear in the range 0.025-2.5 µM (R2 = 0.99). Points represent 












































Ampicillin standard curve linearity 
 
Figure B-6 RP-HPLC Standard curve for ampicillin, peak area vs concentration of ampicillin. 
Ampicillin was linear in the range 0.025-1 µM (R2 = 0.99). Points represent the mean of three 
independent experiments ±SD. 
 
Tetracycline standard curve linearity 
 
Figure B-7 RP-HPLC Standard for curve tetracycline, peak area vs concentration of 
tetracycline.Tetracycline was linear in the range 0.025-1 µM (R2 = 0.99). Points represent the 
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